WO2018149852A1 - Hydrophobic compounds for optically active devices - Google Patents

Hydrophobic compounds for optically active devices Download PDF

Info

Publication number
WO2018149852A1
WO2018149852A1 PCT/EP2018/053625 EP2018053625W WO2018149852A1 WO 2018149852 A1 WO2018149852 A1 WO 2018149852A1 EP 2018053625 W EP2018053625 W EP 2018053625W WO 2018149852 A1 WO2018149852 A1 WO 2018149852A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
atoms
formula
chcf
linear
Prior art date
Application number
PCT/EP2018/053625
Other languages
French (fr)
Inventor
Martin SCHRAUB
Lars Dobelmann-Mara
Stefan RIEDMUELLER
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to ES18703798T priority Critical patent/ES2850898T3/en
Priority to PL18703798T priority patent/PL3583091T3/en
Priority to US16/485,844 priority patent/US11014901B2/en
Priority to EP18703798.1A priority patent/EP3583091B1/en
Publication of WO2018149852A1 publication Critical patent/WO2018149852A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16—Intraocular lenses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • G02B1/041—Lenses

Definitions

  • the present invention relates to novel compounds, particularly to
  • novel compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.
  • Cataract is a general term for an affection of the eye that leads to a loss of vision and in the extreme to blindness by clouding of the normally clear lens of the eye. It is the major cause of blindness in the world, affecting more than 100 million people. Due to the fact that its major cause is age and the population's average age is increasing, it is expected that the number of cataracts will continue to increase substantially in the future.
  • Intraocular lens In preparation of surgery current state-of-the-art surgical methods employ eye mapping so as to approximate the refractive power best suited to the respective patient.
  • cataract surgery is one of the most widely used and safest surgical procedures it is not without specific post-surgery problems.
  • the refractive power of the implanted intraocular lens (IOL) is insufficient for restoring good vision.
  • Such problems may, for example, be caused by changes in eye geometry as consequence of the surgery as well as irregular wound healing and positioning errors that result in the artificial lens not having the optimal optical properties.
  • the patient will still require corrective vision aids, e.g. glasses, to be able to see correctly.
  • the resulting refractive power of the implanted artificial lens is so far removed from the required refractive power that further surgery will be required. Particularly for aged persons this is not desirable because the body's capability for healing is reduced with increasing age.
  • there is the risk of attracting endophthalmitis, an inflammation of the eye which can even lead to a complete loss of vision or worse, loss of the eye.
  • WO 2016/200401 A1 describes liquid crystal materials having
  • hydrophobic fluorocarbon polymer is known from Jean-Marc technik, J Cataract Refract Surg. 1998, 24, 371 -379. Teflon AF® (Dupont de
  • Nemours is a poly(tetra-fluoroethylene co-hexafluoro-propyl-2
  • cydodethoxydifluoroethylene Constituted entirely of high-energy bonds, it is stable at temperatures up to 260°C and chemically very resistant.
  • the refractive index is 1 .32. It transmits light from 200 to 2000 nm with a constant light absorption below 5%.
  • the contact angle with water is 129 degrees.
  • the surface modification is described using a PMMA IOL (model 808A, Kabi Pharmacia Production B.V.) having an overall diameter of 12.0 mm and optic diameter of 6.5 mm which is coated by immersing the lense in a 5% solution of Teflon AF in a fluorocarbon solvent (CsFis) for 3 seconds and then placing it at a temperature of 37°C to evaporate the solvent. As a result, the surface of the PMMA IOL was completely coated with Teflon AF.
  • CsFis fluorocarbon solvent
  • the invention relates to compounds of formula (I)
  • X is O, S or NRo, Y is independently of each other O, S or a bond, n is 0 or 1 ,
  • n 0 or 1
  • n+m 1 or 2
  • Xi, X2, X3, X4 are each independently of each other CR' or N,
  • ⁇ , X7 are each independently CR' or N,
  • R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 8 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms
  • R' is at each occurrence independently selected from the group consisting of H, F, a linear or branched, non- halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a linear or branched hydroxyalkyl group having 1 to 20 C atoms, a non- halogenated, partially or completely halogenated cycloalkyi group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyi group having 1 to 20 C atoms,
  • R0 is at each occurrence independently selected from the group consisting of a linear or branched alkyl group having 1 to 10 C atoms or a cycloalkyi group having 3 to 6 C atoms,
  • R1 is a polymerizable group selected from the group
  • Rs, R9, R10 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non-fluorinated, partially or completely fluorinated alkyl having 1 to 20 C atoms or aryl with 6 to 14 C atoms,
  • c is 0 or 1 ;
  • alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk " * " denotes at each occurrence independently of each other a linkage to the linker [-R2- Y] n and/or [Y-R 2 ]m,
  • -R2- is -(C(R)2)o- wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or -(C(R) 2 )p-X8-(C(R)2)q-(X9)s-(C(R) 2 ) ⁇ (Xio)t-(C(R)2) u -, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,
  • a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,
  • o is selected from the group consisting of 1 to 20,
  • Xs, X9, X10 are at each occurrence independently O, S or NRo, s, t are at each occurrence independently 0 or 1 ,
  • p, q are at each occurrence independently selected from the group consisting of 1 to 10
  • r, u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for -(C(R) 2 )p-X8-(C(R)2)q-(X9)s-(C(R) 2 ) ⁇ (Xio)t-
  • the invention relates further to compositions comprising at least one of said compounds of formula (I) and/or their polymerized forms as well as to articles comprising at least one polymerized compound of formula (I).
  • the invention relates to a process for forming such article, said process comprising the steps of
  • composition comprising at least one compound of formula (I) and/or an oligomer or polymer as described before;
  • the invention relates to a process for changing the optical properties of an article according to the invention, said process comprising the steps of
  • the compounds of formula (I) and all preferred embodiments of compounds of formula (I) according to the present invention include all stereoisomers or racemic mixtures.
  • the compounds of formula (I) provide several advantages over prior art materials
  • compounds according to the invention are more stable toward UV- irradiation due to lower absorption range. Furthermore the chemical and hydrolytical stability is higher and given due to their intrinsic chemical nature e.g. due to lack of positions prone to nucleophilic attacks, like sp 2 centers and the absence of cyclic lactone structure motifs, compared to coumarin-type photoactive chromophores.
  • T g glass transition temperatures
  • Polymers used in intraocular lens manufacturing have preferably relative high refractive indices, which enable the fabrication of thinner intraocular lenses.
  • the polymer used in an intraocular lens will have a refractive index greater than about 1 .5 and presently most preferably greater than about 1 .55.
  • an asterisk (“ * ") is used within the description of the present invention, it denotes a linkage to an adjacent unit or group or, in case of a polymer, to an adjacent repeating unit or any other group.
  • a linear or branched alkyi group having 1 to 10 C atoms denotes an alkyi group having 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, for example methyl, ethyl, / ' so-propyl, n-propyl, / ' so-butyl, n-butyl, terf-butyl, n-pentyl, 1 -, 2- or 3-methylbutyl, 1 ,1 -, 1 ,2- or 2,2-dimethylpropyl, 1 -ethylpropyl, n-hexyl, n- heptyl, n-octyl, ethylhexyl, n-nonyl or n-decyl.
  • a linear or branched alkyi group having 1 to 20 C atoms include all examples for a linear or branched alkyi group having 1 to 10 C atoms including any alkyi group having 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 and 20 C atoms such as n-undecyl, n-dodecyl, n- tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n-nonadecyl and n-eicosyl.
  • partially halogenated alkyi group denotes that at least one H atom of the alkyi group is replaced by F, CI, Br or I.
  • the alkyi group is partially fluorinated meaning that at least one H atom of the alkyi group is replaced by F.
  • completely halogenated alkyi group denotes that all H atoms of the alkyi group are replaced by F, CI, Br and/or I.
  • the alkyi group is completely fluorinated meaning that all H atoms of the alkyi group are replaced by F.
  • a preferred completely fluorinated alkyi group is
  • halogenated or preferably fluorinated corresponds additionally to other groups such as a halogenated cycloalkyi group, a halogenated alkoxy group or a halogenated thioalkyl group.
  • a cycloalkyl group having 3 to 6 C atoms includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl which may be partially or completely
  • a linear or branched alkoxy group having 1 to 20 C atoms denotes an
  • O-alkyl group having 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example methoxy, ethoxy, /so-propoxy, n- propoxy, / ' so-butoxy, n-butoxy, terf-butoxy, n-pentyloxy, 1 -, 2- or
  • fluorinated alkoxy group is trifluoromethoxy.
  • a linear or branched thioalkyl group having 1 to 20 C atoms denotes a S-alkyl group having 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example thiomethyl, 1 -thioethyl, 1 -thio-/so-propyl, 1 -thio-n-propoyl, 1 -thio-/so-butyl, 1 -thio-n-butyl, 1 -th io-ierf-butyl , 1 -thio-n- pentyl, 1 -thio-1 -, -2- or -3-methylbutyl, 1 -thio-1 ,1 -, -1 ,2- or -2,2- di methyl propyl, 1 -th io- 1 -ethyl propyl , 1 -thio-n-hexyl, 1 -thio-n-
  • a preferred completely fluorinated thioether group is trifluoromethyl thioether.
  • Preferred alkyl and alkoxy radicals have 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms.
  • a polymenzable group is a group which can be subject to or can undergo polymerization thus forming an oligomer or a polymer.
  • Polymerization is the process of taking individual monomers and chaining them together to make longer units. These longer units are called polymers.
  • the compounds of formula (I) as described before and preferably described below are suitable monomers.
  • oligomerized or polymerized thus forms or is part of the backbone of the oligomer or polymer comprising polymerized compounds of formula (I).
  • Suitable polymerizable groups contain at least one double bond or at least one triple bond thus forming polymers where the linking is formed via carbon-carbon bonds.
  • a suitable polymerizable group may contain silicon thus forming polysiloxanes or polysilazanes.
  • the suitable polymerizable groups are selected from the group consisting of
  • Rs, R9, R10 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non- fluorinated, partially or completely fluorinated alkyl having 1 to 20 C atoms or aryl with 6 to 14 C atoms,
  • c is O or l ; trial koxysilyl groups or dialkoxyalkylsilyl groups where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms; and
  • alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk "*" denotes at each occurrence independently of each other a linkage to the linker [-R2- Y] N and/or [Y-R2-]m as described before or preferably described before.
  • a preferred polymerizable group is selected from the group consisting of trimethoxysilyl, triethoxysilyl, diethoxymethylsilyl and the alkenyl group of formula (5) as described before and preferably described below.
  • Aryl with 6 to 14 C atoms is an aryl group preferably selected from the group consisting of phenyl, naphthyl or anthryl, particularly preferably phenyl.
  • Preferred examples for the linker -[B]- are therefore selected from the group of formulae (B-1 ) to (B-34),
  • R' and Ro have a meaning as described before or preferably described below.
  • Compounds of formula (I) as described before are preferred where the linker -[B]- corresponds to formula (1 ) or (2) and Xi, X2, X3 and X 4 have a meaning as described before. Therefore, compounds of formula (I) are preferred where the linker -[B]- corresponds to formulae (B-1 ) to (B-19).
  • the invention therefore relates additionally to compounds of formula (I) as described before wherein -[B]- corresponds to formula (1 ) and (2) and Xi, X2, X3 and X 4 have a meaning as described before.
  • linker -[B]- corresponds to formula (1 ) or (2) and Xi, X3 and X 4 are CR' and R' has at each occurrence independently a meaning as described before or preferably described below. Therefore, compounds of formula (I) are particularly preferred where the linker -[B]- corresponds to formulae (B-1 ), (B-3), (B-8) or (B-9).
  • the invention therefore relates additionally to compounds of formula (I) as described before wherein -[B]- corresponds to formula (1 ) and (2) and Xi, X 3 and X 4 are CR' and R' has at each occurrence independently a meaning as described before or preferably described below.
  • R' is at each occurrence independently selected from the group consisting of H, F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a linear or branched hydroxyalkyi group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyi group having 1 to 20 C atoms.
  • At least one R' in -[B]- as described before or preferably described before is different from H and is selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non- halogenated, a linear or branched hydroxyalkyi group having 1 to 20 C atoms, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyi group having 1 to 20 C atoms.
  • At least two R' are different from H and are independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a linear or branched hydroxyalkyi group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms.
  • R' is at each occurrence independently preferably selected from the group consisting of H, F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.
  • At least one R' in -[B]- as described before or preferably described before is different from H and is selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.
  • At least two R' are different from H and are independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.
  • R' is at each occurrence independently particularly preferably selected from the group consisting of H, F, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n- hexyl, n-heptyl, n-octyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, methoxy, ethoxy, propoxy, trifluoromethoxy and pentafluoroethoxy.
  • R' is at each occurrence independently very particularly preferably selected from the group consisting of H, F, ethyl, n-pentyl, trifluoromethyl, methoxy, and trifluoromethoxy. Therefore, the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (1 ) to (4) and wherein at least one R' within Xi, X2, X3. X4, ⁇ or X 7 is not H.
  • the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1 ) to (B-29) or (B- 31 ) to (B-34) or to preferred linkers as described before, wherein at least one R' is not H and Ro has a meaning as described before or preferably described below.
  • the substituent R' within X 7 in formula (3) is particularly preferred not H.
  • the substituents R3, R4, R5 and R6 are at each occurrence independently R' where R' has a meaning or a preferred or particularly preferred meaning as described before.
  • R5 is preferably H or F.
  • R5 is particularly preferably H.
  • the substituent R 7 corresponds to R' in case m is 0 wherein R' has a meaning or a preferred or particularly preferred meaning as described before.
  • R 7 corresponds to R' which is not H in case m is 0.
  • R' is preferably not H, it is selected from the preferred group consisting of F, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n- heptyl, n-octyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, methoxy, ethoxy, propoxy, trifluoromethoxy and pentafluoroethoxy or from the particular preferred group consisting of F, ethyl, n-pentyl,
  • the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (1 ) to (4) and wherein at least one R' within Xi, X2, X3. X4, ⁇ or X 7 is not H and R 7 is not H in case m is 0.
  • the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1 ) to (B-29) or (B- 31 ) to (B-34) or to preferred linkers as described before, wherein at least one R' is not H and R 7 is not H in case m is 0 and Ro has a meaning as described before or as preferably described below.
  • the substituent R 7 corresponds to Ri in case m is 1 wherein Ri has a meaning or a preferred meaning as described before or further below.
  • Compounds of formula (I) in which m is 1 are preferred having a linker -[B]- selected from the group consisting of formula (1 ) to (4) wherein at least one substituent R' within Xi, X2, X3, X4, ⁇ or X 7 is not H and in which at least one substituent R3, R4 or R6 is not H.
  • the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (1 ) to (4) and wherein at least one R' within Xi, X2, X3. X4, ⁇ or X 7 is not H, in which at least one substituent R3, R4 or R6 is not H and R 7 corresponds to Ri in case m is 1 .
  • the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1 ) to (B-29) or (B- 31 ) to (B-34) or to preferred linkers as described before, wherein at least one R' is not H, in which at least one substituent R3, R4 or R6 is not H and R 7 corresponds to Ri in case m is 1 wherein Ro and Ri has a meaning as described before or further below.
  • Ro is at each occurrence independently preferably methyl, ethyl, / ' so-propyl, 2-methyl-propyl, n-butyl, n-pentyl, 4-methyl-pentyl or cyclopropyl.
  • Ro is particularly preferably ethyl, / ' so-propyl, 2-methyl- propyl, n-pentyl or 4-methyl-pentyl.
  • Ro is particularly preferably methyl or n-butyl.
  • Ro is particularly preferably methyl.
  • polymerizable group Ri This is the case for compounds of formula (I) in which n is 1 or m is 1 and the sum of n and m is 1 .
  • Such compounds can be preferably used as monomers for the preparation of a blank which may be transformed to an ophthalmic device such as an eye-implant or specifically an intraocular lens or to the ophthalmic device as such as described before.
  • the invention is therefore additionally directed to compounds of formula (I) wherein n is 1 and m is 0 which can preferably be described according to formula (l')
  • Ri, -R2-, Y, R3, R4, R5, R6, X, -[B]- and R 7 have a meaning as described before or preferably described before or below.
  • the invention is therefore additionally directed to compounds of formula (I) wherein n is 0 and m is 1 which can preferably be described according to formula (I")
  • Ri, -R2-, Y, R3, R4, R5, R6, X, -[B]- and R 7 have a meaning as described before or preferably described before or below.
  • the compounds of formula (I) as described before or preferably described before contain two polymerizable groups Ri .
  • Such compounds can be preferably used as cross-linking agent for the preparation of a blank which may be transformed to an ophthalmic device such as an eye-implant or specifically an intraocular lens or to the ophthalmic device as such as described before.
  • the invention is therefore additionally directed to compounds of formula (I) wherein n is 1 and m is 1 which can preferably be described according to formula (I'"
  • Ri, -R2-, Y, R3, R4, R5, R6, X, -[B]- and R 7 have a meaning as described before or preferably described before or below.
  • substituents as described before or preferably described before have a polymerizable group as described before or preferably described before or below and have at least one linking element Y-R2-.
  • Y is at each occurrence independently O, S or a bond.
  • the linking element -R2- is selected from the group consisting of -(C(R)2)o- wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms, -(C(R)2) P -X8-(C(R)2) q -(X9) s - (C(R)2)r-(Xio)t-(C(R)2) u -, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and o is selected from the group consisting of 1 to 20, Xe, ⁇ and X10 are at each occurrence O, S or NRo, s and t are at
  • the linking element -R2- is selected from the group consisting of -(C(R) 2 )o- wherein at least two R are F, -(C(R) 2 )p-X8-(C(R)2) q -(X9)s- (C(R)2)r-(Xio)t-(C(R)2) u -, wherein at least two R are F and a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and o, Xe, X9, X10, s, t, p, q, r and u have a meaning as described or preferably described before or below.
  • R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 8 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms.
  • R is preferably at each occurrence independently selected from the group consisting of H, F, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, isobutyl, ethylhexyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 2,2,3,3,3- pentafluoropropyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl and nonafluorobutyl.
  • R is particularly preferably at each occurrence independently selected from the group consisting of H, F, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, isobutyl, ethylhexyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 2,2,3,3,
  • o is selected from the group consisting of 3 to 12, particularly preferably 8 to 12.
  • s is 1 .
  • t is 0 or 1 .
  • Xs, X9 and X10 are O.
  • p and u are each independently 1 , 3, 3, 4, 5 or 6, particularly preferably 1 or 2.
  • q and r are each independently 1 , 2 or 3, particularly preferably 1 .
  • Preferred examples for -R 2 - are -(CH2)3-(CF 2 )-(CH 2 )3-, -(CH2)-(CF 2 )3-(CH 2 )-, -(CH 2 ) 2 -(CF 2 ) 4 -(CH 2 ) 2 -, -(CH2)-[CH(CF 3 )]-(CH2)-, -(CH 2 )-[C(CH3)CF 3 HCH 2 )- , -(CH 2 )-[CH(CH2CF3)]-(CH2)-, -(CH 2 )-[C(CH3)(CH 2 CF 3 )HCH 2 )-, -(CH 2 ) 2 - (CF2)-0-(CF 2 )-0-(CF2)-(CH 2 )2- > -(CH 2 )-(CF 2 )-O-(CF 2 )-O-(CF 2 )-O-(CF 2 )- (CH 2 -,
  • substituents as described before or preferably described before having a polymerizable group as described before or preferably described before or below are preferred in case the substituent -R 2 - within the at least one linking element Y-R 2 - corresponds to -(C(R) 2 ) 0 - wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or -(C(R) 2 ) [ r-X8-(C(R)2 X9 -(C(R)2)r-(Xio)r(C(R)2)u- > wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and all other R, o, Xs, X9, X10, s, t, p, q, r and u have a meaning as described before.
  • the invention therefore relates to compounds of formula (I), ( ⁇ ), (I") and (P) as described before or preferably described before wherein -R2- is at each occurrence independently -(C(R)2)o- wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2) ⁇ (Xio)t-(C(R) 2 )u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and all other R, o, Xs, X9, X10, s, t, p, q, r and u have a meaning as described before.
  • the linking element -(C(R) 2 ) 0 - or -(C(R) 2 )p-X8-(C(R)2)q-(X9)s-(C(R) 2 ) ⁇ (Xio)t-(C(R)2) u - as -R2- is particularly preferably selected from the group consisting of -(CH 2 )3-(CF2)-(CH 2 )3- > -(CH 2 )-(CF 2 )3-(CH 2 )- > -(CH 2 ) 2 -(CF 2 )4- (CH 2 ) 2 -, -(CH 2 )-[CH(CF 3 )]-(CH 2 )-, -(CH 2 )-[C(CH3)CF3]-(CH2)-, -(CH 2 )- [CH(CH 2 CF3)]-(CH2)-, -(CH 2 )-[C(CH3)(CH2CF3)]-(CH2)-, -(
  • the substituent Y-R2-R1 is particularly preferably selected from the group consisting of O-R2-R1, -R2-R1, and S-R2-R1 wherein -R2- has a meaning as described before or preferably or particularly preferably described before and wherein Ri is a polymerizable group selected from the group consisting of a trialkoxysilyl group, a dialkoxyalkylsilyl group, a silyl group of formula (6), (7) or (8) as described before where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or an alkenyl group of formula (5),
  • c is 0 or 1 .
  • the substituent Y-R2-R1 is preferably selected from the group consisting of O-R2-R1, -R2-R1 and S-R2-R1, wherein -R2- is selected from the group consisting of -(CH 2 )3-(CF 2 )-(CH 2 )3-, -(CH 2 )-(CF 2 )3-(CH 2 )- > -(CH 2 ) 2 -(CF 2 ) 4 - (CH 2 ) 2 -, -(CH 2 )-[CH(CF 3 )]-(CH 2 )-, -(CH2)-[C(CH 3 )CF 3 ]-(CH2)- > -(CH 2 )- [CH(CH 2 CF 3 )]-(CH 2 )-, -(CH 2 )-[C(CH3)(CH 2 CF3)]-(CH2)- > -(CH 2 ) 2 -(CF 2 )-0- (CF 2 -0-(CF 2 )-
  • Ri is a polymerizable group selected from the group consisting of a trialkoxysilyl group, a dialkoxyalkylsilyl group, a silyl group of formula (6), (7) or (8) as described before where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or an alkenyl group of formula (5),
  • Rs, R9, R10 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non- fluorinated, partially or completely fluorinated alkyl having 1 to 20 C atoms or aryl with 6 to 14 C atoms,
  • c is 0 or 1 .
  • Rg and Rio are H.
  • Rs is H, methyl, ethyl or phenyl.
  • Preferred alkenyl groups of formula (5) are therefore represented by any one selected from the group consisting of formulae (5-1 ), (5-2), (5-3), (5-4), (5-5 , (5-6), (5-7), (5-8), and (5-9):
  • the alkenyl group represented by formula (5-1 ) is called methacrylate.
  • the alkenyl group represented by formula (5-2) is called acrylate.
  • the preferred groups Ri are preferably combined with preferred groups of the linking element -R2- and/or the linking element Y-R2-. Combinations are excluded where two O atoms or one O atom and one S atom are directly bonded to each other as known for a skilled artisan in the field of organic chemistry.
  • the substituent Y-R2-R1 is therefore particularly preferably selected from the group consisting of
  • Ri is selected from the group consisting of an alkenyl of formula (5-1 ), (5-2), (5-3), (5-4), (5-5), (5-6), (5- 7), (5-8), or (5-9);
  • Ri is selected from the group consisting of an alkenyl of formula (5-1 ), (5-2), (5-3), (5-4), (5-5), (5-6), (5- 7), (5-8), or (5-9);
  • the compounds of formula (I), ( ⁇ ), (I") and ( ⁇ ") comprise a polymerizable group Ri which is a methacryl or an acryl group represented by formula (5-1 ) and (5-2).
  • the invention therefore relates further to compounds of formula (I), ( ⁇ ), (I") and/or (P) as described before or preferably described before wherein Ri is at each occurrence independently an acryl or methacryl group.
  • Examples for compounds of formula (I), ( ⁇ ), (I") and/or (P) are the following compounds O-001 to ⁇ -289, S-001 to S-169 and N-001 to N-172:
  • the compounds of the present application may be synthesized by methods well known to the skilled person. Preferably, all syntheses are carried out under an inert atmosphere using dried solvents.
  • the first type of reaction is a classic aldol-addition with subsequent decarboxylation.
  • the second type of reaction is a Palladium catalyzed Suzuki reaction.
  • the third type of reaction is an ether cleavage in the presence of borontribromide.
  • the fourth type of reaction is a Williamson ether synthesis.
  • the fifth type of reaction is an esterification reaction.
  • the first type of reaction is a classical ring closure via nucleophilic substitution, aldol-addition followed by decarboxylation.
  • a pentyl substituent is introduced via palladium-catalyzed Suzuki reaction.
  • the third type of reaction is an ether cleavage in the presence of borontribromide.
  • the fourth type of reaction is a Williamson ether synthesis followed by an esterification reaction. All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section.
  • the first type of reaction is a Sonogashira reaction followed by a ring closure in the presence of Zinc bromide.
  • an alkyl group on the N atom is introduced via alkyl iodide.
  • the third type of reaction is an ether cleavage in the presence of borontribromide.
  • the fourth type of reaction is a Williamson ether synthesis followed by an esterification reaction.
  • the compounds of formula (I), ( ⁇ ), (I") and/or (P) as described before or preferably described before contain a polymerizable group and are predestinated as monomers for an oligomerization or a polymerization.
  • the invention is therefore further directed to an oligomer or polymer comprising polymerized compounds of formula (I), ( ⁇ ), (I") and/or (P) as described before or preferably described before.
  • polymer generally means a molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass (PAC, 1996, 68, 2291 ).
  • polymer includes homopolymers and co-polymers.
  • oligomer generally means a molecule of intermediate relative molecular mass, the structure of which essentially comprises a small plurality of units derived, actually or conceptually, from molecules of lower relative molecular mass (PAC, 1996, 68, 2291 ).
  • a polymer means a compound having > 30 repeating units
  • an oligomer means a compound with > 1 and ⁇ 30 repeating units.
  • an asterisk (“ * ") denotes a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group.
  • Suitable terminal end groups are known to the skilled artisan and depend on the polymerization method used.
  • the terms "repeating unit” and “monomeric unit” mean the constitutional repeating unit (CRU), which is the smallest constitutional unit the repetition of which constitutes a regular macronnolecule, a regular oligomer molecule, a regular block or a regular chain (PAC, 1996, 68, 2291 ).
  • the molecular weight is given as the number average molecular weight M n or weight average molecular weight Mw, which is determined by gel permeation chromatography (GPC) against polystyrene standards in eluent solvents such as tetrahydrofuran, trichloromethane (TCM, chloroform), chlorobenzene or 1 ,2,4-trichloro- benzene. Unless stated otherwise, tetrahydrofuran is used as solvent.
  • the total number of repeating units n is seen preferably > 30, very preferably > 100, most preferably > 200, and preferably up to 5000, very preferably up to 3000, most preferably up to 2000, including any combination of the
  • the polymers of the present invention include homopolymers, statistical copolymers, random co-polymers, alternating co-polymers and block copolymers, and combinations of the aforementioned.
  • the polymerizable group Ri forms the regioregular, alternated, regiorandom, statistical, block or random homopolymer or co-polymer backbone or is part of the polymer backbone where Ri has a meaning as described or preferably described before.
  • such oligomer or polymer comprises a constitutional unit M° of formulae (5-p-1 ), (5-p-2), (5-p-3)
  • the co-polymer may be an oligomer or polymer comprising one or more polymerized compounds of formula (I), ( ⁇ ), (I") or ( ⁇ ") or a constitutional unit M° of formulae (5-p-1 ), (5-p-2), (5-p-3), which may be the same or different from one another, and one or more constitutional units M 2 , which may be the same or different from one another.
  • Said one or more constitutional units M 2 are chemically different from the units M°.
  • said one or more constitutional units M 2 are derived by polymerization of one or more monomers selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), n-alkyl methacrylates (the n-alkyl groups comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl groups comprising 2-20 C-atoms), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18-hydroxyoctadec
  • alkyl and/or alkoxy groups are at each occurrence independently of each other linear or branched having 1 to 6 C atoms and where the alkenyl group is at each occurrence independently linear having 2 to 4 C atoms.
  • said one or more constitutional units M 2 are derived by polymerization of one or more monomers selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), n-alkyl methacrylates (the n-alkyl groups comprising 2-20 C-atoms), ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16- hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18- hydroxyoctadecyl acrylate
  • said one or more constitutional units M 2 are derived by polymerization of one or more monomers selected from the group consisting of tnalkoxyalkenylsilane, dialkoxyalkylalkenylsilane or a silane of formula (9) and (10),
  • alkyl and/or alkoxy groups are at each occurrence independently of each other linear or branched having 1 to 6 C atoms and where the alkenyl group is at each occurrence independently linear having 2 to 4 C atoms in combination with inventive monomers containing a polymerizable group containing at least one Si atom.
  • the oligomer or polymer according to the invention is a homopolymer, i.e. an oligomer or polymer comprising one or more constitutional unit M° of formulae (5-p-1 ), (5-p-2), (5-p-3), wherein all constitutional units M° are the same.
  • Exemplary polymeric compounds may be selected from the following formulae (P-001 ) to (P-628):
  • a co-polymer according to the invention as described before or preferably described before comprises the one or more constitutional units M° in a molar ratio ml and the one or more constitutional units M 2 in a molar ratio m2, wherein the ratio ml : m2 is at least 0.01 and at most 100.
  • oligomers or polymers according to the invention as described before or preferably described may be cross-linked.
  • the oligomers and polymers of the present invention may be made by any suitable method. It is, however, preferred that the present oligomers and polymers are made by radical polymerization, wherein the polymerization reaction is started by means of a suitable radical polymerization initiator.
  • a suitable radical polymerization initiator is not particularly limited and may be any suitable radical generating compound. Such compounds are well known to the skilled person.
  • Suitable polymerization initiators may be selected from thermal initiators or photoinitiators, i.e. compounds that generate radicals by exposure to heat or irradiation with light of a suitable wavelength. Examples of suitable thermal polymerization initiators may be selected from the groups of compounds comprising one or more peroxide groups, i.e. compounds comprising a group -O-O-, and/or compounds comprising one or more azo groups, i.e. compounds comprising a group -N ⁇ N-
  • Suitable polymerization initiators comprising one or more peroxide groups may, for example, be selected from the groups consisting of t-butyl(peroxy- 2-ethyl-hexanoate), di-(tert-butylcyclohexyl)peroxydicarbonate and benzoyl peroxide.
  • Suitable polymerization initiators comprising one or more azo groups may, for example, be selected from the group consisting of 1 , 1 '- azobis(cyclohexancarbonitrile) and 2,2'azobis(cyclohexanecarbonitrile) (AIBN).
  • a suitable example of a photoinitiator is dimethylaminobenzoate
  • the wavelength required to decompose said photoinitiator is different from the wavelength needed to irradiate the compound of the present application so as to change its optical properties.
  • the radical initiators are used in an amount of at least 0.0001 eq and of at most 0.1 eq of the main monomer.
  • Such radical initiators could be thermal initiators, e.g. azobisisobutyronitrile (AIBN) or photochemical initiators like dimethylaminobenzoate/camphorquinone.
  • the present invention is also directed to a composition
  • a composition comprising at least one compound of formula (I), ( ⁇ ), (I") or ( ⁇ ) as described or preferably described before and/or an oligomer or polymer as described before or preferably described before.
  • a composition comprising at least one compound of formula (I), ( ⁇ ), (I") or ( ⁇ ) as described or preferably described before and an oligomer or polymer as described before is primarily used for the synthesis of block co-polymers with the condition that the oligomer or polymer has at least one reactive group left which may react with the monomers.
  • composition may comprise further different components.
  • further components may, for example, be selected from the group consisting of UV absorbers, antioxidants and cross-linkers.
  • compositions may include or comprise, essentially consist of or consist of the said requisite or optional constituents. All compounds or components which can be used in the compositions are either known and commercially available or can by synthesized by known processes.
  • UV absorber that may be used in the present composition is not particularly limited and can easily be selected from those generally known to the skilled person.
  • suitable UV absorbers are characterized by being unsaturated compounds, preferably compounds comprising one or more selected from group consisting of olefinic groups, aryl groups and heteroaryl groups; these groups may be present in any combination.
  • Suitable UV-absorbers for use in the present composition may, for example, be selected from those comprising a group selected from benzotriazole, benzophenone and triazine.
  • Suitable UV-absorbers are, for example, disclosed in U.S. Pat. Nos. 5,290,892; 5,331 ,073 and 5,693,095.
  • Suitable cross-linkers may be used to impart elastomeric properties to the present composition and the articles produced therewith.
  • any suitable di- or tri-functional monomer may be used as crosslinker.
  • Such monomers are generally well known to the skilled person including at least one compound of formula ( ⁇ ) as described before or preferably described before.
  • Preferred cross-linker may be selected from the following group of compounds
  • Ethylene glycol dimethacrylate (EGDMA) is particularly preferred.
  • Suitable antioxidants are phenyl acrylate derivatives bearing a hindered phenol moiety.
  • a preferred antioxidant is
  • the compounds of formula (I) according to the invention and their oligomers or polymers as described before or preferably described before are particularly well suited for use in optically active devices.
  • the present invention is also directed to articles e.g. blanks which may be transformed into optically active devices comprising at least one compound of formula (I) as described before or preferably described before or at least one oligomer or polymer as described before or preferably described before.
  • Preferred articles are blanks which may be transformed into optically active devices or the optically active devices as such.
  • Preferred optically active devices are ophthalmic devices. Examples of such ophthalmic devices include lenses, keratoprostheses, and cornea inlays or rings. More preferably, said article is a blank which may be transformed into an eye- implant or the eye-implant as such. More preferably, said eye-implant is a lens. Most preferably, such article is a blank which may be transformed into an intraocular lens or the intraocular lens as such, which may, for example, be a posterior chamber intraocular lens or an anterior chamber intraocular lens.
  • a blank of this invention may be produced as a step in the manufacturing process used to create an intraocular lens.
  • a manufacturing process may include the steps of polymer synthesis, polymer sheet casting, blank cutting, optic lathe cutting, optic milling, haptic milling or attachment, polishing, solvent extraction, sterilization and packaging.
  • the present articles according to the invention as described before or preferably described before may be formed by a process comprising the steps of
  • composition comprising at least one compound of formula (I) as defined herein and/or an oligomer or polymer as defined herein; and - subsequently forming the article of said composition.
  • Intraocular lenses in accordance with the present invention are believed to show particularly advantageous properties in that they are flexible enough so as to be rolled or folded and consequently requiring a much smaller incision for them to be inserted into the eye. It is believed that this will allow for improved healing of the eye, particularly in respect to the time for the eye to heal.
  • the type of intraocular lens is not limited in any way. It may, for example, comprise one or more optic and one or more haptic components, wherein the one or more optic components serve as lens and the one or more haptic components are attached to the one or more optic components and hold the one or more optic components in place in the eye.
  • the present intraocular lens may be of a one-piece design or of multi-piece design, depending on whether the one or more optic components and the one or more haptic components are formed from a single piece of material (one- piece design) or are made separately and then combined (multi-piece design).
  • the present intraocular lens is also designed in such a way that it allows to be, for example, rolled up or folded small enough so that it fits through an incision in the eye, said incision being as small as possible, for example, at most 3 mm in length. Additionally, intraocular lenses in accordance with the present invention allow for the non-invasive adjustment of the optical properties, particularly the refractive power, after implantation of the lens into the eye, thus reducing the need for post-surgery vision aids or reducing or totally avoiding follow-up surgery.
  • the present invention is also directed to a process of changing the optical properties of an article as defined or preferably defined herein, said process comprising the steps of
  • said irradiation has a wavelength of at least 250 nm or 300 nm, more preferably of at least 350 nm, even more preferably of at least 400 nm, still even more preferably of at least 450 nm, and most preferably of at least 500 nm.
  • said irradiation has a wavelength of at most 1400 nm or 1300 nm or 1200 nm or 1 100 nm or 1000 nm, more preferably of at most 950 nm or 900 nm, even more preferably of at most 850 nm, still even more preferably of at most 800 nm and most preferably of at most 750 nm. Examples
  • EE is used to denote ethyl acetate.
  • THF is used to denote tetrahydrofuran.
  • Co-polymer-properties can be investigated on blanks, prepared by bulk polymerization of the monomers. Co-monomers, cross-linkers and initiators therefore can be purchased from commercial sources. All chemicals are of highest purity available and can be used as received. Synthesis of precursor materials:
  • This compound is synthesized based on the procedure described in US 2012/308802, preparation example 1 , [0071 ].
  • GSP 1 General remarks & general synthetic procedures (GSP 1) for the reduction of aliphatic diesters or diketones to the corresponding diols:
  • Solid, fine powdered lithiumaluminium hydride (2.0 - 5.0 equiv.) is suspended in dry THF at room temperature.
  • the corresponding diacid- or diester derivative is dissolved in dry THF and the solution is slowly added dropwise to the lithiumaluminium slurry while cooling with an ice bath. After complete addition, the reaction solution is warmed to room temperature and the consumption of the starting material is checked by TLC.
  • Step 3
  • GSP 4 General remarks & general synthetic procedures (GSP 4) for the synthesis of 2-phenyl-benzofurans from hydroxy-benzaldehyde derivatives or dimethyl-thiocarbamic acid 4-formyl-3-hydroxy-phenyl ester derivatives with meth l 2-bromo-2-(4-bromophenyl)acetate:
  • the cooled reaction mixture is diluted with ethyl acetate and HCI solution (2 M). The solution is transferred to a separatory funnel. The organic phase is extracted with HCI solution (2 M) and water and brine. The organic phase is dried over MgS0 4 , filtered and concentrated under reduced pressure. The residue is purified by silica gel column chromatography (heptane/ethyl acetate [5/1 ]) to yield 6-Methoxy-2-(4-pentyl-phenyl)-benzofuran (350 mg, 1 .2 mmol, 66% of theory).
  • the obtained light brown oil is purified using silica gel chromatography (chloroform/methanol; 30/1 ) to afford 2-(2-ethyl-4-pentylphenyl)benzofuran- 6-thiol (400.00 mg, 1 .1 mmol, 53 % of theory).
  • the bromo- functionalized derivatives of the corresponding diols are prepared in advance through reaction of the corresponding diol with HBr in refluxing toluene.
  • the corresponding monomer is dissolved in dry ⁇ , ⁇ -dimethylformamide in a Schlenck-tube with a stirring bar.
  • the solution is degassed performing three times freeze-evacuate-thaw cycles.
  • azoisobutyronitrile AIBN, 0.05 equiv.
  • AIBN azoisobutyronitrile
  • the solution is cooled to room temperature and is then poured dropwise into cold methanol (100 ml methanol / 100 mg monomer) while stirring.
  • the precipitated polymer is collected on a frit or the solution is centrifuged several times to obtain the final polymer material.
  • the cooled reaction mixture is diluted with ethyl acetate and HCI solution (2 M).
  • the solution is transferred to a separatory funnel.
  • the organic phase is extracted with HCI solution (2 M) and water and brine.
  • the organic phase is dried over MgSO 4 , filtered and concentrated under reduced pressure.
  • the residue is purified by silica gel column
  • 6-Methoxy-2-phenyl-benzo[b]thiophene (780.00 mg, 3.25 mmol) is dissolved in Dichloromethane (anhydrous) (20.73 ml, 324.57 mmol) and cooled to 5 °C.
  • Boron tribromide (369.60 ⁇ , 3.89 mmol) is added dropwise to this solution over the course of 10 min, and stirring is continued for 2 h.
  • the reaction mixture is subsequently slowly poured into water, and the organic phase is diluted with ethyl acetate, washed three times with water, dried over MgSO 4 , evaporated in a rotary evaporator. Recrystallization from toluene/heptane (1/10) yielded 2-Phenyl-benzo[b]thiophen-6-ol (657.00 mg, 2.90 mmol, 90 % of theory).
  • R1 means reactant 1
  • R2 means reactant 2
  • [P] means product
  • R1 means reactant 1
  • R2 means reactant 2
  • [P] means product
  • 6-Methoxy-1 -methyl-2-phenylindole (184 mg, 775 ⁇ ) is dissolved in dichloromethane (10 ml) and cooled to 5 °C. Boron tribromide (96.6 ⁇ , 1 .0 mmol) are added dropwise to this solution, and stirring is continued overnight. Water is subsequently slowly added to the mixture, and the organic phase is diluted with ethyl acetate, washed three times with water, dried over MgSO4, evaporated under reduced pressure and filtered through a pad of silica gel with dichloromethane to yield 6-hydroxy-1 -methyl -2- phenylindole (1 17 mg, 524 ⁇ , 68 % of theory).
  • the corresponding aliphatic alcohol is dissolved in dry THF and the solution is cooled with an ice-bath. Triethylamine (4.00 equivs.) is added and the solution is stirred for a few minutes. Then acryloyl chloride or methacryloyl chloride (1 .05 - 2.00 equivs.) is added at ice-bath temperature, while precipitating a colourless solid. The solution is stirred for several hours and is monitored via TLC. Upon completion of the reaction, the suspension is filtrated and washed with THF. The filtrate is evaporated under reduced pressure and purified via column chromatography using cyclohexane / ethyl acetate.
  • the corresponding monomer is dissolved in dry ⁇ , ⁇ -dimethylformamide in a Schlenck-tube with a stirring bar.
  • the solution is degassed performing three times freeze-evacuate-thaw cycles.
  • azoisobutyronitrile AIBN, 0.05 equiv.
  • AIBN azoisobutyronitrile
  • the solution is cooled to room temperature and is then poured dropwise into cold methanol (100 ml methanol / 100 mg monomer) while stirring.
  • the precipitated polymer is collected on a frit or the solution is centrifuged several times to obtain the final polymer material.
  • a composition of MH-indol derivative M-N3 and methyl methacrylate, initiator azobisisobutyronitrile (0.04 eq) and crosslinker ethylene glycol dimethacrylate (0.1 - 0.4 eq) in different ratios is degassed by three freeze- pump-thaw cycles.
  • Two glass plates are coated with a polyethylene sheet and a 0.5 mm thick cell is created between the polyethylene sheets using a silicone rubber gasket.
  • the coated faces of the glass sheets are clipped together using spring clips with a syringe needle being placed between the gasket and the polyethylene sheets.
  • the cavity is then filled with the above formulation through the needle using a gastight syringe. Once the cavity is filled the syringe needle is removed, a final clip is used to seal the mould and the assembly is placed in an oven at 60°C for 24 hours before the oven is ramped to a temperature of 90°C for a period of 3 hours.
  • the moulds are allowed to cool to room temperature before the film is removed from the mould.
  • Example 25 photoinduced refractive index change and glass transition temperature
  • the phase transition temperatures are determined with a TA Instruments Q2000 differential scanning calorimeter during heating in the second heating run with 20 K/min from -100 °C to 200 °C in a hermetic aluminum pans.
  • Irradiations of the blanks are performed with a Coherent Avia 355-7000 UV- Laser.
  • Refractive index change is induced by irradiation at 340 - 365 nm.
  • the refractive indices (n) of the polymer films and blanks at 590 nm are measured on Schmidt+Haensch AR12 before and after irradiation.
  • the following table shows the refractive indices before and after irradiation as well as the change in refractive index (max. ⁇ ).
  • Expected values for the cited polymers are given in the following table:

Abstract

The present invention relates to novel compounds (I) particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.

Description

Hydrophobic compounds for optically active devices
Field of the Invention
The present invention relates to novel compounds, particularly to
compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.
Background of the Invention
Cataract is a general term for an affection of the eye that leads to a loss of vision and in the extreme to blindness by clouding of the normally clear lens of the eye. It is the major cause of blindness in the world, affecting more than 100 million people. Due to the fact that its major cause is age and the population's average age is increasing, it is expected that the number of cataracts will continue to increase substantially in the future.
Effective treatment of cataract is only possible by surgical intervention, whereby the natural lens of the eye is removed through an incision in the cornea and replaced with an artificial lens, often also referred to as
"intraocular lens". In preparation of surgery current state-of-the-art surgical methods employ eye mapping so as to approximate the refractive power best suited to the respective patient.
Even though cataract surgery is one of the most widely used and safest surgical procedures it is not without specific post-surgery problems. It frequently happens that the refractive power of the implanted intraocular lens (IOL) is insufficient for restoring good vision. Such problems may, for example, be caused by changes in eye geometry as consequence of the surgery as well as irregular wound healing and positioning errors that result in the artificial lens not having the optimal optical properties. As a result the patient will still require corrective vision aids, e.g. glasses, to be able to see correctly. In some cases the resulting refractive power of the implanted artificial lens is so far removed from the required refractive power that further surgery will be required. Particularly for aged persons this is not desirable because the body's capability for healing is reduced with increasing age. Furthermore, there is the risk of attracting endophthalmitis, an inflammation of the eye, which can even lead to a complete loss of vision or worse, loss of the eye.
There is therefore a need in the health sector for optically active devices, and particularly for artificial intraocular lenses, that would allow for non- invasive adjustment of refractive power after implantation of the lens, thereby preferably further reducing the need for post-surgery vision aids.
Some developments in this sense have already been made, as for example evidenced by WO 2007/033831 A1 , WO 2009/074520 A2 or US
20100324165 A1 .
WO 2016/200401 A1 describes liquid crystal materials having
photoalignment properties. M. Schraub et al, European Polymer Journal 51 (2014) 21 -27 describes the photochemistry of 3-phenyl-coumarin containing polymethacrylates.
C.H. Krauch et al, Chemische Berichte Jahrg. 99, 1966, 1723 describe photochemical reactions on coumaron.
A. Bouquet et al, Tetrahedron, 1981 , vol. 37, 75 to 81 describe the photochemical behavior of several benzo[b]thiophenes in neutral solutions or in the presence of primary and tertiary amines.
David L. Oldroyd et al, Tetrahedron Letters, 1993, vol. 34, no. 7, 1087-1090 describe photochemical dimerization reactions of N-acylindoles. Poly(methyl methacrylate) (PMMA) intraocular lenses (lOLs) that were coated with Teflon AF®, an amorphous, transparent, and highly
hydrophobic fluorocarbon polymer is known from Jean-Marc Legeais, J Cataract Refract Surg. 1998, 24, 371 -379. Teflon AF® (Dupont de
Nemours) is a poly(tetra-fluoroethylene co-hexafluoro-propyl-2
cydodethoxydifluoroethylene). Constituted entirely of high-energy bonds, it is stable at temperatures up to 260°C and chemically very resistant. The refractive index is 1 .32. It transmits light from 200 to 2000 nm with a constant light absorption below 5%. The contact angle with water is 129 degrees. The surface modification is described using a PMMA IOL (model 808A, Kabi Pharmacia Production B.V.) having an overall diameter of 12.0 mm and optic diameter of 6.5 mm which is coated by immersing the lense in a 5% solution of Teflon AF in a fluorocarbon solvent (CsFis) for 3 seconds and then placing it at a temperature of 37°C to evaporate the solvent. As a result, the surface of the PMMA IOL was completely coated with Teflon AF.
Eun-Ho Sohn et al describe surface properties of poly(methyl methacrylate) (PMMA) films using poly(perfluoromethyl methacrylate)s (PFMMAs) with short perfluorinated side chains. 2,2,2-Trifluoroethyl methacrylate,
1 ,1 ,1 ,3,3,3-hexafluoroisopropyl methacrylate, 2,2,3,3,3-pentafluoropropyl methacrylate, 2,2,3,3,4,4,4-heptafluorobutyl methacrylate were prepared by radical polymerization of the corresponding monomers. Film preparation is reported with PMMA, PFMMA and their blends.
P.L. Beaulieu et al, Journal of Medicinal Chemistry, 2012, 55, 17, 7650- 7666 describes indole derivatives as inhibitors satisfying potency criteria and displaying improved in vitro ADME profiles. However, the compounds disclosed therein suffer from being too stiff and too brittle so that they can't be rolled or folded and are thus not fit to be implanted by state of the art cataract surgical methods, particularly by state of the art micro-incision cataract surgical methods.
Consequently, it is an objective of the present application to provide for novel compounds suitable for ophthalmic devices.
It is also an objective of the present application to provide for compounds, the optical properties of which may be changed, preferably by non-invasive techniques.
It is a further objective of the present application to provide for novel compounds having advantages over currently known compounds, preferably in combination with being suitable for ophthalmic devices.
Advantages such as better flexibility and objectives of the compounds of the present application will be evident to the skilled person from the following detailed description as well as from the examples.
Summary of the Invention
The present inventors have now found that the above objects may be attained either individually or in any combination by the compounds and ophthalmic devices of the present application.
The invention relates to compounds of formula (I)
Figure imgf000005_0001
wherein
X is O, S or NRo, Y is independently of each other O, S or a bond, n is 0 or 1 ,
m is 0 or 1 ,
n+m is 1 or 2,
-[B]- is selected from the group consisting of formula (1 ) to formula (4),
Figure imgf000006_0001
Xi, X2, X3, X4 are each independently of each other CR' or N,
X5 is each independently O, S, C=O or NRo,
ΧΘ, X7 are each independently CR' or N,
R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 8 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms, R' is at each occurrence independently selected from the group consisting of H, F, a linear or branched, non- halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a linear or branched hydroxyalkyl group having 1 to 20 C atoms, a non- halogenated, partially or completely halogenated cycloalkyi group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyi group having 1 to 20 C atoms,
R0 is at each occurrence independently selected from the group consisting of a linear or branched alkyl group having 1 to 10 C atoms or a cycloalkyi group having 3 to 6 C atoms,
R1 is a polymerizable group selected from the group
consisting of
an alkenyl group of formula (5),
Figure imgf000007_0001
wherein
Xio is selected from the group consisting of O, S, C(=O), C(=O)O,
Rs, R9, R10 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non-fluorinated, partially or completely fluorinated alkyl having 1 to 20 C atoms or aryl with 6 to 14 C atoms,
c is 0 or 1 ; and
trialkoxysilyl groups or dialkoxyalkylsilyl groups where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms; and
silyl groups of formula (6), (7) or (8),
Figure imgf000008_0001
where alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk "*" denotes at each occurrence independently of each other a linkage to the linker [-R2- Y]n and/or [Y-R2]m,
-R2- is -(C(R)2)o- wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)^ (Xio)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,
or
a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,
o is selected from the group consisting of 1 to 20,
Xs, X9, X10 are at each occurrence independently O, S or NRo, s, t are at each occurrence independently 0 or 1 ,
p, q are at each occurrence independently selected from the group consisting of 1 to 10, r, u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)^(Xio)t-
(C(R)2)u-, is up to 20 atoms,
are at each occurrence independently R',
is R' in case m is 0 and
is Ri in case m is 1 .
The invention relates further to compositions comprising at least one of said compounds of formula (I) and/or their polymerized forms as well as to articles comprising at least one polymerized compound of formula (I).
In addition, the invention relates to a process for forming such article, said process comprising the steps of
- providing a composition comprising at least one compound of formula (I) and/or an oligomer or polymer as described before;
subsequently forming the article of said composition.
Furthermore, the invention relates to a process for changing the optical properties of an article according to the invention, said process comprising the steps of
- providing an article comprising at least one polymerized compound of formula (I), and
- subsequently exposing said article to irradiation having a wavelength of at least 200 nm and at most 1500 nm.
Detailed Description of the Invention
The compounds of formula (I) and all preferred embodiments of compounds of formula (I) according to the present invention include all stereoisomers or racemic mixtures. The compounds of formula (I) provide several advantages over prior art materials
- by adding a linker -[B]- to the benzo[b]furan, benzo[b]thiophene or benzo[b]pyrrol ring system their melting point or glass transition
temperature will decrease and π stacking will be disturbed, thus becoming better foldable or bendable,
- by incorporating at least one F atom or at least one partially or fully fluorinated alkyl group they develop a non-sticky behavior with
characteristic surfactant properties; through their non-stickiness the compounds show a smoother behavior in a physiological environment.
In comparison to known coumarin-type photoactive chromophores, compounds according to the invention are more stable toward UV- irradiation due to lower absorption range. Furthermore the chemical and hydrolytical stability is higher and given due to their intrinsic chemical nature e.g. due to lack of positions prone to nucleophilic attacks, like sp2 centers and the absence of cyclic lactone structure motifs, compared to coumarin-type photoactive chromophores.
Polymers that are foldable at room temperature generally exhibit glass transition temperatures (Tg) lower than room temperature (ca. 21 °C). They are easily deformable at this temperature without causing physical damage to the polymer, for example by inducing creep, stress or fissures. For polymers in intraocular lenses, Tgs of less than or equal to 15 °C are preferred.
Polymers used in intraocular lens manufacturing have preferably relative high refractive indices, which enable the fabrication of thinner intraocular lenses. Preferably, the polymer used in an intraocular lens will have a refractive index greater than about 1 .5 and presently most preferably greater than about 1 .55. In case an asterisk ("*") is used within the description of the present invention, it denotes a linkage to an adjacent unit or group or, in case of a polymer, to an adjacent repeating unit or any other group. A linear or branched alkyi group having 1 to 10 C atoms denotes an alkyi group having 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, for example methyl, ethyl, /'so-propyl, n-propyl, /'so-butyl, n-butyl, terf-butyl, n-pentyl, 1 -, 2- or 3-methylbutyl, 1 ,1 -, 1 ,2- or 2,2-dimethylpropyl, 1 -ethylpropyl, n-hexyl, n- heptyl, n-octyl, ethylhexyl, n-nonyl or n-decyl. A linear or branched alkyi group having 1 to 20 C atoms include all examples for a linear or branched alkyi group having 1 to 10 C atoms including any alkyi group having 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 and 20 C atoms such as n-undecyl, n-dodecyl, n- tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n-nonadecyl and n-eicosyl.
The term partially halogenated alkyi group denotes that at least one H atom of the alkyi group is replaced by F, CI, Br or I. Preferably, the alkyi group is partially fluorinated meaning that at least one H atom of the alkyi group is replaced by F.
The term completely halogenated alkyi group denotes that all H atoms of the alkyi group are replaced by F, CI, Br and/or I. Preferably, the alkyi group is completely fluorinated meaning that all H atoms of the alkyi group are replaced by F. A preferred completely fluorinated alkyi group is
trifluoromethyl.
The term halogenated or preferably fluorinated corresponds additionally to other groups such as a halogenated cycloalkyi group, a halogenated alkoxy group or a halogenated thioalkyl group. A cycloalkyl group having 3 to 6 C atoms includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl which may be partially or completely
halogenated or fluorinated as explained before. A linear or branched alkoxy group having 1 to 20 C atoms denotes an
O-alkyl group having 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example methoxy, ethoxy, /so-propoxy, n- propoxy, /'so-butoxy, n-butoxy, terf-butoxy, n-pentyloxy, 1 -, 2- or
3-methylbutyloxy, 1 ,1 -, 1 ,2- or 2,2-dimethylpropoxy, 1 -ethyl propoxy, n- hexyloxy, n-heptyloxy, n-octyloxy, ethylhexyloxy, n-nonyloxy, n-decyloxy, n- undecyloxy, n-dodecyloxy, n-tridecyloxy, n-tetradecyloxy, n-pentadecyloxy, n-hexadecyloxy, n-heptadecyloxy, n-octadecyloxy, n-nonadecyloxy and n- eicosyloxy which may be partially or completely halogenated or preferably may be partially or completely fluorinated. A preferred completely
fluorinated alkoxy group is trifluoromethoxy.
A linear or branched thioalkyl group having 1 to 20 C atoms denotes a S-alkyl group having 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example thiomethyl, 1 -thioethyl, 1 -thio-/so-propyl, 1 -thio-n-propoyl, 1 -thio-/so-butyl, 1 -thio-n-butyl, 1 -th io-ierf-butyl , 1 -thio-n- pentyl, 1 -thio-1 -, -2- or -3-methylbutyl, 1 -thio-1 ,1 -, -1 ,2- or -2,2- di methyl propyl, 1 -th io- 1 -ethyl propyl , 1 -thio-n-hexyl, 1 -thio-n-heptyl, 1 -thio-n- octyl, 1 -thio-ethylhexyl, 1 -thio-n-nonyl, 1 -thio-n-decyl, 1 -thio-n-undecyl, 1 - thio-n-dodecyl, 1 -thio-n-tridecyl, 1 -thio-n-tetradecyl, 1 -thio-n-pentadecyl, 1 - thio-n-hexadecyl, 1 -thio-n-heptadecyl, 1 -thio-n-octadecyl, 1 -thio-n- nonadecyl and 1 -thio-n-eicosyl which may be partially or completely halogenated or preferably may be partially or completely fluorinated. A preferred completely fluorinated thioether group is trifluoromethyl thioether. Preferred alkyl and alkoxy radicals have 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A polymenzable group is a group which can be subject to or can undergo polymerization thus forming an oligomer or a polymer.
Polymerization is the process of taking individual monomers and chaining them together to make longer units. These longer units are called polymers. The compounds of formula (I) as described before and preferably described below are suitable monomers.
Within the gist of the invention, the polymerizable group Ri once
oligomerized or polymerized thus forms or is part of the backbone of the oligomer or polymer comprising polymerized compounds of formula (I). Suitable polymerizable groups contain at least one double bond or at least one triple bond thus forming polymers where the linking is formed via carbon-carbon bonds. Alternatively, a suitable polymerizable group may contain silicon thus forming polysiloxanes or polysilazanes.
The suitable polymerizable groups are selected from the group consisting of
an alkenyl group of formula (5),
Figure imgf000013_0001
wherein
Xio is selected from the group consisting of O, S, C(=O), C(=O)O,
Rs, R9, R10 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non- fluorinated, partially or completely fluorinated alkyl having 1 to 20 C atoms or aryl with 6 to 14 C atoms,
c is O or l ; trial koxysilyl groups or dialkoxyalkylsilyl groups where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms; and
silyl groups of formula (6), (7) or (8),
Figure imgf000014_0001
where alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk "*" denotes at each occurrence independently of each other a linkage to the linker [-R2- Y]N and/or [Y-R2-]m as described before or preferably described before. A preferred polymerizable group is selected from the group consisting of trimethoxysilyl, triethoxysilyl, diethoxymethylsilyl and the alkenyl group of formula (5) as described before and preferably described below.
Aryl with 6 to 14 C atoms is an aryl group preferably selected from the group consisting of phenyl, naphthyl or anthryl, particularly preferably phenyl.
The linker -[B]- is selected from the group of formulae (1 ) to (4), wherein Xi, X2, X3, X4 are each independently of each other CR' or N, X5 is each independently O, S, C=O or NRo and ΧΘ and X7 are each independently CR' or N, wherein R' and Ro have a meaning as described before or preferably described below. Preferred examples for the linker -[B]- are therefore selected from the group of formulae (B-1 ) to (B-34),
Figure imgf000015_0001
Figure imgf000016_0001
wherein R' and Ro have a meaning as described before or preferably described below. Compounds of formula (I) as described before are preferred where the linker -[B]- corresponds to formula (1 ) or (2) and Xi, X2, X3 and X4 have a meaning as described before. Therefore, compounds of formula (I) are preferred where the linker -[B]- corresponds to formulae (B-1 ) to (B-19).
The invention therefore relates additionally to compounds of formula (I) as described before wherein -[B]- corresponds to formula (1 ) and (2) and Xi, X2, X3 and X4 have a meaning as described before.
Compounds of formula (I) as described before are particularly preferred where the linker -[B]- corresponds to formula (1 ) or (2) and Xi, X3 and X4 are CR' and R' has at each occurrence independently a meaning as described before or preferably described below. Therefore, compounds of formula (I) are particularly preferred where the linker -[B]- corresponds to formulae (B-1 ), (B-3), (B-8) or (B-9).
The invention therefore relates additionally to compounds of formula (I) as described before wherein -[B]- corresponds to formula (1 ) and (2) and Xi, X3 and X4 are CR' and R' has at each occurrence independently a meaning as described before or preferably described below.
Compounds of formula (I) as described or preferably described before are especially preferred where the linker -[B]- corresponds to formula (1 ) or (2) and X2 is CR' and R' has at each occurrence independently a meaning as described before or preferably described below. Therefore, compounds of formula (I) are especially preferred where the linker -[B]- corresponds to formulae (B-1 ), (B-2), (B-6), (B-7), (B-8), (B-10) or (B-1 1 ). Additionally, compounds of formula (I) having a linker -[B]- which corresponds to formula (B-1 ) or (B-8) are very particularly preferred and R' has at each occurrence independently a meaning as described before or preferably described below. Within this very particular preferred compounds of formula (I), it is preferred to select the linker of formula (B-1 ) and R' has at each occurrence independently a meaning as described before or preferably described below. The invention therefore relates additionally to compounds of formula (I) as described or preferably described before wherein -[B]- corresponds to formula (1 ) and (2) and X2 is CR' and R' has at each occurrence
independently a meaning as described before or preferably described below.
R' is at each occurrence independently selected from the group consisting of H, F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a linear or branched hydroxyalkyi group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyi group having 1 to 20 C atoms. It is preferred that at least one R' in -[B]- as described before or preferably described before is different from H and is selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non- halogenated, a linear or branched hydroxyalkyi group having 1 to 20 C atoms, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyi group having 1 to 20 C atoms. It is particularly preferred that at least two R' are different from H and are independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a linear or branched hydroxyalkyi group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms.
With regard to said substituent R', R' is at each occurrence independently preferably selected from the group consisting of H, F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.
It is preferred that at least one R' in -[B]- as described before or preferably described before is different from H and is selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.
It is particularly preferred that at least two R' are different from H and are independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.
R' is at each occurrence independently particularly preferably selected from the group consisting of H, F, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n- hexyl, n-heptyl, n-octyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, methoxy, ethoxy, propoxy, trifluoromethoxy and pentafluoroethoxy.
R' is at each occurrence independently very particularly preferably selected from the group consisting of H, F, ethyl, n-pentyl, trifluoromethyl, methoxy, and trifluoromethoxy. Therefore, the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (1 ) to (4) and wherein at least one R' within Xi, X2, X3. X4, ΧΘ or X7 is not H. Therefore, the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1 ) to (B-29) or (B- 31 ) to (B-34) or to preferred linkers as described before, wherein at least one R' is not H and Ro has a meaning as described before or preferably described below.
The substituent R' within Xi or X3 in formula (1 ) is particularly preferred not H.
The substituent R' within X7 in formula (3) is particularly preferred not H. As described before, the substituents R3, R4, R5 and R6 are at each occurrence independently R' where R' has a meaning or a preferred or particularly preferred meaning as described before.
R5 is preferably H or F. R5 is particularly preferably H. As described before, the substituent R7 corresponds to R' in case m is 0 wherein R' has a meaning or a preferred or particularly preferred meaning as described before. Preferably, R7 corresponds to R' which is not H in case m is 0. In all cases when R' is preferably not H, it is selected from the preferred group consisting of F, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n- heptyl, n-octyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, methoxy, ethoxy, propoxy, trifluoromethoxy and pentafluoroethoxy or from the particular preferred group consisting of F, ethyl, n-pentyl,
trifluoromethyl, methoxy and trifluoromethoxy. Therefore, the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (1 ) to (4) and wherein at least one R' within Xi, X2, X3. X4, ΧΘ or X7 is not H and R7 is not H in case m is 0.
Therefore, the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1 ) to (B-29) or (B- 31 ) to (B-34) or to preferred linkers as described before, wherein at least one R' is not H and R7 is not H in case m is 0 and Ro has a meaning as described before or as preferably described below.
As described before, the substituent R7 corresponds to Ri in case m is 1 wherein Ri has a meaning or a preferred meaning as described before or further below. Compounds of formula (I) in which m is 1 are preferred having a linker -[B]- selected from the group consisting of formula (1 ) to (4) wherein at least one substituent R' within Xi, X2, X3, X4, ΧΘ or X7 is not H and in which at least one substituent R3, R4 or R6 is not H.
Therefore, the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (1 ) to (4) and wherein at least one R' within Xi, X2, X3. X4, ΧΘ or X7 is not H, in which at least one substituent R3, R4 or R6 is not H and R7 corresponds to Ri in case m is 1 .
Therefore, the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1 ) to (B-29) or (B- 31 ) to (B-34) or to preferred linkers as described before, wherein at least one R' is not H, in which at least one substituent R3, R4 or R6 is not H and R7 corresponds to Ri in case m is 1 wherein Ro and Ri has a meaning as described before or further below.
Compounds of formula (I) with linkers -[B]- as defined before or preferably defined before with the described or preferred substitution pattern on the linker -[B]- and its substituents R3, R4, R5 and R6 as described before or preferably described before are based on a benzo[b]furan ring system in case X is O. Compounds of formula (I) with linkers -[B]- as defined before or preferably defined before with the described or preferred substitution pattern on the linker -[B]- and its substituents R3, R4, R5 and R6 as described before or preferably described before are based on a benzo[b]thiophene ring system in case X is S.
Compounds of formula (I) with linkers -[B]- as defined before or preferably defined before with the described or preferred substitution pattern on the linker -[B]- and its substituents R3, R4, R5 and R6 as described before or preferably described before are based on a benzo[b]pyrrol ring system in case X is NRo and Ro is independently selected from the group consisting of a linear or branched alkyl group having 1 to 10 C atoms or a cycloalkyl group having 3 to 6 C atoms.
Ro is at each occurrence independently preferably methyl, ethyl, /'so-propyl, 2-methyl-propyl, n-butyl, n-pentyl, 4-methyl-pentyl or cyclopropyl.
In case X is NRo, Ro is particularly preferably ethyl, /'so-propyl, 2-methyl- propyl, n-pentyl or 4-methyl-pentyl. In case X5 is NRo, Ro is particularly preferably methyl or n-butyl.
In case Xs, X9 or X10 is NRo, Ro is particularly preferably methyl.
Compounds of formula (I) with linkers and substituents as described before or preferably described before or below are preferred when X is O or S. Compounds of formula (I) with linkers and substituents as described before or preferably described before or below are particularly preferred when X is O. In one preferred embodiment of the invention, the compounds of formula (I) as described before or preferably described before contain one
polymerizable group Ri . This is the case for compounds of formula (I) in which n is 1 or m is 1 and the sum of n and m is 1 . Such compounds can be preferably used as monomers for the preparation of a blank which may be transformed to an ophthalmic device such as an eye-implant or specifically an intraocular lens or to the ophthalmic device as such as described before.
The invention is therefore additionally directed to compounds of formula (I) wherein n is 1 and m is 0 which can preferably be described according to formula (l')
Figure imgf000023_0001
wherein Ri, -R2-, Y, R3, R4, R5, R6, X, -[B]- and R7 have a meaning as described before or preferably described before or below.
The invention is therefore additionally directed to compounds of formula (I) wherein n is 0 and m is 1 which can preferably be described according to formula (I")
Figure imgf000024_0001
wherein Ri, -R2-, Y, R3, R4, R5, R6, X, -[B]- and R7 have a meaning as described before or preferably described before or below.
In another preferred embodiment of the invention, the compounds of formula (I) as described before or preferably described before contain two polymerizable groups Ri . This is the case for compounds of formula (I) in which n is 1 and m is 1 and the sum of n and m is 2. Such compounds can be preferably used as cross-linking agent for the preparation of a blank which may be transformed to an ophthalmic device such as an eye-implant or specifically an intraocular lens or to the ophthalmic device as such as described before.
The invention is therefore additionally directed to compounds of formula (I) wherein n is 1 and m is 1 which can preferably be described according to formula (I'"
Figure imgf000024_0002
wherein Ri, -R2-, Y, R3, R4, R5, R6, X, -[B]- and R7 have a meaning as described before or preferably described before or below.
Compounds of formula (I), (Γ), (I") and (Γ) with linkers -[B]- and
substituents as described before or preferably described before have a polymerizable group as described before or preferably described before or below and have at least one linking element Y-R2-.
Y is at each occurrence independently O, S or a bond.
The linking element -R2- is selected from the group consisting of -(C(R)2)o- wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms, -(C(R)2)P-X8-(C(R)2)q-(X9)s- (C(R)2)r-(Xio)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and o is selected from the group consisting of 1 to 20, Xe, ΧΘ and X10 are at each occurrence O, S or NRo, s and t are at each occurrence independently 0 or 1 , p and q are at each occurrence independently selected from the group consisting of 1 to 10, r and u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for -(C(R)2)P-X8-(C(R)2)q-(X9)s- (C(R)2)^(Xio)t-(C(R)2)u-, is up to 20 C atoms. Preferably, the linking element -R2- is selected from the group consisting of -(C(R)2)o- wherein at least two R are F, -(C(R)2)p-X8-(C(R)2)q-(X9)s- (C(R)2)r-(Xio)t-(C(R)2)u-, wherein at least two R are F and a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and o, Xe, X9, X10, s, t, p, q, r and u have a meaning as described or preferably described before or below.
R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 8 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms. R is preferably at each occurrence independently selected from the group consisting of H, F, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, isobutyl, ethylhexyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 2,2,3,3,3- pentafluoropropyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl and nonafluorobutyl. R is particularly preferably at each occurrence
independently H, F, methyl, 2,2,2-trifluoroethyl or trifluoromethyl.
Preferably, o is selected from the group consisting of 3 to 12, particularly preferably 8 to 12.
Preferably, s is 1 .
Preferably t is 0 or 1 .
Preferably, Xs, X9 and X10 are O.
Preferably, p and u are each independently 1 , 3, 3, 4, 5 or 6, particularly preferably 1 or 2.
Preferably, q and r are each independently 1 , 2 or 3, particularly preferably 1 .
Suitable examples for -R2- are
-(CF2HCH2)-, -(CH2HCF2)-, -(CH2)-(CF2)-(CH2)-, -(CH2)-(CF2)-(CH2)2-, - (CH2)-(CF2)-(CH2)3-, -(CH2)-(CF2)-(CH2)4-, -(CH2)-(CF2)-(CH2)5-, -(CH2)- (CF2)-(CH2)6-, -(CH2)-(CF2)-(CH2)7-, -(CH2)-(CF2)-(CH2)8-, -(CH2)-(CF2)- (CH2)9-, -(CH2)-(CF2)-(CH2)io-, -(CH2)2-(CF2)-(CH2)-, -(CH2)3-(CF2)-(CH2)-, - (CH2)4-(CF2)-(CH2)-, -(CH2)5-(CF2)-(CH2)-, -(CH2)6-(CF2)-(CH2)-, -(CH2)7- (CF2)-(CH2)-, -(CH2)8-(CF2)-(CH2)-, -(CH2)9-(CF2)-(CH2)-, -(CH2)io-(CF2)- (CH2)-, -(CH2)2-(CF2)-(CH2)2-, -(CH2)3-(CF2)-(CH2)3-, -(CH2)4-(CF2)-(CH2)4- , -(CH2)5-(CF2)-(CH2)5-, -(CH2)2-(CF2)-(CH2)-,-(CH2)2-(CF2)-(CH2)3-, -(CH2)2- (CF2)-(CH2)4-, -(CH2)2-(CF2)-(CH2)5-, -(CH2)2-(CF2)-(CH2)6-, -(CH2)2-(CF2)- (CH2)7-, -(CH2)2-(CF2)-(CH2)8-, -(CH2)2-(CF2)-(CH2)9-, -(CH2)3-(CF2)-(CH2)-, -(CH2)3-(CF2)-(CH2)2-, -(CH2)3-(CF2)-(CH2)4-, -(CH2)3-(CF2)-(CH2)5-, -(CH2)3- (CF2)-(CH2)6-, -(CH2)3-(CF2)-(CH2)7-, -(CH2)3-(CF2)-(CH2)8-, -(CH2)4-(CF2)- (CH2)-, -(CH2)4-(CF2)-(CH2)2-, -(CH2)4-(CF2)-(CH2)3-, -(CH2)4-(CF2)-(CH2)5-, -(CH2)4-(CF2)-(CH2)6-, -(CH2)4-(CF2)-(CH2)7-, -(CH2)5-(CF2)-(CH2)-, -(CH2)5- (CF2)-(CH2)2-, -(CH2)5-(CF2)-(CH2)3-, -(CH2)5-(CF2)-(CH2)4-, -(CH2)5-(CF2)- (CH2)6-, -(CH2)6-(CF2)-(CH2)-, -(CH2)6-(CF2)-(CH2)2-, -(CH2)6-(CF2)-(CH2)3-, -(CH2)6-(CF2)-(CH2)4-, -(CH2)6-(CF2)-(CH2)5-,
-(CFH)-(CH2)-, -(CH2)-(CFH)-, -(CH2)-(CFH)-(CH2)-, -(CH2)-(CFH)-(CH2)2-, (CH2)-(CFH)-(CH2)3-, -(CH2)-(CFH)-(CH2)4-, -(CH2)-(CFH)-(CH2)5-, -(CH2)- (CFH)-(CH2)6-, -(CH2)-(CFH)-(CH2)7-, -(CH2)-(CFH)-(CH2)8-, -(CH2)-(CFH)- (CH2)9-, -(CH2)-(CFH)-(CH2)io-, -(CH2)2-(CFH)-(CH2)-, -(CH2)3-(CFH)-(CH2) , -(CH2)4-(CFH)-(CH2)-, -(CH2)5-(CFH)-(CH2)-, -(CH2)6-(CFH)-(CH2)-, - (CH2)7-(CFH)-(CH2)-, -(CH2)8-(CFH)-(CH2)-, -(CH2)9-(CFH)-(CH2)-, -(CH2)io
(CFH)-(CH2)-, -(CH2)2-| .CFHHCH^-, -(CH2)3-(CFH)-(CH2)3-, -(CH2)4-
(CFH)-(CH2)4-, -(CH2)5 -(CFH)-(CH2)5- -(CH2)2-(CFH)-(CH2)-, -(CH2)2-
(CFH)-(CH2)3-, -(CH2)2 -(CFH)-(CH2)4- -(CH2)2-(CFH)-(CH2)5- , -(CH2)2-
(CFH)-(CH2)6-, -(CH2)2 -(CFH)-(CH2)7- -(CH2)2-(CFH)-(CH2)8- , -(CH2)2-
(CFH)-(CH2)9-, -(CH2)3 -(CFH)-(CH2)-, -(CH2)3-(CFH)-(CH2)2-, -(CH2)3-
(CFH)-(CH2)4-, -(CH2)3 -(CFH)-(CH2)5- -(CH2)3-(CFH)-(CH2)6- , -(CH2)3-
(CFH)-(CH2)7-, -(CH2)3 -(CFH)-(CH2)8- -(CH2)4-(CFH)-(CH2)-, -(CH2)4-
(CFH)-(CH2)2-, -(CH2)4 -(CFH)-(CH2)3- -(CH2)4-(CFH)-(CH2)5- , -(CH2)4-
(CFH)-(CH2)6-, -(CH2)4 -(CFH)-(CH2)7- -(CH2)5-(CFH)-(CH2)-, -(CH2)5-
(CFH)-(CH2)2-, -(CH2)5 -(CFH)-(CH2)3- -(CH2)5-(CFH)-(CH2)4- , -(CH2)5-
(CFH)-(CH2)6-, -(CH2)6 -(CFH)-(CH2)-, -(CH2)6-(CFH)-(CH2)2-, -(CH2)6-
(CFH)-(CH2)3-, -(CH2)6 -(CFH)-(CH2)4- -(CH2)6-(CFH)-(CH2)5-
-(CF2)2-(CH2)-, -(CH2)-(CF2)2-, -(CH2)-(CF2)2-(CH2)-, -(CH2)-(CF2)2-(CH2)2-, (CH2)-(CF2)2-(CH2)3-, -(CH2)-(CF2)2-(CH2)4-, -(CH2)-(CF2)2-(CH2)5-, -(CH2)- (CF2)2-(CH2)6-, -(CH2)-(CF2)2-(CH2)7-, -(CH2)-(CF2)2-(CH2)8-, -(CH2)-(CF2)2- (CH2)9-, -(CH2)2-(CF2)2-(CH2)-, -(CH2)3-(CF2)2-(CH2)-, -(CH2)4-(CF2)2-(CH2)- -(CH2)5-(CF2)2-(CH2)-, -(CH2)6-(CF2)2-(CH2)-, -(CH2)7-(CF2)2-(CH2)-, -(CH2)8 (CF2)2-(CH2)-, -(CH2)9-(CF2)2-(CH2)-, -(CH2)2-(CF2)2-(CH2)2-, -(CH2)3-(CF2)2 (CH2)3-, -(CH2)4-(CF2)2-(CH2)4-, -(CH2)5-(CF2)2-(CH2)5-, -(CH2)2-(CF2)2- (CH2)-,-(CH2)2-(CF2)2-(CH2)3-, -(CH2)2-(CF2)2-(CH2)4-, -(CH2)2-(CF2)2-(CH2)i , -(CH2)2-(CF2)2-(CH2)6-, -(CH2)2-(CF2)2-(CH2)7-, -(CH2)2-(CF2)2-(CH2)8-, - (CH2)3-(CF2)2-(CH2)-, -(CH2)3-(CF2)2-(CH2)2-, -(CH2)3-(CF2)2-(CH2)4-, - (CH2)3-(CF2)2-(CH2)5-, -(CH2)3-(CF2)2-(CH2)6-, -(CH2)3-(CF2)2-(CH2)7-, - (CH2)4-(CF2)2-(CH2)-, -(CH2)4-(CF2)2-(CH2)2-, -(CH2)4-(CF2)2-(CH2)3-, - (CH2)4-(CF2)2-(CH2)5-, -(CH2)4-(CF2)2-(CH2)6-, -(CH2)5-(CF2)2-(CH2)-, - (CH2)5-(CF2)2-(CH2)2-, -(CH2)5-(CF2)2-(CH2)3-, -(CH2)5-(CF2)2-(CH2)4-, - (CH2)6-(CF2)2-(CH2)-, -(CH2)6-(CF2)2-(CH2)2-, -(CH2)6-(CF2)2-(CH2)3-, - (CH2)6-(CF2)2-(CH2)4-,
-(CFH)2-(CH2)-, -(CH2)-(CFH)2-, -(CH2)-(CFH)2-(CH2)-, -(CH2)-(CFH)2- (CH2)2-, -(CH2)-(CFH)2-(CH2)3-, -(CH2)-(CFH)2-(CH2)4-, -(CH2)-(CFH)2- (CH2)5-, -(CH2)-(CFH)2-(CH2)6-, -(CH2)-(CFH)2-(CH2)7-, -(CH2)-(CFH)2- (CH2)8-, -(CH2)-(CFH)2-(CH2)9-, -(CH2)2-(CFH)2-(CH2)-, -(CH2)3-(CFH)2- (CH2)-, -(CH2)4-(CFH)2-(CH2)-, -(CH2)5-(CFH)2-(CH2)-, -(CH2)6-(CFH)2- (CH2)-, -(CH2)7-(CFH)2-(CH2)-, -(CH2)8-(CFH)2-(CH2)-, -(CH2)9-(CFH)2- (CH2)-, -(CH2)2-(CFH)2-(CH2)2-, -(CH2)3-(CFH)2-(CH2)3-, -(CH2)4-(CFH)2- (CH2)4-, -(CH2)5-(CFH)2-(CH2)5-, -(CH2)2-(CFH)2-(CH2)-r(CH2)2-(CFH)2- (CH2)3-, -(CH2)2-(CFH)2-(CH2)4-, -(CH2)2-(CFH)2-(CH2)5-, -(CH2)2-(CFH)2- (CH2)6-, -(CH2)2-(CFH)2-(CH2)7-, -(CH2)2-(CFH)2-(CH2)8-, -(CH2)3-(CFH)2- (CH2)-, -(CH2)3-(CFH)2-(CH2)2-, -(CH2)3-(CFH)2-(CH2)4-, -(CH2)3-(CFH)2- (CH2)5-, -(CH2)3-(CFH)2-(CH2)6-, -(CH2)3-(CFH)2-(CH2)7-, -(CH2)4-(CFH)2- (CH2)-, -(CH2)4-(CFH)2-(CH2)2-, -(CH2)4-(CFH)2-(CH2)3-, -(CH2)4-(CFH)2- (CH2)5-, -(CH2)4-(CFH)2-(CH2)6-, -(CH2)5-(CFH)2-(CH2)-, -(CH2)5-(CFH)2- (CH2)2-, -(CH2)5-(CFH)2-(CH2)3-, -(CH2)5-(CFH)2-(CH2)4-, -(CH2)6-(CFH)2- (CH2)-, -(CH2)6-(CFH)2-(CH2)2-, -(CH2)6-(CFH)2-(CH2)3-, -(CH2)6-(CFH)2- (CH2)4-,
-(CF2)3-(CH2)-, -(CH2)-(CF2)3-, -(CH2)-(CF2)3-(CH2)-, -(CH2)-(CF2)3-(CH2)2-, - (CH2)-(CF2)3-(CH2)3-, -(CH2)-(CF2)3-(CH2)4-, -(CH2)-(CF2)3-(CH2)5-, -(CH2)- (CF2)3-(CH2)6-, -(CH2)-(CF2)3-(CH2)7-, -(CH2)-(CF2)3-(CH2)8-, -(CH2)2-(CF2)3- (CH2)-, -(CH2)3-(CF2)3-(CH2)-, -(CH2)4-(CF2)3-(CH2)-, -(CH2)5-(CF2)3-(CH2)-, - (CH2)6-(CF2)3-(CH2)-, -(CH2)7-(CF2)3-(CH2)-, -(CH2)8-(CF2)3-(CH2)-, -(CH2)2- (CF2)3-(CH2)2-, -(CH2)3-(CF2)3-(CH2)3-, -(CH2)4-(CF2)3-(CH2)4-, -(CH2)2-(CF2) (CH2)-,-(CH2)2-(CF2)3-(CH2)3-, -(CH2)2-(CF2)3-(CH2)4-, -(CH2)2-(CF2)3-(CH2)5- -(CH2)2-(CF2)3-(CH2)6-, -(CH2)2-(CF2)3-(CH2)7-, -(CH2)3-(CF2)3-(CH2)-, -(CH2) (CF2)3-(CH2)2-, -(CH2)3-(CF2)3-(CH2)4-, -(CH2)3-(CF2)3-(CH2)5-, -(CH2)3-(CF2) (CH2)6-, -(CH2)4-(CF2)3-(CH2)-, -(CH2)4-(CF2)3-(CH2)2-, -(CH2)4-(CF2)3-(CH2)3 -(CH2)4-(CF2)3-(CH2)5-, -(CH2)5-(CF2)3-(CH2)-, -(CH2)5-(CF2)3-(CH2)2-, -(CH2)5- (CF2)3-(CH2)3-, -(CH2)5-(CF2)3-(CH2)4-, (CH2)6-(CF2)3-(CH2)-, -(CH2)6-(CF2)3- (CH2)2-, -(CH2)6-(CF2)3-(CH2)3-,
-(CF2)4-(CH2)-, -(CH2)-(CF2)4-, -(CH2)-(CF2)4-(CH2)-, -(CH2)-(CF2)4-(CH2)2-, - (CH2)-(CF2)4-(CH2)3-, -(CH2)-(CF2)4-(CH2)4-, -(CH2)-(CF2)4-(CH2)5-, -(CH2)- (CF2)4-(CH2)6-, -(CH2)-(CF2)4-(CH2)7-, -(CH2)-(CF2)4-(CH2)8-, -(CH2)-(CF2)4- (CH2)9-, -(CH2)-(CF2)4-(CH2)io-, -(CH2)2-(CF2)4-(CH2)-, -(CH2)3-(CF2)4-(CH2)- , -(CH2)4-(CF2)4-(CH2)-, -(CH2)5-(CF2)4-(CH2)-, -(CH2)6-(CF2)4-(CH2)-, - (CH2)7-(CF2)4-(CH2)-, -(CH2)2-(CF2)4-(CH2)2-, -(CH2)3-(CF2)4-(CH2)3-, - (CH2)4-(CF2)4-(CH2)4-, -(CH2)5-(CF2)4-(CH2)5-, -(CH2)2-(CF2)4-(CH2)3-, - (CH2)2-(CF2)4-(CH2)4-, -(CH2)2-(CF2)4-(CH2)5-, -(CH2)2-(CF2)4-(CH2)6-, - (CH2)3-(CF2)4-(CH2)2-, -(CH2)3-(CF2)4-(CH2)4-, -(CH2)4-(CF2)4-(CH2)2-, - (CH2)4-(CF2)4-(CH2)3-, -(CH2)5-(CF2)4-(CH2)2-, -(CH2)5-(CF2)4-(CH2)3-, - (CH2)6-(CF2)4-(CH2)2-,
-(CF2)5-(CH2)-, -(CH2)-(CF2)5-, -(CH2)-(CF2)5-(CH2)-, -(CH2)-(CF2)5-(CH2)2-, - (CH2)-(CF2)5-(CH2)3-, -(CH2)-(CF2)5-(CH2)4-, -(CH2)-(CF2)5-(CH2)5-, -(CH2)- (CF2)5-(CH2)6-, -(CH2)2-(CF2)5-(CH2)-, -(CH2)3-(CF2)5-(CH2)-, -(CH2)4-(CF2)5- (CH2)-, -(CH2)5-(CF2)5-(CH2)-, -(CH2)6-(CF2)5-(CH2)-, -(CH2)2-(CF2)5-(CH2)2-, -(CH2)3-(CF2)5-(CH2)3-, -(CH2)4-(CF2)5-(CH2)4-, -(CH2)2-(CF2)5-(CH2)3-, - (CH2)2-(CF2)5-(CH2)4-, -(CH2)2-(CF2)5-(CH2)5-, -(CH2)2-(CF2)5-(CH2)6-, - (CH2)3-(CF2)5-(CH2)2-, -(CH2)3-(CF2)5-(CH2)4-, -(CH2)4-(CF2)5-(CH2)2-, - (CH2)4-(CF2)5-(CH2)3-, -(CH2)5-(CF2)5-(CH2)2-,
-(CHCF3)-(CH2)-, -(CH2)-(CHCF3)-, -(CH2)-(CHCF3)-(CH2)-, -(CH2)- (CHCF3)-(CH2)2-, -(CH2)-(CHCF3)-(CH2)3-, -(CH2)-(CHCF3)-(CH2)4-, -(CH2)- (CHCF3)-(CH2)5-, -(CH2)-(CHCF3)-(CH2)6-, -(CH2)-(CHCF3)-(CH2)7-, -(CH2)- (CHCF3)-(CH2)8-, -(CH2)-(CHCF3)-(CH2)9-, -(CH2)-(CHCF3)-(CH2)io-, - (CH2)2-(CHCF3)-(CH2)-, -(CH2)3-(CHCF3)-(CH2)-, -(CH2)4-(CHCF3)-(CH2)-, - (CH2)5-(CHCF3)-(CH2)-, -(CH2)6-(CHCF3)-(CH2)-, -(CH2)7-(CHCF3)-(CH2)-, - (CH2)8-(CHCF3)-(CH2)-, -(CH2)9-(CHCF3)-(CH2)-, -(CH2)io-(CHCF3)-(CH2)-, - (CH2)2-(CHCF3)-(CH2)2-, -(CH2)3-(CHCF3)-(CH2)3-, -(CH2)4-(CHCF3)-(CH2)4- , -(CH2)5-(CHCF3)-(CH2)5-, -(CH2)2-(CHCF3)-(CH2)3-, -(CH2)2-(CHCF3)- (CH2)4-, -(CH2)2-(CHCF3)-(CH2)5-, -(CH2)2-(CHCF3)-(CH2)6-, -(CH2)2- (CHCF3)-(CH2)7-, -(CH2)2-(CHCF3)-(CH2)8-, -(CH2)2-(CHCF3)-(CH2)9-, - (CH2)3-(CHCF3)-(CH2)2-, -(CH2)3-(CHCF3)-(CH2)4-, -(CH2)3-(CHCF3)-(CH2)5- , -(CH2)3-(CHCF3)-(CH2)6-, -(CH2)3-(CHCF3)-(CH2)7-, -(CH2)3-(CHCF3)- (CH2)8-, -(CH2)4-(CHCF3)-(CH2)2-, -(CH2)4-(CHCF3)-(CH2)3-, -(CH2)4- (CHCF3)-(CH2)5-, -(CH2)4-(CHCF3)-(CH2)6-, -(CH2)4-(CHCF3)-(CH2)7-, -
(CH2)5-(CHCF3)-(CH2)2-, -(CH2)5-(CHCF3)-(CH2)3-, -(CH2)5-(CHCF3)-(CH2)4- , -(CH2)5-(CHCF3)-(CH2)6-, -(CH2)6-(CHCF3)-(CH2)2-, -(CH2)6-(CHCF3)- (CH2)3-, -(CH2)6-(CHCF3)-(CH2)4-, -(CH2)6-(CHCF3)-(CH2)5-,
-(CHCF3)2-(CH2)-, -(CH2)-(CHCF3)2-, -(CH2)-(CHCF3)2-(CH2)-, -(CH2)- (CHCF3)2-(CH2)2-, -(CH2)-(CHCF3)2-(CH2)3-, -(CH2)-(CHCF3)2-(CH2)4-, -
(CH2)-(CHCF3)2-(CH2)5-, -(CH2)-(CHCF3)2-(CH2)6-, -(CH2)-(CHCF3)2-(CH2)7- , -(CH2)-(CHCF3)2-(CH2)8-, -(CH2)-(CHCF3)2-(CH2)9-, -(CH2)2-(CHCF3)2- (CH2)-, -(CH2)3-(CHCF3)2-(CH2)-, -(CH2)4-(CHCF3)2-(CH2)-, -(CH2)5- (CHCF3)2-(CH2)-, -(CH2)6-(CHCF3)2-(CH2)-, -(CH2)7-(CHCF3)2-(CH2)-, - (CH2)8-(CHCF3)2-(CH2)-, -(CH2)9-(CHCF3)2-(CH2)-, -(CH2)2-(CHCF3)2- (CH2)2-, -(CH2)3-(CHCF3)2-(CH2)3-, -(CH2)4-(CHCF3)2-(CH2)4-, -(CH2)5- (CHCF3)2-(CH2)5-, -(CH2)2-(CHCF3)2-(CH2)3-, -(CH2)2-(CHCF3)2-(CH2)4-, - (CH2)2-(CHCF3)2-(CH2)5-, -(CH2)2-(CHCF3)2-(CH2)6-, -(CH2)2-(CHCF3)2- (CH2)7-, -(CH2)2-(CHCF3)2-(CH2)8-, -(CH2)3-(CHCF3)2-(CH2)2-, -(CH2)3- (CHCF3)2-(CH2)4-, -(CH2)3-(CHCF3)2-(CH2)5-, -(CH2)3-(CHCF3)2-(CH2)6-, - (CH2)3-(CHCF3)2-(CH2)7-, -(CH2)4-(CHCF3)2-(CH2)2-, -(CH2)4-(CHCF3)2- (CH2)3-, -(CH2)4-(CHCF3)2-(CH2)5-, -(CH2)4-(CHCF3)2-(CH2)6-, -(CH2)5- (CHCF3)2-(CH2)2-, -(CH2)5-(CHCF3)2-(CH2)3-, -(CH2)5-(CHCF3)2-(CH2)4-, - (CH2)6-(CHCF3)2-(CH2)2-, -(CH2)6-(CHCF3)2-(CH2)3-, -(CH2)6-(CHCF3)2- (CH2)4-,
-(CHCF3)3-(CH2)-, -(CH2)-(CHCF3)3-, -(CH2)-(CHCF3)3-(CH2)-, -(CH2)- (CHCF3)3-(CH2)2-, -(CH2)-(CHCF3)3-(CH2)3-, -(CH2)-(CHCF3)3-(CH2)4-, - (CH2)-(CHCF3)3-(CH2)5-, -(CH2)-(CHCF3)3-(CH2)6-, -(CH2)-(CHCF3)3-(CH2)7- , -(CH2)-(CHCF3)3-(CH2)8-, -(CH2)2-(CHCF3)3-(CH2)-, -(CH2)3-(CHCF3)3- (CH2)-, -(CH2)4-(CHCF3)3-(CH2)-, -(CH2)5-(CHCF3)3-(CH2)-, -(CH2)6-
(CHCF3)3-(CH2)-, -(CH2)7-(CHCF3)3-(CH2)-, -(CH2)8-(CHCF3)3-(CH2)-, - (CH2)2-(CHCF3)3-(CH2)2-, -(CH2)3-(CHCF3)3-(CH2)3-, -(CH2)4-(CHCF3)3- (CH2)4-, -(CH2)2-(CHCF3)3-(CH2)3-, -(CH2)2-(CHCF3)3-(CH2)4-, -(CH2)2- (CHCF3)3-(CH2)5-, -(CH2)2-(CHCF3)3-(CH2)6-, -(CH2)2-(CHCF3)3-(CH2)7-, - (CH2)3-(CHCF3)3-(CH2)2-, -(CH2)3-(CHCF3)3-(CH2)4-, -(CH2)3-(CHCF3)3- (CH2)5-, -(CH2)3-(CHCF3)3-(CH2)6-, -(CH2)4-(CHCF3)3-(CH2)2-, -(CH2)4- (CHCF3)3-(CH2)3-, -(CH2)4-(CHCF3)3-(CH2)5-, -(CH2)5-(CHCF3)3-(CH2)2-, - (CH2)5-(CHCF3)3-(CH2)3-, -(CH2)5-(CHCF3)3-(CH2)4-, -(CH2)6-(CHCF3)3- (CH2)2-, -(CH2)6-(CHCF3)3-(CH2)3-,
-(CHCF3)4-(CH2)-, -(CH2)-(CHCF3)4-, -(CH2)-(CHCF3)4-(CH2)-, -(CH2)- (CHCF3)4-(CH2)2-, -(CH2)-(CHCF3)4-(CH2)3-, -(CH2)-(CHCF3)4-(CH2)4-, - (CH2)-(CHCF3)4-(CH2)5-, -(CH2)-(CHCF3)4-(CH2)6-, -(CH2)-(CHCF3)4-(CH2)7 , -(CH2)-(CHCF3)4-(CH2)8-, -(CH2)-(CHCF3)4-(CH2)9-, -(CH2)-(CHCF3)4- (CH2)io-, -(CH2)2-(CHCF3)4-(CH2)-, -(CH2)3-(CHCF3)4-(CH2)-, -(CH2)4- (CHCF3)4-(CH2)-, -(CH2)5-(CHCF3)4-(CH2)-, -(CH2)6-(CHCF3)4-(CH2)-, - (CH2)7-(CHCF3)4-(CH2)-, -(CH2)2-(CHCF3)4-(CH2)2-, -(CH2)3-(CHCF3)4- (CH2)3-, -(CH2)4-(CHCF3)4-(CH2)4-, -(CH2)5-(CHCF3)4-(CH2)5-, -(CH2)2- (CHCF3)4-(CH2)3-, -(CH2)2-(CHCF3)4-(CH2)4-, -(CH2)2-(CHCF3)4-(CH2)5-, - (CH2)2-(CHCF3)4-(CH2)6-, -(CH2)3-(CHCF3)4-(CH2)2-, -(CH2)3-(CHCF3)4- (CH2)4-, -(CH2)4-(CHCF3)4-(CH2)2-, -(CH2)4-(CHCF3)4-(CH2)3-, -(CH2)5- (CHCF3)4-(CH2)2-, -(CH2)5-(CHCF3)4-(CH2)3-, -(CH2)6-(CHCF3)4-(CH2)2-, -(CHCF3)5-(CH2)-, -(CH2)-(CHCF3)5-, -(CH2)-(CHCF3)5-(CH2)-, -(CH2)- (CHCF3)5-(CH2)2-, -(CH2)-(CHCF3)5-(CH2)3-, -(CH2)-(CHCF3)5-(CH2)4-, - (CH2)-(CHCF3)5-(CH2)5-, -(CH2)-(CHCF3)5-(CH2)6-, -(CH2)2-(CHCF3)5-(CH2) , -(CH2)3-(CHCF3)5-(CH2)-, -(CH2)4-(CHCF3)5-(CH2)-, -(CH2)5-(CHCF3)5- (CH2)-, -(CH2)6-(CHCF3)5-(CH2)-, -(CH2)2-(CHCF3)5-(CH2)2-, -(CH2)3- (CHCF3)5-(CH2)3-, -(CH2)4-(CHCF3)5-(CH2)4-, -(CH2)2-(CHCF3)5-(CH2)3-, - (CH2)2-(CHCF3)5-(CH2)4-, -(CH2)2-(CHCF3)5-(CH2)5-, -(CH2)2-(CHCF3)5- (CH2)6-, -(CH2)3-(CHCF3)5-(CH2)2-, -(CH2)3-(CHCF3)5-(CH2)4-, -(CH2)4- (CHCF3)5-(CH2)2-, -(CH2)4-(CHCF3)5-(CH2)3-, -(CH2)5-(CHCF3)5-(CH2)2-, -[C(CH3)CF3]-(CH2)-, -(CH2)-[C(CH3)CF3]-, -(CH2)-[C(CH3)CF3]-(CH2)-, - (CH2)-[C(CH3)CF3]-(CH2)2-, -(CH2)-[C(CH3)CF3]-(CH2)3-, -(CH2)- [C(CH3)CF3]-(CH2)4-, -(CH2)-[C(CH3)CF3]-(CH2)5-, -(CH2)-[C(CH3)CF3]- (CH2)6-, -(CH2)-[C(CH3)CF3]-(CH2)7-, -(CH2)-[C(CH3)CF3]-(CH2)8-, -(CH2)- [C(CH3)CF3]-(CH2)9-, -(CH2)-[C(CH3)CF3]-(CH2)io-> -(CH2)2-[C(CH3)CF3]- (CH2)-, -(CH2)3-[C(CH3)CF3]-(CH2)-, -(CH2)4-[C(CH3)CF3]-(CH2)-, -(CH2)5- [C(CH3)CF3]-(CH2)-, -(CH2)6-[C(CH3)CF3]-(CH2)-, -(CH2)7-[C(CH3)CF3]- (CH2)-, -(CH2)8-[C(CH3)CF3]-(CH2)-, -(CH2)9-[C(CH3)CF3]-(CH2)-, -(CH2)io- [C(CH3)CF3]-(CH2)-, -(CH2)2-[C(CH3)CF3]-(CH2)2-, -(CH2)3-[C(CH3)CF3]-
(CH2)3-, -(CH2)4-[C(CH3)CF3]-(CH2)4-, -(CH2)5-[C(CH3)CF3]-(CH2)5-, -(CH2)2- [C(CH3)CF3]-(CH2)3-, -(CH2)2-[C(CH3)CF3]-(CH2)4-, -(CH2)2-[C(CH3)CF3]- (CH2)5-, -(CH2)2-[C(CH3)CF3]-(CH2)6-, -(CH2)2-[C(CH3)CF3]-(CH2)7-, -(CH2)2- [C(CH3)CF3]-(CH2)8-, -(CH2)2-[C(CH3)CF3]-(CH2)9-, -(CH2)3-[C(CH3)CF3]- (CH2)2-, -(CH2)3-[C(CH3)CF3]-(CH2)4-, -(CH2)3-[C(CH3)CF3]-(CH2)5-, -(CH2)3- [C(CH3)CF3]-(CH2)6-, -(CH2)3-[C(CH3)CF3]-(CH2)7-, -(CH2)3-[C(CH3)CF3]- (CH2)8-, -(CH2)4-[C(CH3)CF3]-(CH2)2-, -(CH2)4-[C(CH3)CF3]-(CH2)3-, -(CH2)4- [C(CH3)CF3]-(CH2)5-, -(CH2)4-[C(CH3)CF3]-(CH2)6-, -(CH2)4-[C(CH3)CF3]- (CH2)7-, -(CH2)5-[C(CH3)CF3]-(CH2)2-, -(CH2)5-[C(CH3)CF3]-(CH2)3-, -(CH2)5- [C(CH3)CF3]-(CH2)4-, -(CH2)5-[C(CH3)CF3]-(CH2)6-, -(CH2)6-[C(CH3)CF3]-
(CH2)2-, -(CH2)6-[C(CH3)CF3]-(CH2)3-, -(CH2)6-[C(CH3)CF3]-(CH2)4-, -(CH2)6- [C(CH3)CF3]-(CH2)5-,
-[C(CH3)CF3]2-(CH2)-, -(CH2)-[C(CH3)CF3]2-, -(CH2)-[C(CH3)CF3]2-(CH2)-, - (CH2)-[C(CH3)CF3]2-(CH2)2-, -(CH2)-[C(CH3)CF3]2-(CH2)3-, -(CH2)- [C(CH3)CF3]2-(CH2)4-, -(CH2)-[C(CH3)CF3]2-(CH2)5-, -(CH2)-[C(CH3)CF3]2- (CH2)6-, -(CH2)-[C(CH3)CF3]2-(CH2)7-, -(CH2)-[C(CH3)CF3]2-(CH2)8-, -(CH2)- [C(CH3)CF3]2-(CH2)9-, -(CH2)2-[C(CH3)CF3]2-(CH2)-, -(CH2)3-[C(CH3)CF3]2- (CH2)-, -(CH2)4-[C(CH3)CF3]2-(CH2)-, -(CH2)5-[C(CH3)CF3]2-(CH2)-, -(CH2)6- [C(CH3)CF3]2-(CH2)-, -(CH2)7-[C(CH3)CF3]2-(CH2)-, -(CH2)8-[C(CH3)CF3]2- (CH2)-, -(CH2)9-[C(CH3)CF3]2-(CH2)-, -(CH2)2-[C(CH3)CF3]2-(CH2)2-, -(CH2)3- [C(CH3)CF3]2-(CH2)3-, -(CH2)4-[C(CH3)CF3]2-(CH2)4-, -(CH2)5-[C(CH3)CF3]2- (CH2)5-, -(CH2)2-[C(CH3)CF3]2-(CH2)3-, -(CH2)2-[C(CH3)CF3]2-(CH2)4-, - (CH2)2-[C(CH3)CF3]2-(CH2)5-, -(CH2)2-[C(CH3)CF3]2-(CH2)6-, -(CH2)2- [C(CH3)CF3]2-(CH2)7-, -(CH2)2-[C(CH3)CF3]2-(CH2)8-, -(CH2)3-[C(CH3)CF3]2- (CH2)2-, -(CH2)3-[C(CH3)CF3]2-(CH2)4-, -(CH2)3-[C(CH3)CF3]2-(CH2)5-, - (CH2)3-[C(CH3)CF3]2-(CH2)6-, -(CH2)3-[C(CH3)CF3]2-(CH2)7-, -(CH2)4- [C(CH3)CF3]2-(CH2)2-, -(CH2)4-[C(CH3)CF3]2-(CH2)3-, -(CH2)4-[C(CH3)CF3]2- (CH2)5-, -(CH2)4-[C(CH3)CF3]2-(CH2)6-, -(CH2)5-[C(CH3)CF3]2-(CH2)2-, - (CH2)5-[C(CH3)CF3]2-(CH2)3-, -(CH2)5-[C(CH3)CF3]2-(CH2)4-, -(CH2)6- [C(CH3)CF3]2-(CH2)2-, -(CH2)6-[C(CH3)CF3]2-(CH2)3-, -(CH2)6-[C(CH3)CF3]2- (CH2)4-,
-[C(CH3)CF3]3-(CH2)-, -(CH2)-[C(CH3)CF3]3-, -(CH2)-[C(CH3)CF3]3-(CH2)-, - (CH2)-[C(CH3)CF3]3-(CH2)2-, -(CH2)-[C(CH3)CF3]3-(CH2)3-, -(CH2)- [C(CH3)CF3]3-(CH2)4-, -(CH2)-[C(CH3)CF3]3-(CH2)5-, -(CH2)-[C(CH3)CF3]3- (CH2)6-, -(CH2)-[C(CH3)CF3]3-(CH2)7-, -(CH2)-[C(CH3)CF3]3-(CH2)8-, -(CH2)2- [C(CH3)CF3]3-(CH2)-, -(CH2)3-[C(CH3)CF3]3-(CH2)-, -(CH2)4-[C(CH3)CF3]3- (CH2)-, -(CH2)5-[C(CH3)CF3]3-(CH2)-, -(CH2)6-[C(CH3)CF3]3-(CH2)-, -(CH2)7- [C(CH3)CF3]3-(CH2)-, -(CH2)8-[C(CH3)CF3]3-(CH2)-, -(CH2)2-[C(CH3)CF3]3- (CH2)2-, -(CH2)3-[C(CH3)CF3]3-(CH2)3-, -(CH2)4-[C(CH3)CF3]3-(CH2)4-, - (CH2)2-[C(CH3)CF3]3-(CH2)3-, -(CH2)2-[C(CH3)CF3]3-(CH2)4-, -(CH2)2- [C(CH3)CF3]3-(CH2)5-, -(CH2)2-[C(CH3)CF3]3-(CH2)6-, -(CH2)2-[C(CH3)CF3]3- (CH2)7-, -(CH2)3-[C(CH3)CF3]3-(CH2)2-, -(CH2)3-[C(CH3)CF3]3-(CH2)4-, - (CH2)3-[C(CH3)CF3]3-(CH2)5-, -(CH2)3-[C(CH3)CF3]3-(CH2)6-, -(CH2)4- [C(CH3)CF3]3-(CH2)2-, -(CH2)4-[C(CH3)CF3]3-(CH2)3-, -(CH2)4-[C(CH3)CF3]3- (CH2)5-, -(CH2)5-[C(CH3)CF3]3-(CH2)2-, -(CH2)5-[C(CH3)CF3]3-(CH2)3-, - (CH2)5-[C(CH3)CF3]3-(CH2)4-, -(CH2)6-[C(CH3)CF3]3-(CH2)2-, -(CH2)6- [C(CH3)CF3]3-(CH2)3-,
-[C(CH3)CF3]4-(CH2)-, -(CH2)-[C(CH3)CF3]4-, -(CH2)-[C(CH3)CF3]4-(CH2)-, - (CH2)-[C(CH3)CF3]4-(CH2)2-, -(CH2)-[C(CH3)CF3]4-(CH2)3-, -(CH2)- [C(CH3)CF3]4-(CH2)4-, -(CH2)-[C(CH3)CF3]4-(CH2)5-, -(CH2)-[C(CH3)CF3]4- (CH2)6-, -(CH2)-[C(CH3)CF3]4-(CH2)7-, -(CH2)-[C(CH3)CF3]4-(CH2)8-, -(CH2)- [C(CH3)CF3]4-(CH2)9-, -(CH2)-[C(CH3)CF3]4-(CH2)io-, -(CH2)2-[C(CH3)CF3]4- (CH2)-, -(CH2)3-[C(CH3)CF3]4-(CH2)-, -(CH2)4-[C(CH3)CF3]4-(CH2)-, -(CH2)5- [C(CH3)CF3]4-(CH2)-, -(CH2)6-[C(CH3)CF3]4-(CH2)-, -(CH2)7-[C(CH3)CF3]4- (CH2)-, -(CH2)2-[C(CH3)CF3]4-(CH2)2-, -(CH2)3-[C(CH3)CF3]4-(CH2)3-, - (CH2)4-[C(CH3)CF3]4-(CH2)4-, -(CH2)5-[C(CH3)CF3]4-(CH2)5-, -(CH2)2- [C(CH3)CF3]4-(CH2)3-, -(CH2)2-[C(CH3)CF3]4-(CH2)4-, -(CH2)2-[C(CH3)CF3]4- (CH2)5-, -(CH2)2-[C(CH3)CF3]4-(CH2)6-, -(CH2)3-[C(CH3)CF3]4-(CH2)2-, - (CH2)3-[C(CH3)CF3]4-(CH2)4-, -(CH2)4-[C(CH3)CF3]4-(CH2)2-, -(CH2)4- [C(CH3)CF3]4-(CH2)3-, -(CH2)5-[C(CH3)CF3]4-(CH2)2-, -(CH2)5-[C(CH3)CF3]4- (CH2)3-, -(CH2)6-[C(CH3)CF3]4-(CH2)2-,
-[C(CH3)CF3]5-(CH2)-, -(CH2)-[C(CH3)CF3]5-, -(CH2)-[C(CH3)CF3]5-(CH2)-, - (CH2)-[C(CH3)CF3]5-(CH2)2-, -(CH2)-[C(CH3)CF3]5-(CH2)3-, -(CH2)- [C(CH3)CF3]5-(CH2)4-, -(CH2)-[C(CH3)CF3]5-(CH2)5-, -(CH2)-[C(CH3)CF3]5- (CH2)6-, -(CH2)2-[C(CH3)CF3]5-(CH2)-, -(CH2)3-[C(CH3)CF3]5-(CH2)-, -(CH2)4 [C(CH3)CF3]5-(CH2)-, -(CH2)5-[C(CH3)CF3]5-(CH2)-, -(CH2)6-[C(CH3)CF3]5- (CH2)-, -(CH2)2-[C(CH3)CF3]5-(CH2)2-, -(CH2)3-[C(CH3)CF3]5-(CH2)3-, - (CH2)4-[C(CH3)CF3]5-(CH2)4-, -(CH2)2-[C(CH3)CF3]5-(CH2)3-, -(CH2)2- [C(CH3)CF3]5-(CH2)4-, -(CH2)2-[C(CH3)CF3]5-(CH2)5-, -(CH2)2-[C(CH3)CF3]5- (CH2)6-, -(CH2)3-[C(CH3)CF3]5-(CH2)2-, -(CH2)3-[C(CH3)CF3]5-(CH2)4-, - (CH2)4-[C(CH3)CF3]5-(CH2)2-, -(CH2)4-[C(CH3)CF3]5-(CH2)3-, -(CH2)5- [C(CH3)CF3]5-(CH2)2-,
-[CH(CH2CF3)]-(CH2)-, -(CH2)-[CH(CH2CF3)]-, -(CH2)-[CH(CH2CF3)]-(CH2)- -(CH2)-[CH(CH2CF3)]-(CH2)2-, -(CH2)-[CH(CH2CF3)] -(CH2)3-, -(CH2)- [CH(CH2CF3)]-(CH2)4-, -(CH2)-[CH(CH2CF3)]-(CH2)5-, -(CH2)-[CH(CH2CF3)] (CH2)6-, -(CH2)-[CH(CH2CF3)]-(CH2)7-, -(CH2)-[CH(CH2CF3)]-(CH2)8-, - (CH2)-[CH(CH2CF3)]-(CH2)9-, -(CH2)-[CH(CH2CF3)]-(CH2)io-, -(CH2)2- [CH(CH2CF3)]-(CH2)-, -(CH2)3-[CH(CH2CF3)]-(CH2)-, -(CH2)4-[CH(CH2CF3)] (CH2)-, -(CH2)5-[CH(CH2CF3)]-(CH2)-, -(CH2)6-[CH(CH2CF3)]-(CH2)-, - (CH2)7-[CH(CH2CF3)]-(CH2)-, -(CH2)8-[CH(CH2CF3)]-(CH2)-, -(CH2)9-
[CH(CH2CF3)]- ■(CH2)-, -(CH2)io- ■[CH(CH2CF3)]- -(CH2)-, -(CH2)2-
[CH(CH2CF3)]- ■(CH2)2-, -(CH2)3- -[CH(CH2CF3)]- ■(CH2)3-, -(CH2)4-
[CH(CH2CF3)]- ■(CH2)4-, -(CH2)5- ■[CH(CH2CF3)]- ■(CH2)5-, -(CH2)2-
[CH(CH2CF3)]- ■(CH2)3-, -(CH2)2- ■[CH(CH2CF3)]- ■(CH2)4-, -(CH2)2-
[CH(CH2CF3)]- ■(CH2)5-, -(CH2)2- ■[CH(CH2CF3)]- ■(CH2)6-, -(CH2)2-
[CH(CH2CF3)]- ■(CH2)7-, -(CH2)2- ■[CH(CH2CF3)]- ■(CH2)8-, -(CH2)2-
[CH(CH2CF3)]- ■(CH2)9-, -(CH2)3- -[CH(CH2CF3)]- ■(CH2)2-, -(CH2)3-
[CH(CH2CF3)]- ■(CH2)4-, -(CH2)3- ■[CH(CH2CF3)]- ■(CH2)5-, -(CH2)3-
[CH(CH2CF3)]- ■(CH2)6-, -(CH2)3- ■[CH(CH2CF3)]- ■(CH2)7-, -(CH2)3-
[CH(CH2CF3)]- ■(CH2)8-, -(CH2)4- ■[CH(CH2CF3)]- ■(CH2)2-, -(CH2)4-
[CH(CH2CF3)]- ■(CH2)3-, -(CH2)4- ■[CH(CH2CF3)]- ■(CH2)5-, -(CH2)4- [CH(CH2CF3)]-(CH2)6-, -(CH2)4-[CH(CH2CF3)]-(CH2)7-, -(CH2)5- [CH(CH2CF3)]-(CH2)2-, -(CH2)5-[CH(CH2CF3)]-(CH2)3-, -(CH2)5- [CH(CH2CF3)]-(CH2)4-, -(CH2)5-[CH(CH2CF3)]-(CH2)6-, -(CH2)6- [CH(CH2CF3)]-(CH2)2-, -(CH2)6-[CH(CH2CF3)]-(CH2)3-, -(CH2)6- [CH(CH2CF3)]-(CH2)4-, -(CH2)6-[CH(CH2CF3)]-(CH2)5-,
-[CH(CH2CF3)]2-(CH2)-, -(CH2)-[CH(CH2CF3)]2-, -(CH2)-[CH(CH2CF3)]2- (CH2)-, -(CH2)-[CH(CH2CF3)]2-(CH2)2-, -(CH2)-[CH(CH2CF3)]2-(CH2)3-, - (CH2)-[CH(CH2CF3)]2-(CH2)4-, -(CH2)-[CH(CH2CF3)]2-(CH2)5-, -(CH2)-
[CH(CH2CF3)]2- (CH2)6-, -(CH2)-[CH(CH2CF3)]2 -(CH2)7-, -(CH2)-
[CH(CH2CF3)]2- (CH2)8-, -(CH2)-[CH(CH2CF3)]2 -(CH2)9-, -(CH2)2-
[CH(CH2CF3)]2- (CH2)-, -(CH2)3-[CH(CH2CF3)]2 -(CH2)-,■ ■(CH2)4-
[CH(CH2CF3)]2- (CH2)-, -(CH2)5-[CH(CH2CF3)]2 -(CH2)-,■ ■(CH2)6-
[CH(CH2CF3)]2- (CH2)-, -(CH2)7-[CH(CH2CF3)]2 -(CH2)-,■ ■(CH2)8-
[CH(CH2CF3)]2- (CH2)-, -(CH2)9-[CH(CH2CF3)]2 -(CH2)-,■ ■(CH2)2-
[CH(CH2CF3)]2- (CH2)2-, -(CH2)3-[CH(CH2CF3)] 2-(CH2)3- , -(CH2)4-
[CH(CH2CF3)]2- ■(CH2)4- -(CH2)5-[CH(CH2CF3)] 2-(CH2)5- , -(CH2)2-
[CH(CH2CF3)]2- ■(CH2)3- -(CH2)2-[CH(CH2CF3)] 2-(CH2)4- , -(CH2)2-
[CH(CH2CF3)]2- ■(CH2)5- -(CH2)2-[CH(CH2CF3)] 2-(CH2)6- , -(CH2)2-
[CH(CH2CF3)]2- ■(CH2)7- -(CH2)2-[CH(CH2CF3)] 2-(CH2)8- , -(CH2)3-
[CH(CH2CF3)]2- ■(CH2)2- -(CH2)3-[CH(CH2CF3)] 2-(CH2)4- , -(CH2)3-
[CH(CH2CF3)]2- ■(CH2)5- -(CH2)3-[CH(CH2CF3)] 2-(CH2)6- , -(CH2)3-
[CH(CH2CF3)]2 -(CH2)7- -(CH2)4-[CH(CH2CF3)] 2-(CH2)2- , -(CH2)4-
[CH(CH2CF3)]2 -(CH2)3- -(CH2)4-[CH(CH2CF3)] 2-(CH2)5- , -(CH2)4-
[CH(CH2CF3)]2 ■(CH2)6- -(CH2)5-[CH(CH2CF3)] 2-(CH2)2- , -(CH2)5-
[CH(CH2CF3)]2 ■(CH2)3- -(CH2)5-[CH(CH2CF3)] 2-(CH2)4- , -(CH2)6-
[CH(CH2CF3)]2 ■(CH2)2- -(CH2)6-[CH(CH2CF3)] 2-(CH2)3- , -(CH2)6-
[CH(CH2CF3)]2 ■(CH2)4-
-[CH(CH2CF3)]3-(CH2)-, -(CH2)-[CH(CH2CF3)]3-, -(CH2)-[CH(CH2CF3)]3- (CH2)-, -(CH2)-[CH(CH2CF3)]3-(CH2)2-, -(CH2)-[CH(CH2CF3)]3-(CH2)3-, - (CH2)-[CH(CH2CF3)]3-(CH2)4-, -(CH2)-[CH(CH2CF3)]3-(CH2)5-, -(CH2)- [CH(CH2CF3)]3-(CH2)6-, -(CH2)-[CH(CH2CF3)]3-(CH2)7-, -(CH2)- [CH(CH2CF3)]3-(CH2)8-, -(CH2)2-[CH(CH2CF3)]3-(CH2)-, -(CH2)3- [CH(CH2CF3)]3-(CH2)-, -(CH2)4-[CH(CH2CF3)]3-(CH2)-, -(CH2)5- [CH(CH2CF3)]3-(CH2)-, -(CH2)6-[CH(CH2CF3)]3-(CH2)-, -(CH2)7- [CH(CH2CF3)]3-(CH2)-, -(CH2)8-[CH(CH2CF3)]3-(CH2)-, -(CH2)2- [CH(CH2CF3)]3-(CH2)2-, -(CH2)3-[CH(CH2CF3)]3-(CH2)3-, -(CH2)4- [CH(CH2CF3)]3-(CH2)4-, -(CH2)2-[CH(CH2CF3)]3-(CH2)3-, -(CH2)2- [CH(CH2CF3)]3-(CH2)4-, -(CH2)2-[CH(CH2CF3)]3-(CH2)5-, -(CH2)2- [CH(CH2CF3)]3-(CH2)6-, -(CH2)2-[CH(CH2CF3)]3-(CH2)7-, -(CH2)3- [CH(CH2CF3)]3-(CH2)2-, -(CH2)3-[CH(CH2CF3)]3-(CH2)4-, -(CH2)3- [CH(CH2CF3)]3-(CH2)5-, -(CH2)3-[CH(CH2CF3)]3-(CH2)6-, -(CH2)4- [CH(CH2CF3)]3-(CH2)2-, -(CH2)4-[CH(CH2CF3)]3-(CH2)3-, -(CH2)4- [CH(CH2CF3)]3-(CH2)5-, -(CH2)5-[CH(CH2CF3)]3-(CH2)2-, -(CH2)5- [CH(CH2CF3)]3-(CH2)3-, -(CH2)5-[CH(CH2CF3)]3-(CH2)4-, -(CH2)6- [CH(CH2CF3)]3-(CH2)2-, -(CH2)6-[CH(CH2CF3)]3-(CH2)3-,
-[CH(CH2CF3)]4-(CH2)-, -(CH2)-[CH(CH2CF3)]4-, -(CH2)-[CH(CH2CF3)]4- (CH2)-, -(CH2)-[CH(CH2CF3)]4-(CH2)2-, -(CH2)-[CH(CH2CF3)]4-(CH2)3-, - (CH2)-[CH(CH2CF3)]4-(CH2)4-, -(CH2)-[CH(CH2CF3)]4-(CH2)5-, -(CH2)- [CH(CH2CF3)]4-(CH2)6-, -(CH2)-[CH(CH2CF3)]4-(CH2)7-, -(CH2)- [CH(CH2CF3)]4-(CH2)8-, -(CH2)-[CH(CH2CF3)]4-(CH2)9-, -(CH2)- [CH(CH2CF3)]4-(CH2)io-, -(CH2)2-[CH(CH2CF3)]4-(CH2)-, -(CH2)3- [CH(CH2CF3)]4-(CH2)-, -(CH2)4-[CH(CH2CF3)]4-(CH2)-, -(CH2)5- [CH(CH2CF3)]4-(CH2)-, -(CH2)6-[CH(CH2CF3)]4-(CH2)-, -(CH2)7- [CH(CH2CF3)]4-(CH2)-, -(CH2)2-[CH(CH2CF3)]4-(CH2)2-, -(CH2)3- [CH(CH2CF3)]4-(CH2)3-, -(CH2)4-[CH(CH2CF3)]4-(CH2)4-, -(CH2)5- [CH(CH2CF3)]4-(CH2)5-, -(CH2)2-[CH(CH2CF3)]4-(CH2)3-, -(CH2)2- [CH(CH2CF3)]4-(CH2)4-, -(CH2)2-[CH(CH2CF3)]4-(CH2)5-, -(CH2)2- [CH(CH2CF3)]4-(CH2)6-, -(CH2)3-[CH(CH2CF3)]4-(CH2)2-, -(CH2)3- [CH(CH2CF3)]4-(CH2)4-, -(CH2)4-[CH(CH2CF3)]4-(CH2)2-, -(CH2)4- [CH(CH2CF3)]4-(CH2)3-, -(CH2)5-[CH(CH2CF3)]4-(CH2)2-, -(CH2)5- [CH(CH2CF3)]4-(CH2)3-, -(CH2)6-[CH(CH2CF3)]4-(CH2)2-,
-[CH(CH2CF3)]5-(CH2)-, -(CH2)-[CH(CH2CF3)5-, -(CH2)-[CH(CH2CF3)]5- (CH2)-, -(CH2)-[CH(CH2CF3)]5-(CH2)2-, -(CH2)-[CH(CH2CF3)]5-(CH2)3-, - (CH2)-[CH(CH2CF3)]5-(CH2)4-, -(CH2)-[CH(CH2CF3)]5-(CH2)5-, -(CH2)- :CH(CH2CF3)]5-(CH2)6-, -(CH2)2-[CH(CH2CF3)]5-(CH2)-, -(CH2)3- :CH(CH2CF3)]5-(CH2)-, -(CH2)4-[CH(CH2CF3)]5-(CH2)-, -(CH2)5- ;CH(CH2CF3)]5-(CH2)-, -(CH2)6-[CH(CH2CF3)]5-(CH2)-) -(CH2)2- ;CH(CH2CF3)]5-(CH2)2-, -(CH2)3-[CH(CH2CF3)]5-(CH2)3-, -(CH2)4- ;CH(CH2CF3)]5-(CH2)4-, -(CH2)2-[CH(CH2CF3)]5-(CH2)3-, -(CH2)2- ;CH(CH2CF3)]5-(CH2)4-, -(CH2)2-[CH(CH2CF3)]5-(CH2)5-, -(CH2)2- ;CH(CH2CF3)]5-(CH2)6-, -(CH2)3-[CH(CH2CF3)]5-(CH2)2-, -(CH2)3- ;CH(CH2CF3)]5-(CH2)4-, -(CH2)4-[CH(CH2CF3)]5-(CH2)2-, -(CH2)4- ;CH(CH2CF3)]5-(CH2)3-, -(CH2)5-[CH(CH2CF3)]5-(CH2)2-,
-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]-, -(CH2)- ;C(CH3)(CH2CF3)]-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)- [C(CH3)(CH2CF3)]-(CH2)3-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)- [C(CH3)(CH2CF3)]-(CH2)5-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)6-, -(CH2)- [C(CH3)(CH2CF3)]-(CH2)7-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)8-, -(CH2)- [C(CH3)(CH2CF3)]-(CH2)9-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)io-, -(CH2)2 [C(CH3)(CH2CF3)]-(CH2)-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)4- [C(CH3)(CH2CF3)]-(CH2)-, -(CH2)5-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)6- [C(CH3)(CH2CF3)]-(CH2)-, -(CH2)7-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)8- [C(CH3)(CH2CF3)]-(CH2)-, -(CH2)9-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)io- [C(CH3)(CH2CF3)]-(CH2)-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)3- [C(CH3)(CH2CF3)]-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)5 [C(CH3)(CH2CF3)]-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)3-, -(CH2)2 [C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)5-, -(CH2)2 [C(CH3)(CH2CF3)]-(CH2)6-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)7-, -(CH2)2 [C(CH3)(CH2CF3)]-(CH2)8-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)9-, -(CH2)3 [C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)3 [C(CH3)(CH2CF3)]-(CH2)5-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)6-, -(CH2)3 [C(CH3)(CH2CF3)]-(CH2)7-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)8-, -(CH2)4 [C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)4-[C(CH3)(CH2CF3)]-(CH2)3-, -(CH2)4 [C(CH3)(CH2CF3)]-(CH2)5-, -(CH2)4-[C(CH3)(CH2CF3)]-(CH2)6-, -(CH2)4 [C(CH3)(CH2CF3)]-(CH2)7-, -(CH2)5-[C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)5 [C(CH3)(CH2CF3)]-(CH2)3-, -(CH2)5-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)5 [C(CH3) (CH2CF3) ]-(CH2)6-, -(CH2)6-[C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)6-
[C(CH3) (CH2CF3) ]-(CH2)3-, -(CH2)6-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)6-
[C(CH3) (CH2CF3) ]-(CH2)5-,
-[C(CH3 )(CH2CF3 )]2 -(CH2)- -(CH2)-[C(CH3)(CH2CF3)]2-, -(CH2)-
[C(CH3) (CH2CF3) ]2- (CH2)-, -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)2-, ■(CH2)-
[C(CH3) (CH2CF3) ]2- (CH2)3- -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)4-, -(CH2)-
[C(CH3) (CH2CF3) ]2- (CH2)5- -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)6-, -(CH2)-
[C(CH3) (CH2CF3) ]2- (CH2)7- -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)8-, -(CH2)-
[C(CH3) (CH2CF3) ]2- (CH2)9- -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)3-
[C(CH3) (CH2CF3) ]2- (CH2)-, -(CH2)4-[C(CH3)(CH2CF3)]2-(CH2)-, ■(CH2)5-
[C(CH3) (CH2CF3) ]2- (CH2)-, -(CH2)6-[C(CH3)(CH2CF3)]2-(CH2)-, ■(CH2)7-
[C(CH3) (CH2CF3) ]2- (CH2)-, -(CH2)8-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)9-
[C(CH3) (CH2CF3) ]2- (CH2)-, -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)2-, -(CH2)3-
[C(CH3) (CH2CF3) ]2- (CH2)3- -(CH2)4-[C(CH3)(CH2CF3)]2-(CH2)4- , -(CH2)5-
[C(CH3) (CH2CF3) ]2- (CH2)5- -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)3- , -(CH2)2-
[C(CH3) (CH2CF3) ]2- (CH2)4- -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)5- , -(CH2)2-
[C(CH3) (CH2CF3) ]2- [CH2)6- -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)7- , -(CH2)2-
[C(CH3) (CH2CF3) ]2- [CH2)8- -(CH2)3-[C(CH3)(CH2CF3)]2-(CH2)2- , -(CH2)3-
[C(CH3) (CH2CF3) ]2- (CH2)4- -(CH2)3-[C(CH3)(CH2CF3)]2-(CH2)5- , -(CH2)3-
[C(CH3) (CH2CF3) ]2- [CH2)6- -(CH2)3-[C(CH3)(CH2CF3)]2-(CH2)7- , -(CH2)4-
[C(CH3) (CH2CF3) ]2- (CH2)2- -(CH2)4-[C(CH3)(CH2CF3)]2-(CH2)3- , -(CH2)4-
[C(CH3) (CH2CF3) ]2- (CH2)5- -(CH2)4-[C(CH3)(CH2CF3)]2-(CH2)6- , -(CH2)5-
[C(CH3) (CH2CF3) ]2- (CH2)2- -(CH2)5-[C(CH3)(CH2CF3)]2-(CH2)3- , -(CH2)5-
[C(CH3) (CH2CF3) ]2- (CH2)4- -(CH2)6-[C(CH3)(CH2CF3)]2-(CH2)2- , -(CH2)6-
[C(CH3) (CH2CF3) ]2- (CH2)3- -(CH2)6-[C(CH3)(CH2CF3)]2-(CH2)4-
-[C(CH3 )(CH2CF3 )]3 -(CH2)- -(CH2)-[C(CH3)(CH2CF3)]3-, -(CH2)-
[C(CH3) (CH2CF3) ]3- (CH2)-, -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)2-, ■(CH2)-
[C(CH3) (CH2CF3) ]3- (CH2)3- -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)4-, -(CH2)-
[C(CH3) (CH2CF3) ]3- (CH2)5- -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)6-, -(CH2)-
[C(CH3) (CH2CF3) ]3- (CH2)7- -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)8-, -(CH2)2-
[C(CH3) (CH2CF3) ]3- (CH2)-, -(CH2)3-[C(CH3)(CH2CF3)]3-(CH2)-, ■(CH2)4-
[C(CH3) (CH2CF3) ]3- (CH2)-, -(CH2)5-[C(CH3)(CH2CF3)]3-(CH2)-, ■(CH2)6- [C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)7-[C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)e- [C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)2-[C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)3- [C(CH3)(CH2CF3)]3-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]3-(CH2)4-, -(CH2)2 [C(CH3)(CH2CF3)]3-(CH2)3-, -(CH2)2-[C(CH3)(CH2CF3)]3-(CH2)4-, -(CH2)2 [C(CH3)(CH2CF3)]3-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]3-(CH2)6-, -(CH2)2 [C(CH3)(CH2CF3)]3-(CH2)7-, -(CH2)3-[C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)3 [C(CH3)(CH2CF3)]3-(CH2)4-, -(CH2)3-[C(CH3)(CH2CF3)]3-(CH2)5-, -(CH2)3 [C(CH3)(CH2CF3)]3-(CH2)6-, -(CH2)4-[C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)4 [C(CH3)(CH2CF3)]3-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]3-(CH2)5-, -(CH2)5 [C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)5-[C(CH3)(CH2CF3)]3-(CH2)3-, -(CH2)5 [C(CH3)(CH2CF3)]3-(CH2)4-, -(CH2)6-[C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)6 [C(CH3)(CH2CF3)]3-(CH2)3-,
-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]4-, -(CH2)- [C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)2-, -(CH2)- [C(CH3)(CH2CF3)]4-(CH2)3-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)4-, -(CH2)- [C(CH3)(CH2CF3)]4-(CH2)5-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)6-, -(CH2)- [C(CH3)(CH2CF3)]4-(CH2)7-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)8-, -(CH2)- [C(CH3)(CH2CF3)]4-(CH2)9-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)io-, -(CH2)2 [C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)3-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)4- [C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)5-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)6- [C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)7-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)2- [C(CH3)(CH2CF3)]4-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]4-(CH2)3-, -(CH2)4 [C(CH3)(CH2CF3)]4-(CH2)4-, -(CH2)5-[C(CH3)(CH2CF3)]4-(CH2)5-, -(CH2)2 [C(CH3)(CH2CF3)]4-(CH2)3-, -(CH2)2-[C(CH3)(CH2CF3)]4-(CH2)4-, -(CH2)2 [C(CH3)(CH2CF3)]4-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]4-(CH2)6-, -(CH2)3 [C(CH3)(CH2CF3)]4-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]4-(CH2)4-, -(CH2)4 [C(CH3)(CH2CF3)]4-(CH2)2-, -(CH2)4-[C(CH3)(CH2CF3)]4-(CH2)3-, -(CH2)5 [C(CH3)(CH2CF3)]4-(CH2)2-, -(CH2)5-[C(CH3)(CH2CF3)]4-(CH2)3-, -(CH2)6 [C(CH3)(CH2CF3)]4-(CH2)2-,
-[C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]5-, -(CH2)- [C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]5-(CH2)2-, -(CH2)- [C(CH3)(CH2CF3)]5-(CH2)3-, -(CH2)-[C(CH3)(CH2CF3)]5-(CH2)4-, -(CH2)- [C(CH3)(CH2CF3)]5-(CH2)5-, -(CH2)-[C(CH3)(CH2CF3)]5-(CH2)6-, -(CH2)2- [C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)3-[C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)4- [C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)5-[C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)6- [C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)2-[C(CH3)(CH2CF3)]5-(CH2)2-, -(CH2)3- [C(CH3)(CH2CF3)]5-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]5-(CH2)4-, -(CH2)2- [C(CH3)(CH2CF3)]5-(CH2)3-, -(CH2)2-[C(CH3)(CH2CF3)]5-(CH2)4-, -(CH2)2- [C(CH3)(CH2CF3)]5-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]5-(CH2)6-, -(CH2)3- [C(CH3)(CH2CF3)]5-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]5-(CH2)4-, -(CH2)4- [C(CH3)(CH2CF3)]5-(CH2)2-, -(CH2)4-[C(CH3)(CH2CF3)]5-(CH2)3-, -(CH2)5- [C(CH3)(CH2CF3)]5-(CH2)2-,
-(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)- (CH2)2-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-, -(CH2)4-(CF2)-O-(CF2)-O- (CF2)-(CH2)4-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)-(CF2)-O-(CF2)- O-(CF2)-(CH2)3-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)-(CF2)-O- (CF2)-O-(CF2)-(CH2)5-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)6-, -(CH2)-(CF2)- O-(CF2)-O-(CF2)-(CH2)7-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)3- (CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-(CH2)- , -(CH2)5-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)6-(CF2)-O-(CF2)-O-(CF2)- (CH2)-, -(CH2)7-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)2-(CF2)-O-(CF2)-O- (CF2)-(CH2)3-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)2-(CF2)-O- (CF2)-O-(CF2)-(CH2)5-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)6-, -(CH2)3- (CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-(CH2)2- , -(CH2)5-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)6-(CF2)-O-(CF2)-O-(CF2)- (CH2)2-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)4-(CF2)-O-(CF2)-O- (CF2)-(CH2)3-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-(CH2)5-, -(CH2)5-(CF2)-O- (CF2)-O-(CF2)-(CH2)3-,
-(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)-, -(CH2)2-(CF2)-O-(CF2)2-O-(CF2)- (CH2)2-, -(CH2)3-(CF2)-O-(CF2)2-O-(CF2)-(CH2)3-, -(CH2)4-(CF2)-O-(CF2)2-O- (CF2)-(CH2)4-, -(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)2-, -(CH2)-(CF2)-O- (CF2)2-O-(CF2)-(CH2)3-, -(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)4-, -(CH2)- (CF2)-O-(CF2)2-O-(CF2)-(CH2)5-, -(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)6- , -(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)7-, -(CH2)2-(CF2)-O-(CF2)2-O-(CF2)- (CH2)-, -(CH2)3-(CF2)-0-(CF2)2-0-(CF2)-(CH2)-, -(CH2)4-(CF2)-O-(CF2)2-O- (CF2)-(CH2)-, -(CH2)5-(CF2)-0-(CF2)2-0-(CF2)-(CH2)-, -(CH2)6-(CF2)-0- (CF2)2-0-(CF2)-(CH2)-, -(CH2)7-(CF2)-O-(CF2)2-O-(CF2)-(CH2)-, -(CH2)2- (CF2)-0-(CF2)2-0-(CF2)-(CH2)3-, -(CH2)2-(CF2)-O-(CF2)2-O-(CF2)-(CH2)4- , -(CH2)2-(CF2)-0-(CF2)2-0-(CF2)-(CH2)5-, -(CH2)2-(CF2)-0-(CF2)2-0-(CF2)- (CH2)6-, -(CH2)3-(CF2)-0-(CF2)2-0-(CF2)-(CH2)2-, -(CH2)4-(CF2)-O-(CF2)2-O- (CF2)-(CH2)2-, -(CH2)5-(CF2)-0-(CF2)2-0-(CF2)-(CH2)2-, -(CH2)6-(CF2)-0- (CF2)2-0-(CF2)-(CH2)2-, -(CH2)3-(CF2)-0-(CF2)2-0-(CF2)-(CH2)4-> -(CH2)4- (CF2)-0-(CF2)2-0-(CF2)-(CH2)3-, -(CH2)3-(CF2)-O-(CF2)2-O-(CF2)-(CH2)5- , -(CH2)5-(CF2)-0-(CF2)2-0-(CF2)-(CH2)3-,
-(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-
(CH2)2-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)4-(CF2)2-O-(CF2)2- O-(CF2)2-(CH2)4-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)-(CF2)2- O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3- , -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2- (CH2)5-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)6-, -(CH2)-(CF2)2-O-(CF2)2- 0-(CF2)2-(CH2)7-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)3-(CF2)2- O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)- , -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)6-(CF2)2-O-(CF2)2-O- (CF2)2-(CH2)-, -(CH2)7-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)2-(CF2)2-O- (CF2)2-O-(CF2)2-(CH2)3-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)2-
(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)5-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)6- , -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)4-(CF2)2-O-(CF2)2-O- (CF2)2-(CH2)2-, -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)6-(CF2)2-O- (CF2)2-O-(CF2)2-(CH2)2-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)4-
(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)5- , -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-,
-(CH2)-(CF2)-0-(CF2)-0-(CF2)-0-(CF2)-(CH2)-, -(CH2)2-(CF2)-0-(CF2)-0- (CF2)-0-(CF2)-(CH2)2-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)3- , -(CH2)4-(CF2)-0-(CF2)-0-(CF2)-0-(CF2)-(CH2)4-> -(CH2)-(CF2)-0-(CF2)-0- (CF2)-0-(CF2)-(CH2)2-, -(CH2)-(CF2)-0-(CF2)-0-(CF2)-0-(CF2)-(CH2)3- . -(CH^-iCF^-O-iCF^-O-iCF^-O-iCF^-iCH^-, -(CH2)-(CF2)-0-(CF2)-0- (CF2)-O-(CF2)-(CH2)5-, -(CH2)-(CF2)-0-(CF2)-0-(CF2)-0-(CF2)-(CH2)6- , -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)7-, -(CH2)2-(CF2)-O-(CF2)-O- (CF2)-O-(CF2)-(CH2)-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)- , -(ΟΗ2)4-(ΟΡ2)-Ο-(ΟΡ2)-Ο-(ΟΡ2)-Ο-(ΟΡ2)-(ΟΗ2)-, -(CH2)5-(CF2)-O-(CF2)-O- (CF2)-O-(CF2)-(CH2)-, -(CH2)6-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-
, -(ΟΗ2)7-(ΟΡ2)-Ο-(ΟΡ2)-Ο-(ΟΡ2)-Ο-(ΟΡ2)-(ΟΗ2)-, -(CH2)2-(CF2)-O-(CF2)-O- (CF2)-O-(CF2)-(CH2)3-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)4- , -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)5-, -(CH2)2-(CF2)-O-(CF2)-O- (CF2)-O-(CF2)-(CH2)6-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)2- , -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)5-(CF2)-O-(CF2)-O- (CF2)-O-(CF2)-(CH2)2-, -(CH2)6-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)2- , -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)4-(CF2)-O-(CF2)-O- (CF2)-O-(CF2)-(CH2)3-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)5- , -(CH2)5-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-,
-(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)2-(CF2)2-O-(CF2)2- O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2- (CH2)3-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)-(CF2)2- O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O- (CF2)2-(CH2)3-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)- (CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)5-, -(CH2)-(CF2)2-O-(CF2)2-O-
(CF2)2-O-(CF2)2-(CH2)6-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)7- , -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)3-(CF2)2-O- (CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-O- (CF2)2-(CH2)-, -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)6- (CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)7-(CF2)2-O-(CF2)2-O-
(CF2)2-O-(CF2)2-(CH2)-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3- , -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)2-(CF2)2-O- (CF2)2-O-(CF2)2-O-(CF2)2-(CH2)5-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-O- (CF2)2-(CH2)6-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)4- (CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)5-(CF2)2-O-(CF2)2-O-
(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)6-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2- , -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)4-(CF2)2-O- (CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-O- -(CH2)5-, -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-,
Figure imgf000043_0002
Preferred examples for -R2- are -(CH2)3-(CF2)-(CH2)3-, -(CH2)-(CF2)3-(CH2)-, -(CH2)2-(CF2)4-(CH2)2-, -(CH2)-[CH(CF3)]-(CH2)-, -(CH2)-[C(CH3)CF3HCH2)- , -(CH2)-[CH(CH2CF3)]-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)HCH2)-, -(CH2)2- (CF2)-0-(CF2)-0-(CF2)-(CH2)2-> -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)- (CH2 -,
Figure imgf000043_0001
Compounds of formula (I), (Γ), (I") and (Γ") with linkers -[B]- and
substituents as described before or preferably described before having a polymerizable group as described before or preferably described before or below are preferred in case the substituent -R2- within the at least one linking element Y-R2- corresponds to -(C(R)2)0- wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or -(C(R)2)[r-X8-(C(R)2 X9 -(C(R)2)r-(Xio)r(C(R)2)u-> wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and all other R, o, Xs, X9, X10, s, t, p, q, r and u have a meaning as described before. The invention therefore relates to compounds of formula (I), (Γ), (I") and (P) as described before or preferably described before wherein -R2- is at each occurrence independently -(C(R)2)o- wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)^(Xio)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and all other R, o, Xs, X9, X10, s, t, p, q, r and u have a meaning as described before.
The linking element -(C(R)2)0- or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)^ (Xio)t-(C(R)2)u- as -R2- is particularly preferably selected from the group consisting of -(CH2)3-(CF2)-(CH2)3-> -(CH2)-(CF2)3-(CH2)-> -(CH2)2-(CF2)4- (CH2)2-, -(CH2)-[CH(CF3)]-(CH2)-, -(CH2)-[C(CH3)CF3]-(CH2)-, -(CH2)- [CH(CH2CF3)]-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)2-(CF2)-0- (CF2)-0-(CF2)-(CH2)2-, -(CH2)-(CF2)-0-(CF2)-0-(CF2)-0-(CF2)-(CH2)-.
The substituent Y-R2-R1 is particularly preferably selected from the group consisting of O-R2-R1, -R2-R1, and S-R2-R1 wherein -R2- has a meaning as described before or preferably or particularly preferably described before and wherein Ri is a polymerizable group selected from the group consisting of a trialkoxysilyl group, a dialkoxyalkylsilyl group, a silyl group of formula (6), (7) or (8) as described before where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or an alkenyl group of formula (5),
Figure imgf000044_0001
wherein
X10 is selected from the group consisting of O, S, C(=O), C(=O)O Rs, R9, R10 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non- fluorinated, partially or completely fluorinated alkyl having 1 to 20 C atoms or aryl with 6 to 14 C atoms,
c is 0 or 1 .
The substituent Y-R2-R1 is preferably selected from the group consisting of O-R2-R1, -R2-R1 and S-R2-R1, wherein -R2- is selected from the group consisting of -(CH2)3-(CF2)-(CH2)3-, -(CH2)-(CF2)3-(CH2)-> -(CH2)2-(CF2)4- (CH2)2-, -(CH2)-[CH(CF3)]-(CH2)-, -(CH2)-[C(CH3)CF3]-(CH2)-> -(CH2)- [CH(CH2CF3)]-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)-> -(CH2)2-(CF2)-0- (CF2 -0-(CF2)-(CH2 2-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-,
Figure imgf000045_0001
and wherein Ri is a polymerizable group selected from the group consisting of a trialkoxysilyl group, a dialkoxyalkylsilyl group, a silyl group of formula (6), (7) or (8) as described before where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or an alkenyl group of formula (5),
Figure imgf000045_0002
wherein
X10 is selected from the group consisting of O, S, C(=O), C(=O)O,
Rs, R9, R10 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non- fluorinated, partially or completely fluorinated alkyl having 1 to 20 C atoms or aryl with 6 to 14 C atoms,
c is 0 or 1 . Preferably, Rg and Rio are H.
Preferably, Rs is H, methyl, ethyl or phenyl.
Preferably, Xn is C(=O) or C(=O)O.
Preferred alkenyl groups of formula (5) are therefore represented by any one selected from the group consisting of formulae (5-1 ), (5-2), (5-3), (5-4), (5-5 , (5-6), (5-7), (5-8), and (5-9):
Figure imgf000046_0001
The alkenyl group represented by formula (5-1 ) is called methacrylate. The alkenyl group represented by formula (5-2) is called acrylate.
The preferred groups Ri are preferably combined with preferred groups of the linking element -R2- and/or the linking element Y-R2-. Combinations are excluded where two O atoms or one O atom and one S atom are directly bonded to each other as known for a skilled artisan in the field of organic chemistry. The substituent Y-R2-R1 is therefore particularly preferably selected from the group consisting of
O-(CH2)3-(CF2)-(CH2)3-Ri , O-(CH2)-(CF2)3-(CH2)-Ri , O-(CH2)2-(CF2)4- (CH2)2-Ri, O-(CH2)-[CH(CF3)]-(CH2)-Ri, O-(CH2)-[C(CH3)CF3]-(CH2)-Ri, O- (CH2)-[CH(CH2CF3)]-(CH2)-Ri , O-(CH2)-[C(CH3)(CH2CF3)]-(CH2)-Ri , O-(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-Ri, O-(CH2)-(CF2)-O-(CF2)-O- CF2)-O-(CF2)-(CH2)-Ri,
Figure imgf000047_0001
wherein Ri is selected from the group consisting of an alkenyl of formula (5-1 ), (5-2), (5-3), (5-4), (5-5), (5-6), (5- 7), (5-8), or (5-9);
-(CH2)3-(CF2)-(CH2)3-Ri, -(CH2)-(CF2)3-(CH2)-Ri, -(CH2)2-(CF2)4-(CH2)2-Ri, - (CH2)-[CH(CF3)]-(CH2)-Ri, -(CH2)-[C(CH3)CF3]-(CH2)-Ri, -(CH2)- [CH(CH2CF3)]-(CH2)-Ri , -(CH2)-[C(CH3)(CH2CF3)]-(CH2)-Ri , -(CH2)2-(CF2)- O-(CF2)-O-(CF2)-(CH2)2-Ri, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)- Ri,
Figure imgf000047_0002
wherein Ri is selected from the group consisting of an alkenyl of formula (5-1 ), (5-2), (5-3), (5-4), (5-5), (5-6), (5- 7), (5-8), or (5-9);
S-(CH2)3-(CF2)-(CH2)3-Ri , S-(CH2)-(CF2)3-(CH2)-Ri , S-(CH2)2-(CF2)4-(CH2)2- Ri, S-(CH2)-[CH(CF3)]-(CH2)-Ri, S-(CH2)-[C(CH3)CF3]-(CH2)-Ri, S-(CH2)- [CH(CH2CF3)]-(CH2)-Ri , S-(CH2)-[C(CH3)(CH2CF3)]-(CH2)-Ri , S-(CH2)2- (CF2)-O-(CF2)-O-(CF2)-(CH2)2-Ri, S-(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)- (CH2)-Ri,
Figure imgf000048_0001
, wherein Ri is selected from the group consisting of an alkenyl of formula (5-1 ), (5-2), (5-3), (5-4), (5-5), (5-6), (5- 7), (5-8), or (5-9).
Very particularly preferably, the compounds of formula (I), (Γ), (I") and (Γ") comprise a polymerizable group Ri which is a methacryl or an acryl group represented by formula (5-1 ) and (5-2).
The invention therefore relates further to compounds of formula (I), (Γ), (I") and/or (P) as described before or preferably described before wherein Ri is at each occurrence independently an acryl or methacryl group.
Examples for compounds of formula (I), (Γ), (I") and/or (P) are the following compounds O-001 to Ο-289, S-001 to S-169 and N-001 to N-172:
Figure imgf000048_0002
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
5
10
15
20
25
30
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
5
10
15
20
25
30
Figure imgf000148_0001
Figure imgf000149_0001
The compounds of the present application may be synthesized by methods well known to the skilled person. Preferably, all syntheses are carried out under an inert atmosphere using dried solvents.
An exemplary reaction sequence is shown in Scheme 1 for the compound
Ο-149.
Scheme 1 :
Figure imgf000150_0001
The first type of reaction is a classic aldol-addition with subsequent decarboxylation.
The second type of reaction is a Palladium catalyzed Suzuki reaction. The third type of reaction is an ether cleavage in the presence of borontribromide.
The fourth type of reaction is a Williamson ether synthesis.
The fifth type of reaction is an esterification reaction.
All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section. An exemplary reaction sequence is shown in Scheme 2 for the compound
S-1 15.
Scheme 2:
Figure imgf000151_0001
The first type of reaction is a classical ring closure via nucleophilic substitution, aldol-addition followed by decarboxylation. In the second step, a pentyl substituent is introduced via palladium-catalyzed Suzuki reaction. The third type of reaction is an ether cleavage in the presence of borontribromide. The fourth type of reaction is a Williamson ether synthesis followed by an esterification reaction. All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section.
An exemplary reaction sequence is shown in Scheme 3 for the compound N-098 in case "Alkyl" in Scheme 3 is isobutyl and "R" in Scheme 3 is Methyl.
Scheme 3:
Figure imgf000152_0001
The first type of reaction is a Sonogashira reaction followed by a ring closure in the presence of Zinc bromide. In the third step, an alkyl group on the N atom is introduced via alkyl iodide. The third type of reaction is an ether cleavage in the presence of borontribromide. The fourth type of reaction is a Williamson ether synthesis followed by an esterification reaction.
All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section.
As described before, the compounds of formula (I), (Γ), (I") and/or (P) as described before or preferably described before contain a polymerizable group and are predestinated as monomers for an oligomerization or a polymerization.
The invention is therefore further directed to an oligomer or polymer comprising polymerized compounds of formula (I), (Γ), (I") and/or (P) as described before or preferably described before.
The term "polymer" generally means a molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass (PAC, 1996, 68, 2291 ). The term "polymer" includes homopolymers and co-polymers. The term "oligomer" generally means a molecule of intermediate relative molecular mass, the structure of which essentially comprises a small plurality of units derived, actually or conceptually, from molecules of lower relative molecular mass (PAC, 1996, 68, 2291 ). In a preferred sense a polymer means a compound having > 30 repeating units, and an oligomer means a compound with > 1 and < 30 repeating units. Above and below, in formulae showing a polymer, an oligomer, a
compound of formula (I) or a monomeric unit formed from a compound of formula (I), an asterisk ("*") denotes a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group.
Suitable terminal end groups are known to the skilled artisan and depend on the polymerization method used. The terms "repeating unit" and "monomeric unit" mean the constitutional repeating unit (CRU), which is the smallest constitutional unit the repetition of which constitutes a regular macronnolecule, a regular oligomer molecule, a regular block or a regular chain (PAC, 1996, 68, 2291 ). Unless stated otherwise, the molecular weight is given as the number average molecular weight Mn or weight average molecular weight Mw, which is determined by gel permeation chromatography (GPC) against polystyrene standards in eluent solvents such as tetrahydrofuran, trichloromethane (TCM, chloroform), chlorobenzene or 1 ,2,4-trichloro- benzene. Unless stated otherwise, tetrahydrofuran is used as solvent. The degree of polymerization (n) means the number average degree of polymerization given as n = Mn/Mu, wherein Mu is the molecular weight of the single repeating unit as described in J. M. G. Cowie, Polymers:
Chemistry & Physics of Modern Materials, Blackie, Glasgow, 1991 .
In the polymers according to the the present invention, the total number of repeating units n is seen preferably > 30, very preferably > 100, most preferably > 200, and preferably up to 5000, very preferably up to 3000, most preferably up to 2000, including any combination of the
aforementioned lower and upper limits of n. The polymers of the present invention include homopolymers, statistical copolymers, random co-polymers, alternating co-polymers and block copolymers, and combinations of the aforementioned. Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of the words, for example
"comprising" and "comprises", mean "including but not limited to", and are not intended to (and do not) exclude other components Preferably the polymerizable group Ri forms the regioregular, alternated, regiorandom, statistical, block or random homopolymer or co-polymer backbone or is part of the polymer backbone where Ri has a meaning as described or preferably described before. Particularly preferably, such oligomer or polymer comprises a constitutional unit M° of formulae (5-p-1 ), (5-p-2), (5-p-3)
Figure imgf000155_0001
Figure imgf000156_0001
wherein
-R2-, Y, R3, R4, R5, R6, X, -[B]-, R7, Xi 1, Re, R9, R10 and c have a meaning or a preferred meaning as described or preferably described before.
Combinations are excluded where two O atoms or an O atom and a S atom are directly linked to each other as known for a skilled artisan in the field of organic chemistry.
The co-polymer may be an oligomer or polymer comprising one or more polymerized compounds of formula (I), (Γ), (I") or (Γ") or a constitutional unit M° of formulae (5-p-1 ), (5-p-2), (5-p-3), which may be the same or different from one another, and one or more constitutional units M2, which may be the same or different from one another.
Said one or more constitutional units M2 are chemically different from the units M°. Preferably, said one or more constitutional units M2 are derived by polymerization of one or more monomers selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), n-alkyl methacrylates (the n-alkyl groups comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl groups comprising 2-20 C-atoms), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18-hydroxyoctadecyl methacrylate, 2- phenoxyethyl acrylate (EGPEA), Bisphenol A diacrylate-1 EO/Phenol (BPADA), 2-[3'-2'H-benzotriazol- 2'-yl)-4'-hydroxyphenyl]ethyl methacrylate (BTPEM), tnalkoxyalkenylsilane, dialkoxyalkylalkenylsilane or a silane of formula (9) and (10),
Figure imgf000157_0001
where the alkyl and/or alkoxy groups are at each occurrence independently of each other linear or branched having 1 to 6 C atoms and where the alkenyl group is at each occurrence independently linear having 2 to 4 C atoms.
Particularly preferably, said one or more constitutional units M2 are derived by polymerization of one or more monomers selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), n-alkyl methacrylates (the n-alkyl groups comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl groups comprising 2-20 C-atoms), ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16- hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18- hydroxyoctadecyl acrylate, 18-hydroxyoctadecyl methacrylate, 2- phenoxyethyl acrylate (EGPEA), Bisphenol A diacrylate-1 EO/Phenol (BPADA) and 2-[3'-2'H-benzotriazol- 2'-yl)-4'-hydroxyphenyl]ethyl methacrylate (BTPEM) in combination with inventive monomers containing an alkenyl group of formula (5) as described or preferably described before.
Particularly preferably, said one or more constitutional units M2 are derived by polymerization of one or more monomers selected from the group consisting of tnalkoxyalkenylsilane, dialkoxyalkylalkenylsilane or a silane of formula (9) and (10),
Figure imgf000158_0001
where the alkyl and/or alkoxy groups are at each occurrence independently of each other linear or branched having 1 to 6 C atoms and where the alkenyl group is at each occurrence independently linear having 2 to 4 C atoms in combination with inventive monomers containing a polymerizable group containing at least one Si atom.
Alternatively the oligomer or polymer according to the invention is a homopolymer, i.e. an oligomer or polymer comprising one or more constitutional unit M° of formulae (5-p-1 ), (5-p-2), (5-p-3), wherein all constitutional units M° are the same.
Exemplary polymeric compounds may be selected from the following formulae (P-001 ) to (P-628):
Figure imgf000158_0002
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Figure imgf000203_0001
Figure imgf000204_0001
Figure imgf000205_0001
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
Figure imgf000219_0001
Figure imgf000220_0001
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Figure imgf000225_0001
Figure imgf000226_0001
Figure imgf000227_0001
Figure imgf000228_0001
Figure imgf000229_0001
Figure imgf000230_0001
Figure imgf000231_0001
Figure imgf000232_0001
Figure imgf000233_0001
Figure imgf000234_0001
Figure imgf000235_0001
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Figure imgf000240_0001
Figure imgf000241_0001
Figure imgf000242_0001
Figure imgf000243_0001
Figure imgf000244_0001
Figure imgf000245_0001
Figure imgf000246_0001
Figure imgf000247_0001
Figure imgf000248_0001
Figure imgf000249_0001
Figure imgf000250_0001
Figure imgf000251_0001
Figure imgf000252_0001
Figure imgf000253_0001
Figure imgf000254_0001
Figure imgf000255_0001
Figure imgf000256_0001
Figure imgf000257_0001
Figure imgf000258_0001
Preferably a co-polymer according to the invention as described before or preferably described before comprises the one or more constitutional units M° in a molar ratio ml and the one or more constitutional units M2 in a molar ratio m2, wherein the ratio ml : m2 is at least 0.01 and at most 100.
The oligomers or polymers according to the invention as described before or preferably described may be cross-linked.
The oligomers and polymers of the present invention may be made by any suitable method. It is, however, preferred that the present oligomers and polymers are made by radical polymerization, wherein the polymerization reaction is started by means of a suitable radical polymerization initiator. For the purposes of the present invention the type of radical polymerization initiator is not particularly limited and may be any suitable radical generating compound. Such compounds are well known to the skilled person. Suitable polymerization initiators may be selected from thermal initiators or photoinitiators, i.e. compounds that generate radicals by exposure to heat or irradiation with light of a suitable wavelength. Examples of suitable thermal polymerization initiators may be selected from the groups of compounds comprising one or more peroxide groups, i.e. compounds comprising a group -O-O-, and/or compounds comprising one or more azo groups, i.e. compounds comprising a group -N≡N-
Suitable polymerization initiators comprising one or more peroxide groups may, for example, be selected from the groups consisting of t-butyl(peroxy- 2-ethyl-hexanoate), di-(tert-butylcyclohexyl)peroxydicarbonate and benzoyl peroxide.
Suitable polymerization initiators comprising one or more azo groups may, for example, be selected from the group consisting of 1 , 1 '- azobis(cyclohexancarbonitrile) and 2,2'azobis(cyclohexanecarbonitrile) (AIBN). A suitable example of a photoinitiator is dimethylaminobenzoate
/camphorquinone. If a photoinitiator is used as polymerization initiator, it is preferred that the wavelength required to decompose said photoinitiator is different from the wavelength needed to irradiate the compound of the present application so as to change its optical properties. Preferably, the radical initiators are used in an amount of at least 0.0001 eq and of at most 0.1 eq of the main monomer. Such radical initiators could be thermal initiators, e.g. azobisisobutyronitrile (AIBN) or photochemical initiators like dimethylaminobenzoate/camphorquinone. The present invention is also directed to a composition comprising at least one compound of formula (I), (Γ), (I") or (Γ) as described or preferably described before and/or an oligomer or polymer as described before or preferably described before. A composition comprising at least one compound of formula (I), (Γ), (I") or (Γ) as described or preferably described before and an oligomer or polymer as described before is primarily used for the synthesis of block co-polymers with the condition that the oligomer or polymer has at least one reactive group left which may react with the monomers.
Depending upon the intended use such composition may comprise further different components. Such further components may, for example, be selected from the group consisting of UV absorbers, antioxidants and cross-linkers.
The compositions may include or comprise, essentially consist of or consist of the said requisite or optional constituents. All compounds or components which can be used in the compositions are either known and commercially available or can by synthesized by known processes.
The UV absorber that may be used in the present composition is not particularly limited and can easily be selected from those generally known to the skilled person. Generally suitable UV absorbers are characterized by being unsaturated compounds, preferably compounds comprising one or more selected from group consisting of olefinic groups, aryl groups and heteroaryl groups; these groups may be present in any combination.
Suitable UV-absorbers for use in the present composition may, for example, be selected from those comprising a group selected from benzotriazole, benzophenone and triazine. Suitable UV-absorbers are, for example, disclosed in U.S. Pat. Nos. 5,290,892; 5,331 ,073 and 5,693,095.
Suitable cross-linkers may be used to impart elastomeric properties to the present composition and the articles produced therewith. Typically any suitable di- or tri-functional monomer may be used as crosslinker. Such monomers are generally well known to the skilled person including at least one compound of formula (Γ) as described before or preferably described before.
Preferred cross-linker may be selected from the following group of compounds
Figure imgf000261_0001
Ethylene glycol dimethacrylate (EGDMA) is particularly preferred.
Suitable antioxidants are phenyl acrylate derivatives bearing a hindered phenol moiety. A preferred antioxidant is
Figure imgf000262_0001
The compounds of formula (I) according to the invention and their oligomers or polymers as described before or preferably described before are particularly well suited for use in optically active devices.
Hence the present invention is also directed to articles e.g. blanks which may be transformed into optically active devices comprising at least one compound of formula (I) as described before or preferably described before or at least one oligomer or polymer as described before or preferably described before.
Preferred articles are blanks which may be transformed into optically active devices or the optically active devices as such. Preferred optically active devices are ophthalmic devices. Examples of such ophthalmic devices include lenses, keratoprostheses, and cornea inlays or rings. More preferably, said article is a blank which may be transformed into an eye- implant or the eye-implant as such. More preferably, said eye-implant is a lens. Most preferably, such article is a blank which may be transformed into an intraocular lens or the intraocular lens as such, which may, for example, be a posterior chamber intraocular lens or an anterior chamber intraocular lens.
A blank of this invention may be produced as a step in the manufacturing process used to create an intraocular lens. For example, without limitation, a manufacturing process may include the steps of polymer synthesis, polymer sheet casting, blank cutting, optic lathe cutting, optic milling, haptic milling or attachment, polishing, solvent extraction, sterilization and packaging. The present articles according to the invention as described before or preferably described before may be formed by a process comprising the steps of
- providing a composition comprising at least one compound of formula (I) as defined herein and/or an oligomer or polymer as defined herein; and - subsequently forming the article of said composition.
Intraocular lenses in accordance with the present invention are believed to show particularly advantageous properties in that they are flexible enough so as to be rolled or folded and consequently requiring a much smaller incision for them to be inserted into the eye. It is believed that this will allow for improved healing of the eye, particularly in respect to the time for the eye to heal.
The type of intraocular lens is not limited in any way. It may, for example, comprise one or more optic and one or more haptic components, wherein the one or more optic components serve as lens and the one or more haptic components are attached to the one or more optic components and hold the one or more optic components in place in the eye. The present intraocular lens may be of a one-piece design or of multi-piece design, depending on whether the one or more optic components and the one or more haptic components are formed from a single piece of material (one- piece design) or are made separately and then combined (multi-piece design). The present intraocular lens is also designed in such a way that it allows to be, for example, rolled up or folded small enough so that it fits through an incision in the eye, said incision being as small as possible, for example, at most 3 mm in length. Additionally, intraocular lenses in accordance with the present invention allow for the non-invasive adjustment of the optical properties, particularly the refractive power, after implantation of the lens into the eye, thus reducing the need for post-surgery vision aids or reducing or totally avoiding follow-up surgery.
In order to change the optical properties and particularly the refractive power of the intraocular lens it is exposed to irradiation having a
wavelength of at least 200 nm and of at most 1500 nm. Hence, the present invention is also directed to a process of changing the optical properties of an article as defined or preferably defined herein, said process comprising the steps of
- providing an article as defined herein; and
- subsequently exposing said article to irradiation having a wavelength of at least 200 nm and at most 1500 nm.
Preferably, said irradiation has a wavelength of at least 250 nm or 300 nm, more preferably of at least 350 nm, even more preferably of at least 400 nm, still even more preferably of at least 450 nm, and most preferably of at least 500 nm. Preferably, said irradiation has a wavelength of at most 1400 nm or 1300 nm or 1200 nm or 1 100 nm or 1000 nm, more preferably of at most 950 nm or 900 nm, even more preferably of at most 850 nm, still even more preferably of at most 800 nm and most preferably of at most 750 nm. Examples
The following examples are intended to show the advantages of the present compounds in a non-limiting way.
Unless indicated otherwise, all syntheses can be or are carried out under an inert atmosphere using dried (i.e. water-free) solvents. Solvents and reagents are purchased or can be purchased from commercial suppliers. DCM is used to denote dichloromethane. DMF is used to denote
dimethylformamide. EE is used to denote ethyl acetate. THF is used to denote tetrahydrofuran.
Co-polymer-properties can be investigated on blanks, prepared by bulk polymerization of the monomers. Co-monomers, cross-linkers and initiators therefore can be purchased from commercial sources. All chemicals are of highest purity available and can be used as received. Synthesis of precursor materials:
General remarks & general synthetic procedures (GSP) - Trifluormethylation or trif luorethylation of carbon nucleophiles: The introduction of a trifluormethyl- or trifluoroethyl group to the
corresponding carbon nucleophile is performed with 3,3-dimethyl-1 - (trifluoromethyl)-1 ,2-benziodoxole, 5-(trifluoromethyl)dibenzothiophenium triflate as well as phenyl(2,2,2-trifluoroethyl)iodonium
bis((trifluoromethyl)sulfonyl)amid. The experimental procedures for this reactions can be found under the following DOI numbers:
10.1021/jo981065b, 10.1002/chem.200501052, 10.1021/ja00059a009.
Characterization of precursor materials:
Diethyl 2-methylmalonat:
Figure imgf000265_0001
1H NMR (500 MHz, CDCIs) δ 4.23-4.16 (m, 4H), 3.41 (q, 1 H, J = 7.3 Hz), 1 .41 (d, 3H, J = 7.3 Hz), 1 .27 (t, 6H, J = 7.1 Hz).
2,2,3,3,4,4-hexafluoro-5-hydroxypentyl acrylate:
Figure imgf000266_0001
This compound is synthesized based on the procedure described in US 2012/308802, preparation example 1 , [0071 ].
1H NMR (500 MHz, CDCIs) δ 6.52 (dd, 1 H, Ji = 17.3 Hz, J2 = 1 .1 Hz), 6.18 (dd, 1 H, Ji = 17.3 Hz, J2 = 10.5 Hz), 5.97 (dd, 1 H, Ji = 10.5 Hz,
J2 = 1 .1 Hz), 4.66 (t, 2H, J = 14.1 Hz), 4.12-4.05 (m, 2H), 1 .97 (t, 1 H, J = 7.5 Hz).
Example 1 :
General remarks & general synthetic procedures (GSP 1) for the reduction of aliphatic diesters or diketones to the corresponding diols:
Figure imgf000266_0002
Solid, fine powdered lithiumaluminium hydride (2.0 - 5.0 equiv.) is suspended in dry THF at room temperature. The corresponding diacid- or diester derivative is dissolved in dry THF and the solution is slowly added dropwise to the lithiumaluminium slurry while cooling with an ice bath. After complete addition, the reaction solution is warmed to room temperature and the consumption of the starting material is checked by TLC. The
suspension is carefully quenched with 2M H2SO4, additional water is added. For a better workup, the suspension should have a pH of ~7. The phases are separated and extracted with Et.20. The organic phase is washed with H2O, dried over MgSO4 and evaporated under reduced pressure. The crude product is directly used without further purification or purified via column chromatography using cyclohexane / tert. -butyl methyl ether. 1H NMR (500 MHz, CDCIs) δ 3.70 (t, 4H, J = 6.3 Hz), 2.00-1 .90 (m, 4H), 1 .79-1 .74 (m, 4H), 1 .38 (br s, 2H).
Analogously, other diol derivatives are prepared in the same manner:
Figure imgf000267_0001
Example 2: General remarks & general synthetic procedures (GSP 2) for the synthesis of S-(4-formyl-3-hydroxyphenyl) dimethylcarbamothioate derivatives:
Figure imgf000268_0001
Hydroxy-2-methoxybenzaldehyde (5.00 g; 32.2 mmol) is combined with dimethylthiocarbamoyl chloride (5.34 g, 41 .9 mmol) in dimethylformamide (12.52 ml, 161 .0 mmol) in an ice bath. 1 ,8 Diazabicyclo[5.4.0]undec-7-ene (5.05 ml; 33.8 mmol) is added slowly. The reaction is stirred overnight with concomitant warming to RT. The reaction is quenched by pouring on water. The precipitated solid is collected via filtration, washed (3x) with water, and then dried to obtain the crude product. Further purification via
recrystallisation with water and enough EtOH to solve product in the heat yields Dimethyl-thiocarbamic acid 4-formyl-3-methoxy-phenyl ester (5.26 g, 22.0 mmol, 68 % of theory).
Step 2:
Figure imgf000268_0002
Dried Dimethyl-thiocarbamic acid 4-formyl-3-methoxy-phenyl ester (5.26 g, 22.0 mmol) is placed in a round bottom flask that is fitted with a reflux condenser. The apparatus is maintained under an argon atmosphere and the reaction is heated in an oil bath to 185 °C. The reaction is allowed to progress until TLC analysis indicated that the starting material has been consumed (approx. 4 h). The flask is cooled and the brown solid is dissolved in DCM, adsorbed on silica gel and directly purified with column chromatography (hexane/ethyl acetate;7:3) to afford dimethyl-thiocarbamic acid 4-formyl-3-methoxy-phenyl ester (4.07 g, 17.0 mmol, 77 % of theory).
Step 3 :
Figure imgf000269_0001
Boron tribromide (1 .94 ml, 20.4 mmol) is added slowly to a cooled solution of dimethyl-thiocarbamic acid 4-formyl-3-methoxy-phenyl ester (4.07 g, 17.0 mmol) dissolved in Dichloromethane (anhydrous) (27.15 ml, 425.2 mmol). The solution is kept under Ar atmosphere and left to stir while gradually warming to room temperature until consumption of the starting material is observed by TLC. The reaction is then quenched by poring into a stirred 1 M HCI/ice mixture for 10 min. The solution is extracted with ether (2x) and the organic layer is washed with brine, dried with MgSO4 and evaporated. The remaining solid is recrystallized from heptane with addition of toulene until clear solution is obtained. The precipitate is filtered to yield dimethyl- thiocarbamic acid 4-formyl-3-hydroxy-phenyl ester (3.41 g, 15.1 mmol, 89 % of theory).
Example 3:
General remarks & general synthetic procedures (GSP 3) for the bromination of methyl phenylacetate derivatives:
Figure imgf000269_0002
To a stirred solution of the methyl 2-bromophenylacetate (0.86 ml; 5.31 mmol) in dichloromethane (10.2 ml, 159 mmol) are added N- bromosuccinimide (1 .04 g, 5.84 mmol) and azobisisobutyronitrile (43.6 mg, 0.27 mmol) at room temperature and the mixture is stirred at 100 °C for 16 h under argon atmosphere. The reaction mixture is cooled down to room temperature. The mixture is diluted with diethyl ether and filtered. The filtrate is evaporated to dryness. The oily residue containing solid succinimid is diluted with heptane and filtered again. The solvent is removed to afford methyl 2-bromo-2-(4-bromophenyl)acetate (1 .38 g, 4.56 mmol, 86 % of theory).
Analogously, other phenol derivatives are prepared in the same manner:
Figure imgf000270_0001
Example 4:
General remarks & general synthetic procedures (GSP 4) for the synthesis of 2-phenyl-benzofurans from hydroxy-benzaldehyde derivatives or dimethyl-thiocarbamic acid 4-formyl-3-hydroxy-phenyl ester derivatives with meth l 2-bromo-2-(4-bromophenyl)acetate:
Figure imgf000271_0001
2-Hydroxy-4-methoxybenzaldehyde (1 .52 g, 9.99 mmol) and a- bromophenylacetatic acid methyl ester (1 .72 ml, 10.99 mmol) are dissolved in dimethylformamide (50.5 ml, 649 mmol). To the solution is added potassium carbonate (6.90 g, 49.9 mmol). The mixture is stirred at 100 °C for 2 h. The mixture is cooled to 25 °C and portioned to EtOAc and HCI (1 N, aq.). The organic layer is separated, washed with brine and dried over MgSO4. Evaporation of solvent gives brownish oily residue. The residue is dissolved in ethanol (40.9 ml, 699 mmol). To the solution is added potassium hydroxide (5.04 g, 89.9 mmol). The mixture is refluxed for 2 h. The mixture is cooled to ambient temperature and acidified with HCI (cone). The precipitating solid is filtered off and recrystallized from toluene to give 6-methoxy-2-phenyl-benzofuran (1 .07 g, 4.78 mmol, 48 % of theory).
1H NMR (500 MHz, DMSO-de) δ 7.86 (d, J = 8.4 Hz, 2H), 7.53 (d,
J = 8.5 Hz, 1 H), 7.49 (t, J = 7.8 Hz, 2H), 7.38 (t, J = 7.4 Hz, 1 H), 7.26 (d,
J = 1 .9 Hz, 1 H), 6.91 (dd, J = 8.5 Hz, 2.2 Hz, 1 H), 3.84 (s, 3H).
Analogously, other phenol derivatives are prepared in the same manner: R1 means reactant 1 , R2 means reactant 2, [P] means product
Figure imgf000271_0002
Figure imgf000272_0001
Figure imgf000273_0001
Figure imgf000274_0001
Figure imgf000275_0002
Example 5:
General remarks & general synthetic procedures (GSP 5) for the Suzuki reaction of halogen-substituted 2-phenyl-benzofurans with boronic acids:
Figure imgf000275_0001
2-(4-Bromo-phenyl)-6-methoxy-benzofuran (550 mg, 1 .81 mmol), pentylboronic acid (463 mg, 3.99 mmol) and tripotassium phosphate monohydrate (1 .75 g, 7.62 mmol) are dissolved in toluene (19.2 ml, 181 mmol). Then 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl [SPhos] (149 mg, 359 μηηοΙ) and palladium(ll) acetate (40.7 mg, 180 μηηοΙ) are added and the reaction reaction mixture is heated to 120 °C for 1 d. The cooled reaction mixture is diluted with ethyl acetate and HCI solution (2 M). The solution is transferred to a separatory funnel. The organic phase is extracted with HCI solution (2 M) and water and brine. The organic phase is dried over MgS04, filtered and concentrated under reduced pressure. The residue is purified by silica gel column chromatography (heptane/ethyl acetate [5/1 ]) to yield 6-Methoxy-2-(4-pentyl-phenyl)-benzofuran (350 mg, 1 .2 mmol, 66% of theory).
1 H NMR (500 MHz, Chloroform-d) δ 7.65 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 8.5 Hz, 1 H), 7.17 (d, J = 8.1 Hz, 2H), 6.99 (d, J = 2.1 Hz, 1 H), 6.82 (s, 1 H), 6.79 (dd, J = 8.5 Hz, 2.3 Hz, 1 H), 3.80 (s, 3H), 2.59 - 2.54 (m, 2H), 1 .58 (p, J = 7.5 Hz, 2H), 1 .32 - 1 .24 (m, 4H), 0.83 (t, J = 6.9 Hz, 3H).
Analogously, other phenol derivatives are prepared in the same manner: R1 means reactant 1 , R2 means reactant 2, [P] means product
Figure imgf000276_0001
Figure imgf000277_0001
Figure imgf000278_0003
Example 6:
General remarks & general synthetic procedures (GSP 6) for the deprotection to synthesize the phenol or thiol derivatives:
Figure imgf000278_0001
To a solution of 2-(2-ethyl-4-pentylphenyl)-6-methoxybenzofuran in DCM is added BBr3 (2.0 equiv.) at 0 °C. The resulting mixture is heated up to reflux overnight. After cooling down the reaction mixture to room temperature, it is poured on an ice/water mixture, filtrated and the resulting solid is dried in vacuo. The phenol derivative is obtained in 77% of theory.
Figure imgf000278_0002
Dimethyl-thiocarbamic acid 3-(4-chloro-2-trifluoromethyl-phenyl)-coumarin- 7-yl ester (900.00 mg, 2.1 mmol) is dissolved in methanol (2.09 ml, 51 .6 mmol). Sodium hydroxide solution (3N, aq.) (0.42 ml, 1 .3 mmol) is added, and the reaction mixture is heated to reflux overnight. The reaction mixture is cooled to 25 °C and acidified by the addition of HCI (10%, aq.). The milky solution is then extracted with EtOAc (*2) and the combined organic layers are washed with brine then dried with MgSO4, filtered and concentrated. The obtained light brown oil is purified using silica gel chromatography (chloroform/methanol; 30/1 ) to afford 2-(2-ethyl-4-pentylphenyl)benzofuran- 6-thiol (400.00 mg, 1 .1 mmol, 53 % of theory).
Analogously, other phenol and thiol derivatives are prepared in the same manner:
Figure imgf000279_0001
Example 7: General remarks & general synthetic procedures (GSP 7) for the reaction of the corresponding fluorinated diols or monoalcohol with 2 phenylbenzofuran-6-ol (Mitsunobu alkylation type reaction):
Figure imgf000280_0001
To an ice-cooled solution of 2-phenylbenzofuran-6-ol, aliphatic fluorinated diol or monoalcohol (1 .0 equiv.) and triphenylphosphine in THF (1 .43 equiv.), diisopropyl azodicarboxylate (1 .43 equiv.) is added dropwise. After stirring at room temperature overnight, the reaction mixture is evaporated. The crude product is purified by column chromatography (cyclohexane / EE).
Analogously, other phenol derivatives are prepared in the same manner: R1 means reactant 1 , R2 means reactant 2, [P] means product
Figure imgf000280_0002
Figure imgf000281_0001
Figure imgf000282_0001
Example 8:
General remarks & general synthetic procedures (GSP 8) for the reaction of bromo-functionalized hydrophic linkers with 2-(2-ethyl-4- pentylphenyl)-benzofuran-6-thiol:
For the reaction of thiols with the fluorinated aliphatic linker, the bromo- functionalized derivatives of the corresponding diols are prepared in advance through reaction of the corresponding diol with HBr in refluxing toluene.
Figure imgf000283_0001
2-(4-Pentyl-2-(trifluoronnethoxy)phenyl)benzofuran-6-thiol and 8-bromo- 3,3,4,4,5,5,6,6-octafluorooctan-1 -ol (1 .05 equiv.) are dissolved in anhydrous DMF. Then, K2CO3 (4.0 equiv.) is added and the suspension is heated up to reflux until completion of the reaction. The reaction mixture is filtrated and the separated solid is thoroughly washed with additional acetone. The filtrate is concentrated in vacuo and the crude product is purified via column chromatography using cyclohexane / EE as an eluent. 3,3,4,4,5,5,6,6-octafluoro-8-((2-(4-pentyl-2-
(trifluoromethoxy)phenyl)benzofuran-6-yl)thio)octan-1 -ol can be isolated in 76% yield (of theory) as a pale beige solid.
Analogously, other phenol derivatives are prepared in the same manner: R1 means reactant 1 , R2 means reactant 2, [P] means product
Figure imgf000283_0002
Preparation of compounds according to the invention: Example 9: General remarks & general synthetic procedures (GSP 9) for the esterification with acryloyl chloride or methacryloyl chloride to the corresponding monomer:
Figure imgf000284_0001
The corresponding aliphatic alcohol is dissolved in dry THF and the solution is cooled with an ice-bath. T ethylamine (4.00 equivs.) is added and the solution is stirred for a few minutes. Then acryloyl chloride or methacryloyl chloride (1 .05 - 2.00 equivs.) is added at ice-bath temperature, while precipitating a colourless solid. The solution is stirred for several hours and is monitored via TLC. Upon completion of the reaction, the suspension is filtrated and washed with THF. The filtrate is evaporated under reduced pressure and purified via column chromatography using cyclohexane / ethyl acetate.
Analogously, other phenol derivatives are prepared in the same manner: R means reactant, [P] means product
Figure imgf000284_0002
Figure imgf000285_0001
Figure imgf000286_0001
Example 10:
General remarks & general synthetic procedures (GSP 10) for the for the solvent polymerization of the monomers:
The corresponding monomer is dissolved in dry Ν,Ν-dimethylformamide in a Schlenck-tube with a stirring bar. The solution is degassed performing three times freeze-evacuate-thaw cycles. After that, azoisobutyronitrile (AIBN, 0.05 equiv.) is added in one portion to the degassed solution, which is heated up to 65 °C in an oil bath for a minimum of three days. The solution is cooled to room temperature and is then poured dropwise into cold methanol (100 ml methanol / 100 mg monomer) while stirring. The precipitated polymer is collected on a frit or the solution is centrifuged several times to obtain the final polymer material.
Examples of polymers within this invention are given in the following table:
Figure imgf000286_0002
Figure imgf000287_0001
Figure imgf000288_0001
Figure imgf000289_0002
Synthesis of precursor materials:
Example 1 1 :
General remarks & general synthetic procedures (GSP 11) for the synthesis of 6-Methox -2-phenyl-benzothiophene:
Figure imgf000289_0001
2-Mercapto-4-methoxy-benzaldehyde (944 mg, 5.61 mmol) and a- Bromophenylacetatic acid methyl ester (969 μΙ, 6.17 mmol) are dissolved in dimethylformamide (28.4 ml, 364 mmol). To the solution is added potassium carbonate (3.88 g, 28.1 mmol). The mixture is stirred at 100 °C for 2 h. The mixture is cooled to 25 °C and portioned to EtOAc and HCI (1 N, aq). The organic layer is separated, washed with brine and dried over MgSO4. Evaporation of solvent gives a colorless solid. The residue is recrystallized from ethanol to yield 6-methoxy-2-phenyl-benzo[b]thiophene (780 mg, 3.25 mmol, 58 % of theory). 1 H NMR (500 MHz, DMSO-d6) δ 7.77 (s, 1 H), 7.76 - 7.72 (m, 3H), 7.57 (d, J = 2.4 Hz, 1 H), 7.47 (t, J = 7.7 Hz, 2H), 7.36 (t, J = 7.3 Hz, 1 H), 7.02 (dd, J = 8.7 Hz, 2.4 Hz, 1 H), 3.85 (s, 3H).
Analogously prepared benzo[b]thiophenes:
Figure imgf000290_0002
Example 12:
General remarks & general synthetic procedures (GSP 12) for the Suzuki reaction of the corresponding halogenated 2-phenyl- benzothiophenes with boronic acids:
Figure imgf000290_0001
2-(4-Bromo-phenyl)-6-methoxy-benzo[b]thiophene (480 mg, 1 .51 mmol), pentylboronic acid (209 mg, 1 .80 mmol) and tripotassium phosphate monohydrate (1 .45 g, 6.31 mmol) are dissolved in toluene (15 ml, 150 mmol). Then 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl [SPhos] (124 mg, 0.301 mmol) and palladium(ll) acetate (8.4 mg, 0.040 mmol) are added and the reaction reaction mixture is heated to 90 °C upon completion of the reaction. The cooled reaction mixture is diluted with ethyl acetate and HCI solution (2 M). The solution is transferred to a separatory funnel. The organic phase is extracted with HCI solution (2 M) and water and brine. The organic phase is dried over MgSO4, filtered and concentrated under reduced pressure. The residue is purified by silica gel column
chromatography (heptane/ethyl acetate [5/1 ]) to yield 6-methoxy-2-(4- pentylphenyl)benzo[b]thiophene (390 mg, 1 .26 mmol, 84 % of theory).
1 H NMR (500 MHz, CDCI3) δ 7.63 (d, 1 H, J = 8.7 Hz), 7.59 (d, 2H, J =8.2 Hz), 7.41 (s, 1 H), 7.30 (d, 1 H, J = 2.4 Hz), 7.25 (d, 2H, J = 8.1 Hz), 6.98 (dd, 1 H, J = 8.7 Hz, 2.4 Hz), 3.89 (s, 3H), 2.61 - 2.58 (m, 2H), 1 .56 (p, 2H, J = 7.5 Hz), 1 .30 - 1 .22 (m, 4H), 0.83 (t 3H, J = 6.9 Hz, 3H).
Analogously, other Suzuki derivatives are prepared in the same manner: R1 means reactant 1 , R2 means reactant 2, [P] means product
Figure imgf000291_0001
Figure imgf000292_0002
Selected NMR data for
Figure imgf000292_0001
1 H NMR (500 MHz, CDCI3) δ 7.63 (d, 1 H, J = 8.7 Hz), 7.60 (d, 2H, J =8.2 Hz), 7.41 (s, 1 H), 7.31 (d, 1 H, J = 2.4 Hz), 7.24 (d, 2H, J = 8.1 Hz), 6.97 (dd, 1 H, J = 8.7 Hz, 2.4 Hz), 3.8 (s, 3H), 2.69 (q, 2H, J = 7.6 Hz), 1 .27 (t, 3H, J = 7.6 Hz).
Example 13:
General remarks & general synthetic procedures (GSP 13) for the de rotection of the benzothiophene ethers to the phenol derivatives:
Figure imgf000293_0001
6-Methoxy-2-phenyl-benzo[b]thiophene (780.00 mg, 3.25 mmol) is dissolved in Dichloromethane (anhydrous) (20.73 ml, 324.57 mmol) and cooled to 5 °C. Boron tribromide (369.60 μΙ, 3.89 mmol) is added dropwise to this solution over the course of 10 min, and stirring is continued for 2 h. The reaction mixture is subsequently slowly poured into water, and the organic phase is diluted with ethyl acetate, washed three times with water, dried over MgSO4, evaporated in a rotary evaporator. Recrystallization from toluene/heptane (1/10) yielded 2-Phenyl-benzo[b]thiophen-6-ol (657.00 mg, 2.90 mmol, 90 % of theory).
1 H NMR (500 MHz, DMSO-d6) δ 9.65 (s, 1 H), 7.70-7.69 (m, 3H), 7.64 (d, 1 H, J = 8.6 Hz), 7.44 (t, 2H, J = 7.7 Hz), 7.33 (t, 1 H, J = 7.4 Hz), 7.27 (d, 1 H, J = 1 .7 Hz), 6.88 (dd, 1 H, J = 8.5 Hz, 2.3 Hz).
Analogously, other derivatives are prepared in the same manner: R means reactant, [P] means product
Figure imgf000293_0002
Figure imgf000294_0002
Selected NMR data for
Figure imgf000294_0001
1 H NMR (500 MHz, DMSO-d6) δ 9.61 (s, 1 H), 7.65 (d, 1 H, J = 8.4 Hz), 7.59 (d, 2H, J =8.3 Hz), 7.35 (s, 1 H), 7.29 (d, 1 H, J = 2.1 Hz), 7.21 (d, 2H, J = 8.3 Hz), 7.01 (dd, 1 H, J = 8.3 Hz, 2.1 Hz), 2.73 (q, 2H, J = 7.4 Hz), 1 .29 (t, 3H, J = 7.4 Hz).
Example 14:
General remarks & general synthetic procedures (GSP 14) for the reaction of the corresponding fluorinated diol with 2-Phenyl- benzo[b]thiophen-6-ol (Mitsunobu alkylation type reaction):
Figure imgf000295_0001
To an ice-cooled solution of 2-phenyl-benzo[b]thiophen-6-ol, aliphatic fluorinated diol or monoalcohol (1 .0 equiv.) and triphenylphosphine in THF (1 .43 equiv.), diisopropyl azodicarboxylate (1 .43 equiv.) is added dropwise. After stirring at room temperature overnight, the reaction mixture is evaporated. The crude product is purified by column chromatography (cyclohexane / EE).
Analogously, other derivatives are prepared in the same manner:
R1 means reactant 1 , R2 means reactant 2, [P] means product
Figure imgf000295_0002
Figure imgf000296_0001
Figure imgf000297_0001
Preparation of compounds according to the invention:
Example 15: General remarks & general synthetic procedures (GSP 15) for the esterification with acryloyl chloride or methacryloyl chloride to the corresponding monomer:
Figure imgf000298_0001
The corresponding aliphatic alcohol is dissolved in dry THF and the solution is cooled with an ice-bath. T ethylamine (4.00 equivs.) is added and the solution is stirred for a few minutes. Then acryloyl chloride or methacryloyl chloride (1 .05 - 2.00 equivs.) is added at ice-bath temperature, while precipitating a colourless solid. The solution is stirred for several hours and is monitored via TLC. Upon completion of the reaction, the suspension is filtrated and washed with THF. The filtrate is evaporated under reduced pressure and purified via column chromatography using cyclohexane / ethyl acetate. Analogously, other acrylate or methacrylate derivatives are prepared in the same manner: R means reactant, [P] means product
Figure imgf000298_0002
Figure imgf000299_0001
Figure imgf000300_0001
Example 16:
General remarks & general synthetic procedures (GSP 16) for the solvent polymerization of the monomers:
The corresponding monomer is dissolved in dry Ν,Ν-dimethylformamide in a Schlenck-tube with a stirring bar. The solution is degassed performing three times freeze-evacuate-thaw cycles. After that, azoisobutyronitrile
(AIBN, 0.05 equiv.) is added in one portion to the degassed solution, which is heated up to 65 °C in an oil bath for a minimum of three days. The solution is cooled to room temperature and is then poured dropwise into cold methanol (100 ml methanol / 100 mg monomer) while stirring. The precipitated polymer is collected on a frit or the solution is centrifuged several times to obtain the final polymer material.
Examples of polymers within this invention are given in the following table:
Figure imgf000300_0002
Figure imgf000301_0001
Figure imgf000302_0003
Synthesis of precursor materials:
Example 17:
General remarks & general synthetic procedures (GSP 17) for the synthesis of 5-methoxy-2-(phenylethynyl)aniline:
Figure imgf000302_0002
Bis(triphenylphosphine)palladium(ll) dichloride (32.1 mg, 45.8 μιτιοΙ), copper(l) iodide (17.8 mg, 91 .5 μιτιοΙ), 2-iodo-5-methoxyaniline (1 .2 g, 4.6 mmol), phenylacetylene (572.5 ml, 5.5 mmol), and diethylamine (10 ml) are refluxed until consumption of the starting materials monitored by TLC. The residue is chromatographed on silica gel (heptane/EE, 10/1 ) to afford 5- Methoxy-2-(phenylethynyl)aniline (818 mg, 3.7 mmol, 80 % of theory).
1 H NMR (500 MHz, Chloroform-d) δ 7.54 (d, J = 6.7 Hz, 2H), 7.36 (q, J = 8.9 Hz, 7.7 Hz, 2H), 7.32 (q, J = 8.9 Hz, 8.5 Hz, 2H), 6.34 (dd, J = 8.5 Hz, 2.4 Hz, 1 H), 6.30 (d, J = 2.3 Hz, 1 H), 3.82 (s, 3H).
Example 18:
General remarks & general synthetic procedures (GSP 18) for the synthesis of 6-methoxy-2-phenylindole:
Figure imgf000302_0001
To a refluxing solution of 5-Methoxy-2-(phenylethynyl)aniline (826 mg, 3,7 mmol) in toluene (40 ml) is added zinc bromide (420.8 mg, 1 ,8 mmol) in one portion. After refluxing for 3 d, the reaction mixture is washed with water and extracted with dichloromethane. The combined extracts are dried over MgSO4, filtered, and the solvent is removed under reduced pressure. The solid is passed through a pad of silica gel (heptane/dichloromethane; 5/1 ) to afford 6-methoxy-2-phenylindole (585 mg, 2.6 mmol, 71 % of theory) and is used in the next step without further analyses. Example 19:
General remarks & general synthetic procedures (GSP 19) for the s nthesis of 6-methoxy-1 -methyl-2-phenylindole:
Figure imgf000303_0001
To a solution of 6-methoxy-2-phenylindole (488 mg, 2.2 mmol) in
dimethylformamide (25 ml) is added methyl iodide (304 μΙ, 4.8 mmol) followed by sodium hydride (182 mg, 4.6 mmol). The mixture is stirred at room temperature for 16 h. Then the mixture is poured onto an ice/NaOH (2M) mixture and the resulting emulsion is extracted with dichloromethane. After drying over MgSO4, the solution is evaporated to dryness. The residue is purified by column chromatography over silica gel eluting with
dichloromethane to yield 198 mg (826 μιτιοΙ, 38 % of theory) of the title compound.
1 H NMR (500 MHz, Chloroform-d) δ 7.54 (d, J = 8.2 Hz, 1 H), 7.52 (d, J = 7.0 Hz, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.41 (d, J = 7.3 Hz, 1 H), 6.86 (s, 1 H), 6.85 (dd, J = 8.4 Hz, 1 .4 Hz, 1 H), 6.52 (s, 1 H), 3.94 (s, 3H), 3.73 (s, 3H).
Analogously, other derivatives are prepared in the same manner:
R1 means reactant 1 , R2 means reactant 2, [P] means product
Figure imgf000304_0001
Figure imgf000305_0002
Example 20:
General remarks & general synthetic procedures (GSP 20) for the s nthesis of 6-hydroxy-1 -methyl-2-phenylindole:
Figure imgf000305_0001
6-Methoxy-1 -methyl-2-phenylindole (184 mg, 775 μιτιοΙ) is dissolved in dichloromethane (10 ml) and cooled to 5 °C. Boron tribromide (96.6 μΙ, 1 .0 mmol) are added dropwise to this solution, and stirring is continued overnight. Water is subsequently slowly added to the mixture, and the organic phase is diluted with ethyl acetate, washed three times with water, dried over MgSO4, evaporated under reduced pressure and filtered through a pad of silica gel with dichloromethane to yield 6-hydroxy-1 -methyl -2- phenylindole (1 17 mg, 524 μιτιοΙ, 68 % of theory).
1 H NMR (500 MHz, Chloroform-d) δ 7.54 - 7.46 (m, 5H), 7.41 (t, 1 H, J = 6.4 Hz), 6.84 (d, 1 H, J = 2.2 Hz), 6.72 (dd, 1 H, J = 8.4 Hz, 2.3 Hz), 6.51 (s, 1 H), 4.62 (s, 1 H), 3.70 (s, 3H).
Analogously, other derivatives are prepared in the same manner:
Figure imgf000306_0002
Example 21 :
General remarks & general synthetic procedures (GSP 21) for the reaction of the corresponding fluorinated diol or monoalcohol with 6- Hydroxy-1 -methyl-2-phenylindole (Mitsunobu alkylation type reaction):
Figure imgf000306_0001
To an ice-cooled solution of 6-hydroxy-1 -methyl-2-phenylindole, aliphatic fluorinated diol or monoalcohol (1 .0 equiv.) and triphenylphosphine in THF (1 .43 equiv.), diisopropyl azodicarboxylate (1 .43 equiv.) is added dropwise. After stirring at room temperature overnight, the reaction mixture is evaporated. The crude product is purified by column chromatography (cyclohexane / EE). Analogously, other derivatives are prepared in the same manner: R1 means reactant 1 , R2 means reactant 2, [P] means product
Figure imgf000307_0001
Figure imgf000308_0001
Figure imgf000309_0001
Figure imgf000310_0002
Preparation of compounds according to the invention:
Example 22:
General remarks & general synthetic procedures (GSP 22) for the esterification with acryloyl chloride or methacryloyl chloride to the corresponding monomer:
Figure imgf000310_0001
The corresponding aliphatic alcohol is dissolved in dry THF and the solution is cooled with an ice-bath. Triethylamine (4.00 equivs.) is added and the solution is stirred for a few minutes. Then acryloyl chloride or methacryloyl chloride (1 .05 - 2.00 equivs.) is added at ice-bath temperature, while precipitating a colourless solid. The solution is stirred for several hours and is monitored via TLC. Upon completion of the reaction, the suspension is filtrated and washed with THF. The filtrate is evaporated under reduced pressure and purified via column chromatography using cyclohexane / ethyl acetate.
Analogously, other acrylate or methacrylate derivatives are prepared in the same manner: R means reactant, [P] means product
Figure imgf000311_0001
Figure imgf000312_0001
Figure imgf000313_0001
Example 23:
General remarks & general synthetic procedures (GSP 23) for the solvent polymerization of the monomers:
The corresponding monomer is dissolved in dry Ν,Ν-dimethylformamide in a Schlenck-tube with a stirring bar. The solution is degassed performing three times freeze-evacuate-thaw cycles. After that, azoisobutyronitrile (AIBN, 0.05 equiv.) is added in one portion to the degassed solution, which is heated up to 65 °C in an oil bath for a minimum of three days. The solution is cooled to room temperature and is then poured dropwise into cold methanol (100 ml methanol / 100 mg monomer) while stirring. The precipitated polymer is collected on a frit or the solution is centrifuged several times to obtain the final polymer material.
Examples of polymers within this invention are given in the following table:
Figure imgf000314_0001
Examples of application:
Example 24 - General bulk polymerization procedure to produce blank
A composition of MH-indol derivative M-N3 and methyl methacrylate, initiator azobisisobutyronitrile (0.04 eq) and crosslinker ethylene glycol dimethacrylate (0.1 - 0.4 eq) in different ratios is degassed by three freeze- pump-thaw cycles.
Two glass plates are coated with a polyethylene sheet and a 0.5 mm thick cell is created between the polyethylene sheets using a silicone rubber gasket. The coated faces of the glass sheets are clipped together using spring clips with a syringe needle being placed between the gasket and the polyethylene sheets. The cavity is then filled with the above formulation through the needle using a gastight syringe. Once the cavity is filled the syringe needle is removed, a final clip is used to seal the mould and the assembly is placed in an oven at 60°C for 24 hours before the oven is ramped to a temperature of 90°C for a period of 3 hours. The moulds are allowed to cool to room temperature before the film is removed from the mould.
Examples directed to the properties of the compounds
Example 25 - photoinduced refractive index change and glass transition temperature The phase transition temperatures are determined with a TA Instruments Q2000 differential scanning calorimeter during heating in the second heating run with 20 K/min from -100 °C to 200 °C in a hermetic aluminum pans.
Irradiations of the blanks are performed with a Coherent Avia 355-7000 UV- Laser.
Common photoactive polymers that undergo refractive index change upon irradiation with UV-light exhibit glass transition temperatures as low as 34°C. Polymer films for refractive index measurements are prepared by spin coating or drop casting from 1 -8 wt% solutions of the polymers in
chloroform onto silicon wafers or quartz plates. For production of bulk polymer blanks, the monomers are melted under vacuum. Appropriate amounts of a radical initiator and cross-linker are mixed in and quickly filled into a heated polymerization chamber. Cross-linked polymer plates are obtained.
Refractive index change is induced by irradiation at 340 - 365 nm. The refractive indices (n) of the polymer films and blanks at 590 nm are measured on Schmidt+Haensch AR12 before and after irradiation. The following table shows the refractive indices before and after irradiation as well as the change in refractive index (max. Δη). Expected values for the cited polymers are given in the following table:
Figure imgf000316_0001

Claims

Patent claims 1. Connpounds of formula I)
Figure imgf000317_0001
wherein
X is O, S or NRo,
Y is independently of each other O, S or a bond, n is 0 or 1 ,
m is 0 or 1 ,
n+m is 1 or 2,
-[B]- is selected from the group consisting of formula (1 ) to formula (4),
Figure imgf000317_0002
Xi, X2, X3, X4 are each independently of each other CR' or N, X5 is each independently O, S, C=O or NRo,
ΧΘ, X7 are each independently CR' or N, R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 8 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms, R' is at each occurrence independently selected from the group consisting of H, F, a linear or branched, non- halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a linear or branched hydroxyalkyl group having 1 to 20 C atoms, a non- halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms,
R0 is at each occurrence independently selected from the group consisting of a linear or branched alkyl group having 1 to 10 C atoms or a cycloalkyl group having 3 to 6 C atoms,
R1 is a polymerizable group selected from the group
consisting of
an alkenyl group of formula (5),
Figure imgf000318_0001
wherein
Xio is selected from the group consisting of O, S
C(=0), C(=0)0, Rs, R9, R10 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non-fluorinated, partially or completely fluorinated alkyl having 1 to 20 C atoms or aryl with 6 to 14 C atoms,
c is 0 or 1 ; and
trial koxysilyl groups or dialkoxyalkylsilyl groups where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms; and
silyl groups of formula (6), (7) or (8),
Figure imgf000319_0001
where alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk "*" denotes at each occurrence independently of each other a linkage to the linker [-R2- Y]n and/or [Y-R2]m,
-R2- is -(C(R)2)o- or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)^
(Xio)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,
or
a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,
o is selected from the group consisting of 1 to 20,
Xs, X9, Xio are at each occurrence independently O, S, or NRo, s, t are at each occurrence independently 0 or 1 ,
p, q are at each occurrence independently selected from the group consisting of 1 to 10,
r, u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)^(Xio)t-
(C(R)2)u-, is up to 20 atoms,
R3, R4, R5, R6 are at each occurrence independently R',
R7 is R' in case m is 0 and
R7 is Ri in case m is 1 .
2. Compounds according to claim 1 wherein -[B]- corresponds to formula (1 ) or formula (2).
3. Compounds according to claim 1 or 2 wherein Xi, X3 and X4 in formulae (1 ) or (2) are CR' and R' has at each occurrence independently a meaning as indicated in claim 1 .
4. Compounds according to one or more of claims 1 to 3 wherein X2 is CR' and R' has a meaning as indicated in claim 1 .
5. Compounds according to one or more of claims 1 to 4 wherein at least one R' within Xi, X2, X3, X4, ΧΘ, or X7 in formulae (1 ) to (4) is not H.
6. Compounds according to one or more of claims 1 to 5 wherein n is 1 and m is 0 said compounds being of formula (Γ)
Figure imgf000321_0001
wherein Ri, -R2-, Y, R3, R4, R5, R6, X, -[B]-, and R7 have a mean indicated in one of claims 1 to 5.
7. Compounds according to one or more of claims 1 to 5 wherein n is 0 and m is 1 said com ounds being of formula (I")
Figure imgf000321_0002
wherein Ri, -R2-, Y, R3, R4, R5, R6, X, -[B]- and R7 have a meaning as indicated in one of claims 1 to 5.
8. Compounds according to one or more of claims 1 to 5 wherein n is 1 and m is 1 said com ounds being of formula (Γ")
Figure imgf000321_0003
wherein Ri, -R2-, Y, R3, R4, R5, R6, X, -[B]- and R7 have a meaning as indicated in one of claims 1 to 5.
9. Compounds according to one or more of claims 1 to 8 wherein -R2- is at each occurrence independently -(C(R)2)o- or -(C(R)2)P-X8-(C(R)2)q- (X9)s-(C(R)2)r-(Xio)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and all other R, o, Xs, X9, X10, s, t, p, q, r, and u have a meaning as indicated in claim 1 .
10. Compounds according to one or more of claims 1 to 9 wherein Ri is at each occurrence independently an acryl or methacryl radical.
1 1 . Oligomer or polymer comprising polymerized compounds of formula (I) as described in one or more of claims 1 to 10.
12. Composition comprising at least one compound of formula (I) according to one or more of claims 1 to 10 and/or an oligomer or polymer according to claim 1 1 .
13. Article comprising at least one polymerized compound of formula (I) according to one or more of claims 1 to 10 or at least one oligomer or polymer of claim 1 1 .
14. Article according to claim 13 wherein said article is a blank which may be transformed into an eye implant or an eye implant, preferably an intraocular lens.
15. Process of forming an article of claim 13 or 14, said process comprising the steps of
- providing a composition comprising at least one compound of
formula (I) according to one or more of claims 1 to 10 and/or an oligomer or polymer according to claim 1 1 ;
- subsequently forming the article of said composition.
16. Process of changing the optical properties of an article according to claim 13 or 14, said process comprising the steps of
- providing an article according to claim 13 or 14, and
- subsequently exposing said article to irradiation having a wavelength of at least 200 nm and at most 1500 nm.
PCT/EP2018/053625 2017-02-15 2018-02-14 Hydrophobic compounds for optically active devices WO2018149852A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES18703798T ES2850898T3 (en) 2017-02-15 2018-02-14 Hydrophobic Compounds for Optically Active Devices
PL18703798T PL3583091T3 (en) 2017-02-15 2018-02-14 Hydrophobic compounds for optically active devices
US16/485,844 US11014901B2 (en) 2017-02-15 2018-02-14 Hydrophobic compounds for optically active devices
EP18703798.1A EP3583091B1 (en) 2017-02-15 2018-02-14 Hydrophobic compounds for optically active devices

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17156329.9A EP3363787A1 (en) 2017-02-15 2017-02-15 Hydrophobic compounds for optically active devices
EP17156329.9 2017-02-15

Publications (1)

Publication Number Publication Date
WO2018149852A1 true WO2018149852A1 (en) 2018-08-23

Family

ID=58212900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/053625 WO2018149852A1 (en) 2017-02-15 2018-02-14 Hydrophobic compounds for optically active devices

Country Status (7)

Country Link
US (1) US11014901B2 (en)
EP (2) EP3363787A1 (en)
ES (1) ES2850898T3 (en)
HU (1) HUE052436T2 (en)
PL (1) PL3583091T3 (en)
PT (1) PT3583091T (en)
WO (1) WO2018149852A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212543A1 (en) 2019-04-18 2020-10-22 Merck Patent Gmbh Compounds for optically active devices
WO2020216928A1 (en) 2019-04-26 2020-10-29 Merck Patent Gmbh System and method
WO2021233800A1 (en) 2020-05-20 2021-11-25 Merck Patent Gmbh Azacoumarin and azathiocoumarin derivatives for use in optically active devices
WO2022012798A1 (en) 2020-07-15 2022-01-20 Merck Patent Gmbh Optically active devices
EP4015512A1 (en) 2020-12-16 2022-06-22 AMO Ireland Optically active devices
EP4036085A1 (en) 2021-01-27 2022-08-03 AMO Ireland Compounds for optically active ophthalmic devices
US11702396B2 (en) 2017-02-15 2023-07-18 Johnson & Johnson Surgical Vision, Inc. Hydrophobic compounds for optically active devices
US11753387B2 (en) 2017-02-15 2023-09-12 Johnson & Johnson Surgical Vision, Inc. Compounds for optically active devices
US11958819B2 (en) 2015-08-21 2024-04-16 Johnson & Johnson Surgical Vision, Inc. Compounds for optically active devices

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290892A (en) 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
US5331073A (en) 1992-11-09 1994-07-19 Allergan, Inc. Polymeric compositions and intraocular lenses made from same
US5693095A (en) 1995-06-07 1997-12-02 Alcon Laboratories, Inc. High refractive index ophthalmic lens materials
WO2007033831A1 (en) 2005-09-23 2007-03-29 Schmidt Intraocularlinsen Gmbh Intraocular lens
WO2009074521A1 (en) * 2007-12-11 2009-06-18 *Acri.Tec Gmbh Ophthalmologic composition and use thereof
WO2009074520A2 (en) 2007-12-11 2009-06-18 *Acri.Tec Gmbh Copolymer and ophthalmological composition
US20120308802A1 (en) 2010-02-04 2012-12-06 Soon-Hwa Jung Novel fluorinated compound, a composition comprising the same, and a production method for a film using the same
WO2016200401A1 (en) 2015-06-12 2016-12-15 Transitions Optical, Inc. Alignment compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3363786A1 (en) * 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
EP3363791A1 (en) * 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophilic compounds for optically active devices

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290892A (en) 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
US5331073A (en) 1992-11-09 1994-07-19 Allergan, Inc. Polymeric compositions and intraocular lenses made from same
US5693095A (en) 1995-06-07 1997-12-02 Alcon Laboratories, Inc. High refractive index ophthalmic lens materials
WO2007033831A1 (en) 2005-09-23 2007-03-29 Schmidt Intraocularlinsen Gmbh Intraocular lens
WO2009074521A1 (en) * 2007-12-11 2009-06-18 *Acri.Tec Gmbh Ophthalmologic composition and use thereof
WO2009074520A2 (en) 2007-12-11 2009-06-18 *Acri.Tec Gmbh Copolymer and ophthalmological composition
US20100324165A1 (en) 2007-12-11 2010-12-23 Helmut Ritter Ophthalmological Composition And Use Thereof
US20120308802A1 (en) 2010-02-04 2012-12-06 Soon-Hwa Jung Novel fluorinated compound, a composition comprising the same, and a production method for a film using the same
WO2016200401A1 (en) 2015-06-12 2016-12-15 Transitions Optical, Inc. Alignment compounds

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
A. BOUQUET ET AL., TETRAHEDRON, vol. 37, 1981, pages 75 - 81
C.H. KRAUCH ET AL., CHEMISCHE BERICHTE JAHRG, vol. 99, 1966, pages 1723
DAVID L. OLDROYD ET AL., TETRAHEDRON LETTERS, vol. 34, no. 7, 1993, pages 1087 - 1090
J. M. G. COWIE, POLYMERS: CHEMISTRY & PHYSICS OF MODERN MATERIALS, 1991
JEAN-MARC LEGEAIS, J CATARACT REFRACT SURG, vol. 24, 1998, pages 371 - 379
M. SCHRAUB ET AL., EUROPEAN POLYMER JOURNAL, vol. 51, 2014, pages 21 - 27
P.L. BEAULIEU ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 17, 2012, pages 7650 - 7666
PAC, vol. 68, 1996, pages 2291
PIERRE L. BEAULIEU ET AL: "Discovery of the First Thumb Pocket 1 NS5B Polymerase Inhibitor (BILB 1941) with Demonstrated Antiviral Activity in Patients Chronically Infected with Genotype 1 Hepatitis C Virus (HCV)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 17, 13 September 2012 (2012-09-13), US, pages 7650 - 7666, XP055356857, ISSN: 0022-2623, DOI: 10.1021/jm3006788 *
SCHRAUB MARTIN ET AL: "Photoinduced refractive index changes of 3-phenyl-coumarin containing polymers for ophthalmic applications", EUROPEAN POLYMER JOURNAL, PERGAMON PRESS LTD. OXFORD, GB, vol. 51, 1 December 2013 (2013-12-01), pages 21 - 27, XP028810223, ISSN: 0014-3057, DOI: 10.1016/J.EURPOLYMJ.2013.11.014 *
THANH TRUONG ET AL: "General Method for Functionalized Polyaryl Synthesis via Aryne Intermediates", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 136, no. 24, 18 June 2014 (2014-06-18), pages 8568 - 8576, XP055356858, ISSN: 0002-7863, DOI: 10.1021/ja504886x *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11958819B2 (en) 2015-08-21 2024-04-16 Johnson & Johnson Surgical Vision, Inc. Compounds for optically active devices
US11702396B2 (en) 2017-02-15 2023-07-18 Johnson & Johnson Surgical Vision, Inc. Hydrophobic compounds for optically active devices
US11753387B2 (en) 2017-02-15 2023-09-12 Johnson & Johnson Surgical Vision, Inc. Compounds for optically active devices
WO2020212543A1 (en) 2019-04-18 2020-10-22 Merck Patent Gmbh Compounds for optically active devices
WO2020216928A1 (en) 2019-04-26 2020-10-29 Merck Patent Gmbh System and method
EP4327779A2 (en) 2019-04-26 2024-02-28 AMO Ireland System and method
WO2021233800A1 (en) 2020-05-20 2021-11-25 Merck Patent Gmbh Azacoumarin and azathiocoumarin derivatives for use in optically active devices
WO2022012798A1 (en) 2020-07-15 2022-01-20 Merck Patent Gmbh Optically active devices
WO2022012799A1 (en) 2020-07-15 2022-01-20 Merck Patent Gmbh Optically active devices
WO2022128832A1 (en) 2020-12-16 2022-06-23 Merck Patent Gmbh Optically active devices
EP4015512A1 (en) 2020-12-16 2022-06-22 AMO Ireland Optically active devices
WO2022161895A1 (en) 2021-01-27 2022-08-04 AMO Ireland Optically active devices
EP4036085A1 (en) 2021-01-27 2022-08-03 AMO Ireland Compounds for optically active ophthalmic devices

Also Published As

Publication number Publication date
PT3583091T (en) 2021-02-03
US11014901B2 (en) 2021-05-25
ES2850898T3 (en) 2021-09-01
EP3363787A1 (en) 2018-08-22
US20200055833A1 (en) 2020-02-20
PL3583091T3 (en) 2021-04-19
EP3583091B1 (en) 2020-11-04
HUE052436T2 (en) 2021-04-28
EP3583091A1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
WO2018149852A1 (en) Hydrophobic compounds for optically active devices
US11753387B2 (en) Compounds for optically active devices
AU2018222556B2 (en) Bis-compounds for optically active devices
US11014900B2 (en) Hydrophilic compounds for optically active devices
CN110382473B (en) Hydrophobic compounds for optically active devices
EP3583100B1 (en) Compounds containing si atoms for optically active devices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18703798

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018703798

Country of ref document: EP

Effective date: 20190916